Xxxxxxxx Xxxxxx 2000/32/ES
ze xxx 19. xxxxxx 2000,
xxxxxx xx xx xxxxxxx xxxxx přizpůsobuje xxxxxxxxxxx xxxxxxx xxxxxxxx Xxxx 67/548/XXX o xxxxxxxxxx právních x xxxxxxxxx xxxxxxxx xxxxxxxxxx xx klasifikace, xxxxxx x xxxxxxxxxx nebezpečných xxxxx [1]
(Xxxx x xxxxxxxx pro XXX)
XXXXXX XXXXXXXXXX XXXXXXXXXXXX,
x ohledem xx Xxxxxxx o xxxxxxxx Xxxxxxxxxx xxxxxxxxxxxx,
x xxxxxxx na xxxxxxxx Xxxx 67/548/XXX xx xxx 27. xxxxxx 1967 x xxxxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxx týkajících xx xxxxxxxxxxx, xxxxxx x xxxxxxxxxx xxxxxxxxxxxx látek [2], xxxxxxxxx xxxxxxxxxx xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx 1999/33/XX [3], x xxxxxxx xx xxxxxx 28 xxxxxxx xxxxxxxx,
xxxxxxxx x xxxxx xxxxxxx:
(1) Příloha X xxxxxxxx 67/548/XXX xxxxxxxx seznam xxxxxxxxxxxx xxxxx společně x xxxxxxxxxx údaji x xxxxxxxxxxx x xxxxxxxxxx xxxxx xxxxx. Současné xxxxxxx x technické xxxxxxxx xxxxxxx, že xx xxx xxx xxxxxx xxxxxxxxxxxx xxxxx x xxxxxxx příloze xxxxxxxxxxx. Některé xxxxxxxx xxxxx xxxxxxxx xxxxxxxx xxxxxx xxxxxxxx xxxxxx xxxxxxxxx a xxxxxxx X x příloze X.
(2) Příloha XXX xxxxxxxx 67/548/XXX xxxxxxxx xxxxxx xxx xxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxx x xxxxxxxxx. Xxxxxxx XX směrnice 67/548/XXX xxxxxxxx xxxxxx xxx x xxxxxxxxxxxxxx xxxxxx xxxxxxxxxx xx xxxxxxxxxxxx xxxxx x xxxxxxxxx. Příloha VI xxxxxxxx 67/548/EHS xxxxxxxx xxxxx xx xxxxxxxxxxx x k xxxxxxxxxx xxxxxxxxxxxx látek a xxxxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxxxxx xxxxxx xxxxxxxx oddílů xxxxxx III, XX x XX.
(3) V xxxxxxx V xxxxxxxx 67/548/XXX xx xxxxxxx xxxxxx xxx stanovení xxxxxxxxx-xxxxxxxxxx vlastností, xxxxxxxx x xxxxxxxxxxx xxxxx x xxxxxxxxx. Je xxxxxxxx xxxxxxxxxxx xxxx xxxxxxx technickému xxxxxxx.
(4) Xxxxxxx XX xxxxxxxx 67/548/XXX obsahuje předpisy xxxxxxxx se xxxxxxx xxxxxxxx xxxxx otevření xxxxx. Xxxx předpisy xx xxxx být xxxxxxxxxxxx a aktualizovány. Xx xxxxxxxx xxxxxxxx xxxxxx, kde xx xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxx xxxxxxxxx.
(5) Xxxxxxxx xxxx xxxxxxxx xxxx x xxxxxxx xx xxxxxxxxxxx Xxxxxx xxx přizpůsobení technickému xxxxxxx xxxxxxx xxx xxxxxxxxxx technických xxxxxxxx xxxxxxx xx úseku xxxxxxxxxxxx xxxxx x xxxxxxxxx,
XXXXXXX TUTO SMĚRNICI:
Xxxxxx 1
Xxxxxxxx 67/548/XXX xx mění takto:
1. Xxxxxxx X xx xxxx takto:
a) xxxxxxxxxxxx xxxxxxxx x xxxxxxxxx xx xxxxxxxxx poznámkou X v xxxxxxx 1X této směrnice;
b) xxxxxxxxxxxx xxxxx x xxxxxxx A xx xxxxxxxxx řádky v xxxxxxx 1X této xxxxxxxx;
x) odpovídající položky xx nahrazují xxxxxxxxx x xxxxxxx 1C xxxx xxxxxxxx;
x) xxxxxxxx xx xxxxxxx x xxxxxxx 1D xxxx xxxxxxxx.
2. Xxxxxxxxxxxx xxxx x příloze III xx nahrazuje standardní xxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx x příloze 2 xxxx směrnice.
3. Xxxxxxx XX xx xxxx xxxxx:
x) odpovídající xxxxxx x příloze XX xx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxx xxxxxxxx xxxxxxxxx v xxxxxxx 3X xxxx xxxxxxxx;
x) xxxxxxxxxxxx xxxxxx x xxxxxxx IV xx nahrazují kombinovanými xxxxxxxxxxxx xxxxxx xxx xxxxxxxx zacházení x xxxxxxx 3X této xxxxxxxx.
4. Část X xxxxxxx X se xxxx xxxxx:
x) xxxxxxxx X.10 se xxxxxxxxx xxxxxx v xxxxxxx 4X této směrnice;
b) xxxxxxxx B.11 se xxxxxxxxx xxxxxx x xxxxxxx 4X této xxxxxxxx;
x) xxxxxxxx X.12 xx xxxxxxxxx xxxxxx x xxxxxxx 4X xxxx xxxxxxxx;
x) xxxxxxxx X.13 a B.14 xx xxxxxxxxx xxxxxx x xxxxxxx 4X xxxx xxxxxxxx;
x) xxxxxxxx X.17 se xxxxxxxxx xxxxxx x příloze 4X xxxx xxxxxxxx;
x) xxxxxxxx B.23 xx xxxxxxxxx textem v xxxxxxx 4X xxxx xxxxxxxx. Xxxxx xxxxxxxx X.23 ve xxxxxxxxxxx xx mění xxxxxxxxxxxxx xxxxxxxx;
x) xxxxxx xx xxxx x xxxxxxx 4X xxxx xxxxxxxx.
5. Xxxxxxx xx xxxxxx xxxxxxx xxxxxxxx xxxxx x xxxxx X xxxxxxx X.
6. Odpovídající xxxxx x xxxxxxx XX xx xxxxxxxxx xxxxx x xxxxxxx 5 xxxx směrnice.
7. Xxxxxxx IX se xxxx způsobem xxxxxxxx x příloze 6 xxxx xxxxxxxx.
Xxxxxx 2
1. Členské xxxxx xxxxxx x xxxxxxxx právní x xxxxxxx xxxxxxxx xxxxxxxx xxx dosažení xxxxxxx x xxxxx xxxxxxxx xxxxxxxxxx do 1. xxxxxx 2001. Xxxxxxxxxx x xxxx xxxxxxx Xxxxxx.
Xxxx předpisy přijaté xxxxxxxxx xxxxx musí xxxxxxxxx xxxxx na xxxx směrnici nebo xxxx xxxxxx xxxxx xxx učiněn při xxxxxx úředním vyhlášení. Xxxxxx odkazu si xxxxxxx xxxxxxx xxxxx.
2. Xxxxxxx xxxxx xxxxx Xxxxxx xxxxx xxxxxxxx xxxxxxxxxx vnitrostátních xxxxxxxx xxxxxxxx, xxxxx přijmou x oblasti působnosti xxxx xxxxxxxx, x xxxxxxxxxx tabulku mezi xxxxxxxx x přijatými xxxxxxxxxxxxxx ustanoveními.
Xxxxxx 3
Xxxx xxxxxxxx xxxxxxxx v platnost xxxxxx xxxx po xxxxxxxxx x Úředním xxxxxxxx Evropských xxxxxxxxxxxx.
Xxxxxx 4
Tato směrnice xx xxxxxx členským xxxxxx.
V Xxxxxxx xxx 19. xxxxxx 2000.
Xx Xxxxxx
Xxxxxx Xxxxxxxöx
xxxxxx Xxxxxx
[1] Xxxxxxx xx xxxxxxxxxxxx xx xxxxxxx xxxxx.
[2] Xx. xxxx. 196, 16.8.1967, x. 1.
[3] Xx. věst. X 199, 30.7.1999, x. 57.
XXXXXXX 1A
PŘEDMLUVA X XXXXXXX X
Xxxxxxxxxx xxxxxxxx xxxxxxxxxx xx xxxxxxxxxxxx, xxxxxxxxxxx a označování xxxxx
(Xxxxxx xx xxxxxxx xxxxx)
XXXXXXX 1X
"XXXXXXX A
|
Z |
Symbol |
ES |
DA |
DE |
EL |
EN |
FI |
FR |
IT |
NL |
PT |
SV |
|
18 |
Ar |
Argón |
Argon |
Argon |
Αργό |
Argon |
Argon |
Argon |
Argon |
Argon |
Árgon |
Argon |
|
64 |
Gd |
Gadolinio |
Gadolinium |
Gadolinium |
Γαδολίνιο |
Gadolinium |
Gadolinium |
Gadolinium |
Gadolinio |
Gadolinium |
Gadolínio |
Gadolinium" |
PŘÍLOHA 1X
|
Xxxxxxxx xxxxx |
Xxxxxxxx xxxxx |
Xxxxxxxx x látkám |
Číslo XX |
Xxxxx XXX |
Xxxxxxxxxxx |
Xxxxxxxx |
Xxxxxxxxxxxx xxxxxx |
Xxxxxxxx x xxxxxxxxxx |
|
006–011–00–7 |
xxxxxxxx (XXX) 1-xxxxxx-X-xxxxxxxxxxxxxx |
200–555–0 |
63–25–2 |
Xxxx. kat. 3; X40 Xx; R22 X; X50 |
Xx; X X: 22–40–50 X: (2-)22–24–36/37–46–61 |
|||
|
006–013–00–8 |
xxxxxx-xxxxxxx (XXX) xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx |
205–293–0 |
137–42–8 |
Xx; X22 X31 C; X34 X43 N; X50–53 |
X; X X: 22–31–34–43–50/53 S: (1/2-)26–36/37/39–45–60–61 |
|||
|
006–015–00–9 |
xxxxxx (XXX) 3-(3,4-dichlorfenyl)-1,1-dimethylmočovina |
206–354–4 |
330–54–1 |
Karc. xxx. 3; X40 Xxxx. xxx. 3; X40 Xx; X22–48/22 X; X50–53 |
Xx; X R: 22–40–48/22–50/53 S: (2-)13–22–23–37–46–60–61 |
|||
|
006–016–00–4 |
xxxxxxxx (XXX) 2- xxxxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
204–043–8 |
114–26–1 |
X; X25 X; X50–53 |
X; X X: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–017–00-X |
xxxxxxxx (XXX) 2-xxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxxx-X-(X-xxxxxxxxxxxxxxx)xxxx |
204–123–2 |
116–06–3 |
X+; X26/28 X; X24 N; X50–53 |
X+; X R: 24–26/28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–018–00–5 |
xxxxxxxxx (ISO) 4-(xxxxxxxxxxxxx)-3-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
217–990–7 |
2032–59–9 |
X; R24/25 N; X50–53 |
X; N X: 24/25–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
006–019–00–0 |
xx-xxxxx (XXX) S-(2,3-dichlorallyl)-N,N-diisopropylthiokarbamát |
218–961–1 |
2303–16–4 |
Karc. xxx. 3; R40 Xx; X22 X; X50–53 |
Xx; X X: 22–40–50/53 X: (2-)25–36/37–60–61 |
|||
|
006–020–00–6 |
xxxxxx (XXX) 4-xxxxxxxx-2-xx-1-xx-X -(3-chlorfenyl)karbamát |
202–930–4 |
101–27–9 |
Xn; X22 X43 X; R50–53 |
Xn; X R: 22–43–50/53 X: (2-)24–36/37–60–61 |
|||
|
006–023–00–2 |
merkaptodimethur (XXX) xxxxxxxxxx 3,5-xxxxxxxx-4-(xxxxxxxxxxxxxx)xxxxx-X -xxxxxxxxxxxxxx |
217–991–2 |
2032–65–7 |
X; X25 X; X50–53 |
X; X X: 25–50/53 X: (1/2-)22–37–45–60–61 |
|||
|
006–024–00–8 |
xxxxxx-xxxxxxx (XXX) xxxxxxx-X-xxxxxxxxx-xxxxxxxxxxxxxx |
205–443–5 |
140–93–2 |
Xx; R22 Xx; X38 X; X51–53 |
Xx; X X: 22–38–51/53 X: (2-)13-61 |
|||
|
006–026–00–9 |
xxxxxxxxxx (XXX) 2,2-xxxxxxxx-2,3-xxxxxxx-1-xxxxxxxxxx-7-xx-X-xxxxxxxxxxxxxx |
216–353–0 |
1563–66–2 |
X+; X26/28 N; X50–53 |
X+; X X: 26/28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–028–00-X |
dinobuton (XXX) 2-(1-methylpropyl)-4,6-dinitrofenyl-isopropyl-karbonát 2-sek-butyl-4,6-dinitrofenyl-isopropyl-karbonát |
213–546–1 |
973–21–7 |
T; X25 X; X50–53 |
X; X R: 25–50/53 X: (1/2-)37–45–60–61 |
|||
|
006–029–00–5 |
xxxxxxxxx (ISO) 2-(1,3-xxxxxxxx-2-xx)xxxxx-X-xxxxxxxxxxxxxx |
230–253–4 |
6988–21–2 |
X; X25 X; X51–53 |
X; X R: 25–51/53 S: (1/2-)37–45–61 |
|||
|
006–033–00–7 |
xxxxxxxxx (XXX) 3-(3-xxxxx-4-xxxxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
243–433–2 |
19937–59–8 |
X; X50–53 |
X X: 5 0/ 5 3 X: 60-61 |
|||
|
006–034–00–2 |
xxxxxxx (XXX) X-xxxxxx-X-xxxxx-X-xxxxxxxxxxxxxxxxx |
214–215–4 |
1114–71–2 |
Xx; X22 N; X51–53 |
Xx; X X: 22–51/53 X: (2-)23-61 |
|||
|
006–035–00–8 |
pirimikarb (ISO) 2-(xxxxxxxxxxxxx)- 5,6-xxxxxxxx xxxxxxxxx-4-xx-X,X-xxxxxxxxxxxxxxxx |
245–430–1 |
23103–98–2 |
X; X25 X; X50–53 |
X; X X: 25–50/53 X: (1/2)22–37–45–60–61 |
|||
|
006–037–00–9 |
promekarb (XXX) 3-xxxxxxxxx-5-xxxxxxxxxxx-X-xxxxxxxxxxxxxx |
220–113–0 |
2631–37–0 |
X; X25 N; X50–53 |
X; X R: 25–50/53 X: (1/2-)24–37–45–60–61 |
|||
|
006–038–00–4 |
xxxxxxxxx (XXX) 2-chlorallyl-N,N-dimethyldithiokarbamát |
E |
202–388–9 |
95–06–7 |
Karc. kat. 2; X45 Xx; X22 N; X50–53 |
X; X R: 45–22–50/53 X: 53–45–60–61 |
||
|
006–039–00-X |
xxx-xxxxx (XXX) X-(2,3,3-xxxxxxxxxxxxx)-X,X-xxxxxxxxxxxxxxxxxxxxxxx |
218–962–7 |
2303–17–5 |
Xx; R22–48/22 X43 X; X50–53 |
Xx; X X: 22–43–48/22–50/53 X: (2-)24–37–60–61 |
|||
|
006–042–00–6 |
xxxxxxx (XXX) 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxxx |
205–766–1 |
150–68–5 |
Xxxx. xxx. 3; R40 Xx; R22 N; X50–53 |
Xx; X X: 22–40–50/53 S: (2-)36/37–60–61 |
|||
|
006–043–00–1 |
monuron-TCA 3-(4-xxxxxxxxxx)-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
140–41–0 |
Xx; X36/38 Karc. xxx. 3; X40 X; X50–53 |
Xx; N X: 36/38–40–50/53 X: (2-)36/37–60–61 |
|||
|
006–045–00–2 |
xxxxxxxx (XXX) xxxxxx-X-[(X-xxxxxxxxxxxxxxx)xxx]xxxxxxxxxxxxxx |
240–815–0 |
16752–77–5 |
X+; X28 X; X50–53 |
X+; X X: 28–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–046–00–8 |
bendiokarb (XXX) 2,2-xxxxxxxx-1,3-xxxxxxxxxxx-4-xx-X-xxxxxxxxxxxxxx |
245–216–8 |
22781–23–3 |
X; R23/25 Xx; X21 X; X50–53 |
X; X X: 21–23/25–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
006–047–00–3 |
xxxxxxxxx (ISO) xxxx: 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx x 3-(1-xxxxxxxxxxx)xxxxx-X-xxxxxxxxxxxxxxx |
— |
8065–36–9 |
X; X24/25 X; X50–53 |
X; X X: 24/25–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
006–048–00–9 |
xxxxxxxxxxxx (XXX) 2-[(xxxxxxxxxxxxx)xxxxxx]xxxxx-X-xxxxxxxxxxxxxx |
249–981–9 |
29973–13–5 |
Xx; X22 X; R50–53 |
Xn; N X: 22–50/53 S: (2-)60-61 |
|||
|
006–050–00–X |
xxxxxxx-XXX 3-xxxxx-1,1-xxxxxxxxxxxxxxx-xxxxxxxxxxxxxx |
— |
4482–55–7 |
Xx; X38 X; X50–53 |
Xx; N X: 38–50/53 X: (2-)60-61 |
|||
|
006–053–00–6 |
xxxxxxxxxx (XXX) 2-isopropylfenyl-N-methylkarbamát |
220–114–6 |
2631–40–5 |
Xn; X22 N; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
006–054–00–1 |
xxxxxxxxxx (XXX) 4-(xxxxxxxxxxxxx)-3,5-xxxxxxxxxxxxx-X-xxxxxxxxxxxxxx |
206–249–3 |
315–18–4 |
X+; X28 Xx; X21 X; R50–53 |
T+; X R: 21–28–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
006–057–00–8 |
xxxxxxxxxx (XXX) 2-xxxxx-6-(xxxxxxxxxxxxxx)xxxxxxx |
217–682–2 |
1929–82–4 |
Xx; X22 X; X51–53 |
Xx; N X: 22–51/53 X: (2-)24-61 |
|||
|
006–060–00–4 |
xxxxxxxxxxx (XXX) 2-xxxxxx-4,4-xxxxx-5,6-xxxxxxx-4λ4-1,4-xxxxxxxx-3-xxxxxxxxxxxx |
226–066–2 |
5259–88–1 |
Xx; X22 X52–53 |
Xx R:22–52/53 X: (2-)61 |
|||
|
006–069–00–3 |
xxxxxxxxx-xxxxxx (XXX) 1,2-di[3-(methoxykarbonyl)thioureido]benzen |
245–740–7 |
23564–05–8 |
Muta. xxx. 3; X40 X; X50–53 |
Xx; X X: 40–50/53 X: (2-)36/37–60–61 |
|||
|
006–070–00–9 |
xxxxxxxxxxx N-cyklohexyl-N-methoxy-2,5-dimethyl-3-furamid |
262–302–0 |
60568–05–0 |
Karc. kat. 3; X40 N; X50–53 |
Xx; X R: 40–50/53 X: (2-)36/37–60–61 |
|||
|
006–088–00–7 |
xxxxxxxxxxx (XXX) ethyl-N -[({[(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)oxy]karbonyl}methylamino)sulfanyl]-N-isopropyl-β-alaninát(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)-N-({[2-(ethoxykarbonyl)ethyl]isopropylamino}sulfanyl)-N-methylkarbamát |
— |
82560–54–1 |
T; X23/25 X; X50–53 |
X; X R: 23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
007–012–00–5 |
N,N-dimethylhydrazin 1,1-dimethylhydrazin |
E |
200–316–0 |
57–14–7 |
F; X11 Xxxx. xxx. 2; X45 X; X23/25 X; X34 X; R51–53 |
F; T; X X: 45–11–23/25–34–51/53 X: 53–45–61 |
||
|
007–013–00–0 |
N,N-dimethylhydrazin 1,2-dimethylhydrazin |
E |
— |
540–73–8 |
Karc. xxx. 2; R45 X; R23/24/25 X; X51–53 |
X; N X: 45–23/24/25–51/53 S: 53–45–61 |
C ≥ 25 %: X; R45–23/24/25 3 % &xx; X &xx; 25 %: X; R45–20/21/22 0,01 % &xx; C &xx; 3 %: X; X45 |
|
|
009–003–00–1 |
xxxxxxxx fluorovodíková … % |
B |
231–634–8 |
7664–39–3 |
T+; R26/27/28 X; R35 |
T+; X X: 26/27/28–35 X: (1/2-)7/9–26–36/37–45 |
X ≥ 7 %: X+; X; X26/27/28–35 1 % ≤ X &xx; 7 %: X; X23/24/25–34 0,1 % ≤ X &xx; 1 %: Xn; X20/21/22–36/37/38 |
|
|
015–039–00–9 |
xxxxxxx-xxxxxx (XXX) O,O-dimethyl-S -[(4(3 X)-xxx-1,2,3-xxxxxxxxxxxx-3-xx)xxxxxx]-xxxxxxxxxxxxxxx |
201–676–1 |
86–50–0 |
X+; X26/28 X; X24 X43 X; R50–53 |
T+; X X: 24–26/28–43–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
015–048–00–8 |
xxxxxxxx (ISO) X,X-xxxxxxxx-X-[3-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxx]-xxxxxxxxxxxxx |
200–231–9 |
55–38–9 |
Xxxx. xxx. 3; X40 X; X23–48/25 Xx; X21/22 X; X50–53 |
X; X R: 21/22–23–40–48/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
015–056–00–1 |
azinfos-ethyl (XXX) X,X-xxxxxxx-X-[(4(3 X)-xxx-1,2,3-xxxxxxxxxxxx-3-xx)xxxxxx]-xxxxxxxxxxxxxxx |
220–147–6 |
2642–71–9 |
X+; X28 X; X24 X; X50–53 |
X+; X X: 24–28–50/53 X: (1/2-)28–36/37–45–60–61 |
|||
|
015–140–00–8 |
triazofos (XXX) X,X-xxxxxxx-X-(1-xxxxx-1 X- 1,2,4-xxxxxxx-3-xx)-xxxxxxxxxxxxx |
245–986–5 |
24017–47–8 |
X; X23/25 Xx; X21 N; X50–53 |
X; X R: 21–23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
016–013–00-X |
xxxxxxx xxxxxxx |
234–129–0 |
10545–99–0 |
X14 X; X34 X; X50 |
X; X R: 14–34–50 X: (1/2-)26–36/37/39–45–61 |
C ≥ 10 %: X; X34 5 % ≤ X &xx; 10 %: Xx; R36/37/38 |
||
|
016–014–00–5 |
chlorid siřičitý |
— |
13451–08–6 |
R14 X; R34 N; X50 |
X; X R: 14–34–50 S: (1/2-)26–36/37/39–45–61 |
X ≥ 10 %: X; X34 5 % ≤ C &xx; 10 %: Xx; X36/37/38 |
||
|
016–023–00–4 |
xxxxxxxx-xxxxxx |
X |
201–058–1 |
77–78–1 |
Xxxx. kat. 2; X45 Xxxx. xxx. 3; X40 X+; X26 X; X25 C; X34 X43 |
X+ R: 45–25–26–34–43 X: 53-4 5 |
X ≥ 25 %: X+; X45–25–26–34–43 10 % ≤ X &xx; 25 %: X+; X45–22–26–34–43 7 % ≤ X &xx; 10 %: X+; X45–22–26–36/ 37/38–43 5 % ≤ X &xx; 7 %: X; R45–22–23–36/37/38–43 3 % ≤ X < 5 %: X; X45–22–23–43 1 % ≤ X &xx; 3 %: T; X45–23–43 0,1 % ≤ X < 1 %: T; R45–20 0,01 % ≤ X &xx; 0,1 %:X; X45 |
|
|
016–024–00-X |
xxxxxxxx (XXX) xxx(xxxxxxxxxxxxxxxxxxx)xxxxxxxx |
X,X′-xxxxxxxx-xxxxxxxxxxx(xxxxxxxxxxx)215–993–8 |
1468–37–7 |
Xx; X22 N; X50–53 |
Xx; N X: 22–50/53 S: (2-)60-61 |
|||
|
016–071–00–6 |
3-xxxxx-6,13-xxxxxxx-10-[(3-{[4-xxxxx-6-(2-xxxxxxxxxxxxxxxx)- 1,3,5-xxxxxxx-2-xx]xxxxx}xxxxxx)xxxxx][1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx xxxxxxxx |
410–130–3 |
136248–03–8 |
X43 |
Xx R: 43 X: (2-)22–24–37 |
|||
|
022–001–00–5 |
chlorid xxxxxxxxxx |
231–441–9 |
7550–45–0 |
X14 X; R34 |
C X: 14-34 S: (1/2-)7/8–26–36/37/39–45 |
X ≥ 10 %: X; R34 5 % ≤ X < 10 %: Xi; X36/37/38 |
||
|
030–004–00–8 |
xxxxxxxxxxxxx [1] diethylzinek [2] |
208–884–1 [1] 209–161–3 [2] |
544–97–8 [1] 557–20–0 [2] |
X14 X; X17 X; X34 X; R50–53 |
F; X; N R: 14–17–34–50/53 X: (1/2-)16–43–45–60–61 |
|||
|
050–002–00–0 |
xxxxxxxxx (XXX) tricyklohexyl(hydroxy)stannan tricyklohexylstannium-hydroxid |
236–049–1 |
13121–70–5 |
Xn; X20/21/22 N; R50–53 |
Xn; X X: 20/21/22–50/53 X: (2-)13–60–61 |
|||
|
050–012–00–5 |
xxxxxxxxxxxxxxxxxxxxxx [1] xxxxx(xxxxxxxxxxxxx)xxxxxxx [2] butyl(tricyklohexyl)stannan [3] |
215–910–5 [1] 221–437–5 [2] 230–358–5 [3] |
1449–55–4 [1] 3091–32–5 [2] 7067–44–9 [3] |
Xx; X20/21/22 X; R50–53 |
Xn; X X: 20/21/22–50/53 S: (2-)26–28–60–61 |
X ≥ 1 %: Xx; X20/21/22 |
1 |
|
|
050–017–00–2 |
xxxxxxxxxxxxxx (XXX) 1,1,1,3,3,3-xxxxxxx(2-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxx |
236–407–7 |
13356–08–6 |
X+; X26 Xx; X36/38 N; X50/53 |
X+; X X: 26–36/38–50/53 S: (1/2-)28–36/37–45–60–61 |
|||
|
082–009–00–X |
žluť (xxxxxxxxxxxx xxxxxxxx) XX Xxxxxxx Yellow 34 (XX 77603) XX xxxxxxxxxx xxxx 34 (XX 77603) |
215–693–7 |
1344–37–2 |
Xxxx. xxx. 3; X40 Xxxx. xxx. 1; X61 Xxxx. kat. 3; X62 X33 X; X50–53 |
X; N X: 61–33–40–50/53–62 X: 53–45–60–61 |
1 |
||
|
082–010–00–5 |
xxxxxx (xxxxxxx-xxxxxxxxxx-xxxxx olovnatý) XX Xxxxxxx Xxx 104 (XX 77605) XX xxxxxxxxxx xxxxxx 104 (XX 77605) |
235–759–9 |
12656–85–8 |
Xxxx. xxx. 3; R40 Xxxx. xxx. 1; X61 Xxxx. kat. 3; X62 X33 N; X50–53 |
X; X X: 61–33–40–50/53–62 S: 53–45–60–61 |
1 |
||
|
601–024–00-X |
xxxxx [1] xxxxxxxxxxxx [2] |
202–704–5 [1] 203–132–9 [2] |
98–82–8 [1] 103–65–1 [2] |
X10 Xx; R65 Xi; X37 N; X51–53 |
Xx; X X: 10–37–51/53–65 X: (2-)24–37–61–62 |
4 |
||
|
601–032–00–3 |
xxxxx[x]xxxxx benzo[def]chrysen |
200–028–5 |
50–32–8 |
Karc. xxx.2; X45 Xxxx. xxx. 2; X46 Xxxx. kat. 2; X60–61 N; X50–53 |
X; X R: 45–46–60–61–50/53 X: 53–45–60–61 |
|||
|
601–034–00–4 |
xxxxx[x]xxxxxxxxxxxxxxx |
205–911–9 |
205–99–2 |
Xxxx. xxx.2; X45 N; X50–53 |
X; X X: 45–50/53 X: 53–45–60–61 |
|||
|
602–035–00–2 |
1,4-xxxxxxxxxxxxx x-xxxxxxxxxxxxx |
203–400–5 |
106–46–7 |
Xx; X36 X; R50–53 |
Xi; X R: 36–50/53 X: (2-)24/25–46–60–61 |
|||
|
602–054–00–6 |
3-xxxxxxx-1-xx allyljodid |
209–130–4 |
556–56–9 |
R10 X; X34 |
X R: 10-34 X: (1/2-)7–26–45 |
|||
|
603–076–00–9 |
xxx-2-xx-1,4-xxxx |
203–788–6 |
110–65–6 |
X; X23/25 Xn; X21–48/22 X; R34 |
T R: 21–23/25–34–48/22 X: (1/2-)26–36/37/39–45 |
X ≥ 50 %: X; X21–23/25–34–48/22 25 % ≤ X &xx; 50 %: X; X21–23/25–36/38–48/22 10 % ≤ X &xx; 25 %: Xx; X20/22–48/22 3 % ≤ X &xx; 10 %: Xx; X20/22 |
||
|
603–091–00–0 |
xxx-4-xxxxxxxxx-1-xxxxxx-7-xxxxxxxxxx[2.2.1]xxxxxx-2-xx |
402–470–6 |
87172–89–2 |
X; X8 Xx; X22 Xx; X36 |
X; Xn X: 8–22–36 X: (2-)26 |
|||
|
603–093–00–1 |
xxx-(±)-4-xxxxxxxxx-1-xxxxxx-2-[(2-xxxxxxxxxxxx)xxx]-7-xxxxxxxxxx[2.2.1]xxxxxx |
402–410–9 |
87818–31–3 |
Xx; X20 X; X51–53 |
Xx; X X: 20–51/53 X: (2-)23-61 |
|||
|
603–097–00–3 |
1,1', 1′′-nitrilotripropan-2-ol xxxxxxxxxxxxxxxxxx |
204–528–4 |
122–20–3 |
Xx; X36 X52–53 |
Xx X:36–52/53 S: (2-)26-61 |
|||
|
603–117–00–0 |
xxxxxx-2-xx xxxxxxxxxxxxxxxx isopropanol |
200–661–7 |
67–63–0 |
F; R11 Xx; X36 X67 |
X; Xx R: 11–36–67 X: (2-)7–16–24/25–26 |
|||
|
604–020–00–6 |
bifenyl-2-ol 2-hydroxybifenyl 2-xxxxxxxxxx (XXX) |
201–993–5 |
90–43–7 |
Xx; R36/37/38 X; X50 |
Xx; X X: 36/37/38–50 X: (2-)22-61 |
|||
|
604–021–00–1 |
2-xxxxxxxxxx, xxxxx xxx xxxxxxx-2-xxxxxxxxxxxx 2-bifenylát sodný xxxxxxx-xxxxxxx-2-xxxx |
205–055–6 |
132–27–4 |
Xx; X22 Xx; X37/38–41 X; X50 |
Xx; X X: 37/38–41–50 X: (2-)22–26–61 |
|||
|
604–024–00–8 |
4,4'-(4-xxxxxxxxxxxx-2,2-xxxx)xxxxxxx 2,2-bis(4-hydroxyfenyl)-4-methylpentan |
401–720–1 |
6807–17–6 |
Repr. xxx. 2; R60 Xx; X36 N; X50–53 |
X; X X: 60–36–50/53 X: 53–45–60–61 |
|||
|
604–041–00–0 |
xxxxxxxxxxx [1] xxxxxxxxxxx-xxxxxxx [2] 5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxxx xxxxxxxx [1] xxxxxxx-5-[2-xxxxx-4-(xxxxxxxxxxxxxx)xxxxxx]-2-xxxxxxxxxxxx [2] |
256–634–5 [1] 263–560–7 [2] |
50594–66–6 [1] 62476–59–9 [2] |
Xx; R22 Xx; X38–41 N; X50–53 |
Xx; X R: 22–38–41–50/53 X: (2-)24–39–60–61 |
|||
|
604–043–00–1 |
xxxxxxxxxxxxxxxx (4-xxxxxxxxxxxx)xxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx 4-(benzyloxy)fenol |
203–083–3 |
103–16–2 |
Xi; X36 R43 |
Xi X: 36-43 X: (2-)24/25–26–37 |
|||
|
604–044–00–7 |
xxxxxxxx 4-xxxxxxxxxxxx hydrochinonmonomethylether |
205–769–8 |
150–76–5 |
Xn; X22 Xx; X36 X43 |
Xx X: 22–36–43 X: (2-)24/25–26–37/39–46 |
|||
|
605–016–00–7 |
xxxxxxx… % xxxxxxxxx… % |
X |
203–474–9 |
107–22–2 |
Xxxx. xxx. 3; X40 Xn; R20 Xx; R36/38 X43 |
Xx X: 20–36/38–40–43 X: (2-)36/37 |
X ≥ 10 %: Xx; X20–36/38–40–43 1 % ≤ X < 10 %: Xn; X40–43 |
|
|
606–016–00-X |
xxxxxx (XXX) 2-(xxxxxxxxxxxxxxx)xxxxx-1,3-xxxx |
201–462–8 |
83–26–1 |
X; X25–48/25 X; X50–53 |
X; N X: 25–48/25–50/53 X: (1/2-)37–45–60–61 |
|||
|
606–018–00–0 |
xxxxxxx (ISO) 2,3-xxxxxxx-1,4-xxxxxxxxxxx |
204–210–5 |
117–80–6 |
Xx; X22 Xx; X36/38 X; X50–53 |
Xx; X X: 22–36/38–50/53 X: (2-)26–60–61 |
|||
|
606–019–00–6 |
xxxxxxxxxx (XXX) perchlorpentacyklo[5.3.0.02,6.03,9.04,8]dekan-5-on xxxxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx 1,2,4,5,6,7,8,8,9,10-dekachlorpentacyklo[5.3.0.02,6.04,10.05,9]dekan-3-on |
205–601–3 |
143–50–0 |
Karc. xxx. 3; R40 X; X24/25 X; X50–53 |
X; X X: 24/25–40–50/53 X: (1/2-)22–36/37–45–60–61 |
|||
|
606–034–00–8 |
xxxxxxxxxx (XXX) 4-xxxxx-6-xxxx-xxxxx-3-(xxxxxxxxxxxxxx)-1,2,4-xxxxxxx-5(4 H)-on 4-amino-6-terc-butyl-3-(methylsulfanyl)-4,5-dihydro-1,2,4-triazin-5-on |
244–209–7 |
21087–64–9 |
Xn; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
606–035–00–3 |
xxxxxxxxxxx (XXX) 5-xxxxx-4-xxxxx-2-xxxxxxxxxxxxxx-3(2X)-xx xxxxxxx |
216–920–2 |
1698–60–8 |
X43 X; X50–53 |
Xx; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
606–036–00–9 |
chinomethionát (XXX) 6-methyl-2 X-[1,3]xxxxxxxx[4,5-x]xxxxxxxxxx-2-xx |
219–455–3 |
2439–01–2 |
Xxxx. xxx. 3; X62 Xx; X20/21/22–48/22 Xx; X36 X43 X; X50–53 |
Xx; X X: 20/21/22–36–43–48/22–50/53–62 X: (2-)24–37–60–61 |
|||
|
606–037–00–4 |
xxxxxxxxxxx (XXX) 1-(4-chlorfenoxy)- 3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-on |
256–103–8 |
43121–43–3 |
Xn; X22 X; R51–53 |
Xn; X X: 22–51/53 X: (2-)61 |
|||
|
606–044–00–2 |
2,4,6-trimethylbenzofenon xxxxx(2,4,6-xxxxxxxxxxxxxx)xxxxxxxx |
403–150–9 |
954–16–5 |
Xx; X22 Xi; R36 X; X50–53 |
Xx; X X: 22–36–50/53 S: (2-)26–60–61 |
|||
|
607–043–00-X |
xxxxxxx (XXX) 3,6-xxxxxxx-2-xxxxxxxxxxxxxxx xxxxxxxx |
217–635–6 |
1918–00–9 |
Xx; R22 Xx; X41 X52–53 |
Xx; X X: 22–41–52/53 X: (2-)26-61 |
|||
|
607–057–00–6 |
xxxxxxxxx (XXX) 3-[1-(4-xxxxxxxxxx)-3-xxxxxxxx]-4-xxxxxxxxxxxxxx3-[1-(4-xxxxxxxxxx)-3-xxxxxxxx]-4-xxxxxxx-2 X-xxxxxxx-2-xx |
201–378–1 |
81–82–3 |
Xx; X48/22 X52–53 |
Xx X:48/22–52/53 S: (2-)37-61 |
|||
|
607–058–00–1 |
xxxxxxxxx (XXX) fumarin (RS)-3-[1-(2-furyl)-3-oxobutyl)]-4-hydroxykumarin (XX)-3-[1-(2-xxxxx)-3-xxxxxxxx)]-4-xxxxxxx-2 X -chromen-2-on 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxxxxxxxxx 3-[1-(2-xxxxx)-3-xxxxxxxx]-4-xxxxxxx-2 H -xxxxxxx-2-xx |
204–195–5 |
117–52–2 |
X; R25–48/25 X52–53 |
X X:25–48/25–52/53 X: (1/2-)37–45–61 |
|||
|
607–079–00–6 |
kelevan (XXX) xxxxx-4-xxx-5-(xxxxxxxx-5-xxxxxxxxxxxxxxxxx[5.3.0.02,6.03,9.04,8]xxxxx-5-xx)xxxxxxxxx xxxxx-5-(1,2,3,5,6,7,8,9,10,10-xxxxxxxxx-4-xxxxxxxxxxxxxxxxx[5.2.1.02,6.03,9.05,8]xxxxx-4-xx)-4-xxxxxxxxxxxx xxxxx-5-(1,2,4,5,6,7,8,8,9,10-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx[5.3.0.02,6.04,10.05,9]xxxxx-3-xx)-4-xxxxxxxxxxxx |
— |
4234–79–1 |
X; R24 Xx; X22 X; R51–53 |
T; X X: 22–24–51/53 X: (1/2-)36/37–45–61 |
|||
|
607–097–00–4 |
xxxxxx-1,2,4-xxxxxxxxx-1,2-xxxxxxxx 1,2-xxxxxxxx xxxxxx-1,2,4-xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxx |
209–008–0 |
552–30–7 |
Xx; X37–41 R42/43 |
Xn X: 37–41–42/43 S: (2-)22–26–36/37/39 |
|||
|
607–143–00–3 |
xxxxxxxxx xxxxxxxx valerová xxxxxxxx |
203–677–2 |
109–52–4 |
X; X34 R52–53 |
C X:34–52/53 X: (1/2-)26–36–45–61 |
|||
|
607–152–00–2 |
2,3,6-XXX (XXX) 2,3,6-xxxxxxxxxxxxxxxx xxxxxxxx |
200–026–4 |
50–31–7 |
Xx; X22 X; R51–53 |
Xn; X X: 22–51/53 X: (2-)61 |
|||
|
607–153–00–8 |
xxxxxxxxx (XXX) (4-xxxxx-2-xxx-2,3-xxxxxxx-1,3-xxxxxxxxxxxx-3-xx)xxxxxx xxxxxxxx |
223–297–0 |
3813–05–6 |
Xx; X36/38 X52–53 |
Xx X:36/38–52/53 X: (2-)22-61 |
|||
|
607–156–00–4 |
xxxxxxxxxxx (XXX) 4-xxxxxxxxxx-4-xxxxxxxxxxx-1-xxxxxxxx |
201–270–4 |
80–33–1 |
Xx; X22 Xx; R38 X; X50–53 |
Xx; X R: 22–38–50/53 X: (2-)37–60–61 |
|||
|
607–158–00–5 |
xxxxx xxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx |
223–498–3 |
3926–62–3 |
X; X25 Xx; X38 X; X50 |
X; X X: 25–38–50 X: (1/2-)22–37–45–61 |
|||
|
607–159–00–0 |
xxxxxxxxxxxxxx (XXX) ethyl-2,2-bis(4-chlorfenyl)-2-hydroxyacetát ethyl-4,4'-dichlorbenzilát |
208–110–2 |
510–15–6 |
Xn; X22 X; X50–53 |
Xx; X X: 22–50/53 X: (2-)60-61 |
|||
|
607–176–00–3 |
Směs: α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-xxxxxxxxxxx(xxxxxxxxxx);α-{3-[3-(2 X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxx}-ω-({3-[3-(2 H-benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propionyl}oxy)poly(oxyethylen) |
400–830–7 |
— |
R43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)36/37–61 |
|||
|
607–188–00–9 |
xxxxxxx-xxxxxxxx-X-(2-xxxxxxxxxxxx)-X-(xxxxxxx-9-xx-1-xx)xxxxxxxxxx |
402–970–4 |
— |
X43 N; R51–53 |
Xi; X X: 43–51/53 X: (2-)24/37–61 |
|||
|
607–209–00–1 |
Xxxx: X,X′-xxxxxxxxxxx-xxxxxxxxxxxx(xxxxxxxxxxx); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx); X,X′-xxxxxxxxxxx-xxxxxxxxxxxxxx(xxxxxxxxxxx) |
403–030–6 |
— |
Xx; R22 X43 X; X50–53 |
Xx; X R: 22–43–50/ 53 X: (2-)36/37–60–61 |
|||
|
607–213–00–3 |
xxxxx-3,3-xxx(xxxx-xxxxxxxxxxxx)xxxxxxxx |
403–320–2 |
67567–23–1 |
X; X2 X; X7 X10 N; X51–53 |
X; X X: 2–7–10–51/53 X: (2-)3/7–14–33–36/37/39–61 |
|||
|
607–217–00–5 |
2-xxxxxxxxxxx-[4-(7-xxxxx-2,6-xxxxx-2,6-xxxxxxx-1,5-xxxxx-x-xxxxxxx-3-xx)xxxxxx]xxxxxx |
403–960–2 |
— |
X43 X53 |
Xx X: 43-53 X: (2-)24–37–61 |
|||
|
607–243–00–7 |
xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [1] natrium-3,6-dichlor-o-anisát [1] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [2] xxx(2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [2] (2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxx-2-xxxxxxxxxxxxxx [3] (2-xxxxxxxxxxxx)xxxxxxx-3,6-xxxxxxxxxxxxx [3] |
217–846–3 [1] 246–590–5 [2] 258–527–9 [3] |
1982–69–0 [1] 25059–78–3 [2] 53404–28–7 [3] |
X52–53 |
X: 52/53 S: 61 |
|||
|
607–248–00–4 |
Xxxxxxxx-xxxxxxx Xxxxxxx-X-(1-xxxxxx)xxxxxxxx |
205–073–4 |
132–67–2 |
Xx; X22 |
Xx X: 22 S: (2) |
|||
|
607–249–00-X |
(xxxxxxxxxxxxx)xxx[xxx(xxxxxxxxxxxxx)]-xxxxxxxxx tripropylenglykol-diakrylát XXXXX |
256–032–2 |
42978–66–5 |
Xx; X36/37/38 X43 X; X51–53 |
Xx; X R:36/37/38–43–51/53 X: (2-)24–37–61 |
X ≥ 10 %: Xi; X36/37/38–43 1 % ≤ X &xx; 10 %: Xi; X43 |
||
|
607–252–00–6 |
λ-xxxxxxxxxxx (XXX) Xxxx (1:1): (X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 X)-xxx-3-((X)-2-xxxxx-3,3,3-xxxxxxxxxxxx-1-xx-1-xx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x(X)-[(3-xxxxxxxxxxx)xxxxxxxxxx]-(1 S)-cis-3-((Z)-2-chlor-3,3,3-trifluorprop-1-en-1-yl)-2,2-dimethylcyklopropan-1-karboxylát |
415–130–7 |
91465–08–6 |
T+; X26 X; R25 Xx; X21 X; X50–53 |
X+; X X: 21–25–26–50/53 X: (1/2-)28–36/37/39–38–45–60–61 |
|||
|
607–255–00–2 |
xxxxxxxxxx (XXX) [(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx kyselina |
— |
69377–81–7 |
R52–53 |
R: 52/53 X: 61 |
|||
|
608–003–00–4 |
akrylonitril |
D E |
203–466–5 |
107–13–1 |
F; Xxx Karc. xxx. 2; R45 T; X23/24/25 Xx; R37/38–41 X43 X; R51–53 |
F; X; X X: 45–11–23-/24/25–37/38–41–43–51/53 S: 9–16–53–45–61 |
X ≥ 20 %: X; R45–23/24/25–37/38–41–43 10 % ≤ X &xx; 20 %: X; R45–23/24/25–41–43 5 % ≤ C &xx; 10 %: X; X45–23/24/25–36–43 1 % ≤ C &xx; 5 %:T; X45–23/24/25–43 0,2 % ≤ X < 1 %:T; X45–20/21/22 0,1 % ≤ X < 0,2 %: X; X45 |
43 |
|
608–016–00–5 |
2,3,5,6-xxxxxxxxxx-1,4-xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxx |
401–550–8 |
1897–41–2 |
X43 X; X50–53 |
Xx; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
609–030–00–4 |
dinoterb (XXX) 2-xxxx-xxxxx-4,6-xxxxxxxxxxxx |
X |
215–813–8 |
1420–07–1 |
Xxxx. xxx. 2; X61 X+; R28 X; X24 X44 X; R50–53 |
T+; X X: 61–24–28–44–50/53 S: 53–45–60–61 |
||
|
609–040–00–9 |
xxxxxxxx (XXX) (2,4-xxxxxxxxxxxx)(4-xxxxxxxxxx)xxxxx |
X |
217–406–0 |
1836–75–5 |
Xxxx. xxx. 2; X45 Xxxx. kat. 2; X61 Xx; X22 X; R50–53 |
T; X X: 45–61–22–50/53 S: 53–45–60–61 |
||
|
609–044–00–0 |
xxxxxxxx (XXX) 1,2,4,5-xxxxxxxxxx-3-xxxxxxxxxxx |
204–178–2 |
117–18–0 |
Xx; X22 R43 X; X50–53 |
Xx; X X: 22–43–50/53 X: (2-)24–37–60–61 |
|||
|
611–008–00–4 |
4-aminoazobenzen 4-(xxxxxxxx)xxxxxx |
200–453–6 |
60–09–3 |
Xxxx. kat. 2; X45 X; R50–53 |
T; X R: 45–50/53 X: 53–45–60–61 |
|||
|
611–013–00–1 |
4-hydroxy-3-{4-[2-methoxy-4-(3-sulfonatofenylazo)fenylazo]-3-methylfenylazo}-6-(3-sulfonatoanilino)naftalen-2-sulfonát trilithný |
403–650–7 |
117409–78–6 |
E; X2 N; X51–53 |
X; X X: 2–51/53 X: (2-)35-61 |
|||
|
611–031–00-X |
4,4'-[(4-iminocyklohexa-2,5-dien-1-yliden)methylen]dianilin-hydrochlorid XX Xxxxx Xxx 9 XX xxxxxxx xxxxxx 9 |
209–321–2 |
569–61–9 |
Xxxx. kat. 2; X45 |
X X: 45 X: 53-45 |
|||
|
612–035–00–4 |
2-xxxxxxxxxxxxx o-anisidin |
E |
201–963–1 |
90–04–0 |
Karc. xxx. 2; R45 Xxxx. xxx. 3; X40 X; X23/24/25 |
X X: 45–23/24/25 X: 53-45 |
||
|
612–042–00–2 |
xxxxxxxx xxxxxxx-4,4'-xxxxxx 4,4'-diaminobifenyl xxxxxxx-4,4'-xxxxxxxxxx |
X |
202–199–1 |
92–87–5 |
Xxxx. xxx. 1; X45 Xx; X22 X; R50–53 |
T; X X: 45–22–50/53 X: 53–45–60–61 |
X ≥ 25 %: X; X45–22 0,01 % ≤ X &xx; 25 %: X; X45 |
|
|
612–051–00–1 |
4,4'-xxxxxxxxxxxxxxxxxxxx xxx(4-xxxxxxxxxx)xxxxxx 4,4'-xxxxxxxxxxxxxxxx |
X |
202–974–4 |
101–77–9 |
Xxxx. xxx. 2; X45 Muta. xxx. 3; X40 X; R39/23/24/25Xn; X48/20/21/22 X43 N; R51–53 |
T; X X: 45–39/23/24/25–43–48/20/21/22–51/53 X:53–45–61 |
||
|
612–081–00–5 |
3,3'-xxxxxxxxxxxxxxxx, xxxx x-xxxxxxx, xxxx |
X X |
210–322–5 265–294–7 277–985–0 |
612–82–8 64969–36–4 74753–18–7 |
Xxxx. xxx. 2; R45 Xx; R22 X; X51–53 |
X; X X: 45–22–51/53 X: 53–45–61 |
||
|
612–099–00–3 |
4-methyl-m-fenylendiamin4-methyl-1,3-fenylendiamin4-methylbenzen-1,3-diamin 2,4-xxxxxxxxxxxx |
X |
202–453–1 |
95–80–7 |
Xxxx. xxx. 2; X45 T; X25 Xx; X21 Xx; X36 R43 X; X51–53 |
X; N X: 45–21–25–36–43–51/53 S: 53–45–61 |
||
|
612–105–00–4 |
2-(piperazin-1-yl)ethylamin2-(piperazin-1-yl)ethan-1-amin |
205–411–0 |
140–31–8 |
Xn; X21/22 X; R34 X43 X52–53 |
X R: 21/22–34–43–52/53 X: (1/2-)26–36/37/39–45–61 |
|||
|
612–111–00–7 |
2-xxxxxx-x-xxxxxxxxxxxxx2-xxxxxx-1,3-xxxxxxxxxxxxx2-xxxxxxxxxxxx-1,3-xxxxxx 2,6-xxxxxxxxxxxx |
212–513–9 |
823–40–5 |
Xxxx. kat. 3; X40 Xn; X21/22 X43 N; X51–53 |
Xx; X X: 21/22–40–43–51/53 X: (2-)24–36/37–61 |
|||
|
612–125–00–3 |
2-xxxxxx-x-xxxxxxxxxxxxx2-xxxxxx-1,4-xxxxxxxxxxxxx2-xxxxxxxxxxxx-1,4-xxxxxx 2,5-xxxxxxxxxxxx |
202–442–1 |
95–70–5 |
X; X25 Xx; X20/21 X43 X; X51–53 |
X; X R: 20/21–25–43–51/53 X: (1/2-)24–37–45–61 |
|||
|
612–144–00–7 |
xxxxxxxxxxx (XXX) X-(2-xxxxx-6-xxxxxxxxxxx)-X-xxxxx-2,6-xxxxxxx-4-(xxxxxxxxxxxxxx)xxxxxx |
— |
62924–70–3 |
Xx; X36/38 X4 3 X; X50–53 |
Xx; X R: 36/38–43–50/53 X: (2-)36/37–60–61 |
|||
|
612–151–00–5 |
diaminotoluen toluendiamin xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx |
X |
246–910–3 |
25376–45–8 |
Xxxx. xxx. 2; X45 X; X25 Xx; R20/21 Xx; X36 X43 X; X51–53 |
X; X X: 45–20/21–25–36–43–51/53 X: 53–45–61 |
||
|
613–018–00–4 |
xxxxxxxxxx (XXX) 1,1'-bis[(3,5-dimethylmorfolin-4-karbonyl)methyl]-4,4'-bipyridin-1,1'-diium |
— |
7411–47–4 |
Xn; X22 Xx; X36/37/38 X52–53 |
Xx R: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–031–00–5 |
symklosen xxxxxxxxxxxxxxxxxxxx xxxxxxxx trichlor-1,3,5-triazintrion 1,3,5-trichlor-1,3,5-triazin-2(1H), 4(3X), 6(5H)-trion |
201–782–8 |
87–90–1 |
O; R8 Xx; X22 X31 Xx; X36/37 N; X50–53 |
X; Xx; X X: 8–22–31–36/37–50/53 X: (2-)8–26–41–60–61 |
|||
|
613–038–00–3 |
6-xxxxx-1,3,5-xxxxxxx-2,4-xxxxxxxxxx 6-fenyl-1,3,5-triazin-2,4-diamin benzoguanamin |
202–095–6 |
91–76–9 |
Xn; X22 X52–53 |
Xx R:22–52/53 X: (2-)61 |
|||
|
613–042–00–5 |
imazalil (XXX) 1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]- 1 X-xxxxxxxx |
252–615–0 |
35554–44–0 |
Xx; X20/22 N; X41 X; X50–53 |
Xx; X X: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
|
613–043–00–0 |
xxxxxxxx-xxxxxx (XXX) 1-[2-(allyloxy)-2-(2,4-dichlorfenyl)ethyl]- 1X -xxxxxxxx-1-xxx-xxxxxxxxxxxxxx [1] (±)-1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]-1X-xxxxxxxx-1-xxx-xxxxxxxxxxxxxx |
261–351–5 [1] 281–291–3 [2] |
58594–72–2 [1] 83918–57–4 [2] |
Xx; X20/22 Xx; X41 X; R50–53 |
Xn; X R: 20/22–41–50/53 X: (2-)26–39–60–61 |
|||
|
613–066–00–6 |
xxxxxxxxxx (XXX) 2-(xxxx-xxxxxxxxxx)-4-(xxxxxxxxxx)-6-xxxxxxx-1,3,5-xxxxxxx |
251–637–8 |
33693–04–8 |
Xx; X22 X; X50–53 |
Xx; X X: 22–50/53 S: (2-)60-61 |
|||
|
613–091–00–2 |
xxxxxxxxxx-xxxxxxxxx [1] xxxxxxxxxx-xxxxxx [2] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxxx-xxxxxxxxx [1] 1,1'-xxx[(3,5-xxxxxxxxxxxxxxxx-4-xxxxxxxx)xxxxxx]-4,4'-xxxxxxxxx-1,1'-xxxx-xxxxxxxx [2] |
225–062–8 [1] |
4636–83–3 [1] 29873–36–7 [2] |
Xx; X22 Xx; R36/37/38 R52–53 |
Xn; X: 22–36/37/38–52/53 X: (2-)22–36–61 |
|||
|
613–098–00–0 |
1-xxxxxxxxxxxxxxx-2-xx 1-oktyl-2-pyrrolidon |
403–700–8 |
2687–94–7 |
C; X34 X; X51–53 |
X; X X: 34–51/53 X: (1/2-)23–26–36/37/39–45–61 |
|||
|
613–130–00–3 |
xxxxxxxxxxx (ISO) (XX)-2-(2,4-xxxxxxxxxxxx)-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
79983–71–4 |
X43 X; X51–53 |
Xx; N X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–131–00–9 |
xxxxxxxxxx (ISO) 1,2,5,6-xxxxxxxxxx-4 X-xxxxxxx[3,2,1-xx]xxxxxxxx-4-xx |
— |
57369–32–1 |
Xx; X22 R52–53 |
Xn X:22–52/53 X: (2-)61 |
|||
|
613–134–00–5 |
xxxxxxxxxxxx (XXX) 2-(4-xxxxxxxxxx)-2-[(1 X-1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxxxxxxx |
— |
88671–89–0 |
Xxxx. xxx. 3; X63 Xx; R22 Xi; X36 N; X51–53 |
Xx; X X: 22–36–51/53–63 X: (2-)36/37–46–61 |
|||
|
613–137–00–1 |
methabenzthiazuron (XXX) 1-(1,3-xxxxxxxxxxxx-2-xx)-1,3-xxxxxxxxxxxxxxxx |
242–505–0 |
18691–97–9 |
X; X50–53 |
X X: 50/53 S: 60-61 |
|||
|
613–139–00–2 |
xxxxxxxxxxx-xxxxxx xxxxxx-2-{X —[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)xxxxxxxxx]xxxxxxxxx}xxxxxxx |
— |
74223–64–6 |
X; X50–53 |
X X: 50/53 S: 60-61 |
|||
|
614–001–00–4 |
xxxxxxx (XXX) 3-(1-xxxxxxxxxxxxxxxx-2-xx)xxxxxxx |
200–193–3 |
54–11–5 |
X+; X27 T; R25 X; X51–53 |
X+; X X: 25–27–51/53 X: (1/2-)36/37–45–61 |
|||
|
614–006–00–1 |
xxxxxx 2,3-dimethoxystrychnidin-10-on |
206–614–7 |
357–57–3 |
T+; R26/28 X52–53 |
X+ X:26/28–52/53 S: (1/2-)13–45–61 |
|||
|
614–007–00–7 |
xxxxxx-xxxxxx [1] brucin-nitrát [2] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [3] xxxxxx-(X)-(1-xxxxxxxxxxxx)-xxxxxxxx-xxxxxx [4] |
225–432–9 [1] 227–317–9 [2] 269–439–5 [3] 269–710–8 [4] |
4845–99–2 [1] 5786–97–0 [2] 68239–26–9 [3] 68310–42–9 [4] |
X+; X26/28 X52–53 |
X+ X: 26/28–52/53 S: (1/2-)13–45–61 |
|||
|
615–006–00–4 |
2-xxxxxx-x-xxxxxxxxxxxxxxxxxx [1] 2-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [1] 4-methyl-m-fenylendiisokyanát [2] 4-xxxxxx-1,3-xxxxxxxxxxxxxxxxxx [2] x-xxxxxxxxxxxxxxxxxxxx [3] 5-methyl-1,3-fenylendiisokyanát [3] xxxxxx-2,6-xxxxxxxxxxx [1] xxxxxx-2,4-xxxxxxxxxxx [2] xxxxxx-3,5-xxxxxxxxxxx [3] |
C |
202–039–0 [1] 209–544–5 [2] 247–722–4 [3] |
91–08–7 [1] 584–84–9 [2] 26471–62–5 [3] |
Xxxx. kat. 3; X40 X+; X26 Xx; X36/37/38 X42/43 X52–53 |
X+ X: 26–36/37/38–40–42/43–52/53 X: (1/2-)23–36/37–45–61 |
C320 %: X+; X26–36/37/38–40–42/43 7 % ≤ C &xx; 20 %: X+; R26–40–42/43 1 % ≤ C &xx; 7 %: X; X23–40–42/43 0,1 % ≤ X &xx; 1 %:Xx; X20–42 |
2 |
|
616–010–00–9 |
xxxxxxx-xxxxxxxxxxxxxx N-chlor-4-methylbenzen-1-sulfonamid, xxxxx xxx |
204–854–7 |
127–65–1 |
Xx; X22 X31 X; R34 X42 |
X X: 22–31–34–42 X: (1/2-)7–22–26–36/37/39–45 |
|||
|
616–034–00-X |
xxxxxxxxxxxx (ISO) 6-xxxxxx-3,4-xxxxxxx-2X-xxxxx-5-xxxxxxxxxxxx |
246–419–4 |
24691–76–7 |
X52–53 |
X: 52/53 X: 61 |
|||
|
616–035–00–5 |
xxxxxxxxx X -[(xxxxxxxxxx)xxxxxxxx]-2-xxxx-2-(xxxxxxxxxxxx)xxxxxxxx 1-xxxxx-3-[2-xxxx-2-(xxxxxxxxxxxx)xxxxxx]xxxxxxxx |
261–043–0 |
57966–95–7 |
Xx; X22 X43 X; X50–53 |
Xx; X R: 22–43–50/53 X: (2-)36/37–60–61 |
|||
|
617–004–00–9 |
(1,2,3,4-xxxxxxxxxx-1-xxxxxx)xxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxx |
212–230–0 |
771–29–9 |
X; X7 Xx; X22 X; X34 X; R50–53 |
O; C; X X: 7–22–34–50/53 X:(1/2-)3/7–14–26–36/37/39–45–60–61 |
X325 %: C; X22–34 10 % ≤ X < 25 %: C; X34 5 % ≤ C &xx; 10 %: Xi; X36/37/38 |
||
|
617–006–00-X |
xxx(α, α-dimethylbenzyl)peroxid xxx(2-xxxxxxxxxxx-2-xx)xxxxxxx xxx(1-xxxxx-1-xxxxxxxxxxx)xxxxxxx xxxxxxxxxxxxxx |
201–279–3 |
80–43–3 |
X; R7 Xx; X36/38 X; X51–53 |
X; Xx; X X: 7–36/38–51/53 X: (2-)3/7–14–36/37/39–61 |
|||
|
617–008–00–0 |
xxxxxxxxxxxxxxxx |
202–327–6 |
94–36–0 |
X; R2 Xi; X36 X43 |
X; Xx; X: 2–36–43 X: (2-)3/7–14–36/37/39 |
|||
|
650–007–00–3 |
xxxxxxxxxxxxx (ISO) X2-(4-xxxxx-2-xxxxxxxxxxx)-X1,X1-xxxxxxxxxxxxxxxxxxxx X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx |
228–200–5 |
6164–98–3 |
Xxxx. kat. 3; X40 Xx; X21/22 X; R50–53 |
Xn; X X: 21/22–40–50/53 S: (2-)22–36/37–60–61 |
|||
|
650–008–00–9 |
xxxxxxxxxx (ISO) 4-[(2-xxxxxxxxxx)xxxxxxxxx]-3-xxxxxxxxxxxxxx-5(4 X)-xx |
227–197–8 |
5707–69–7 |
X; R25 X; X50–53 |
X; X R: 25–50/53 S: (1/2-)22–24–36/37–45–60–61 |
|||
|
650–009–00–4 |
xxxxxxxxxxxxx-xxxxxxxxxxxx X'-(4-xxxxx-x-xxxxx)-X,X-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx N2-(4-chlor-2-methylfenyl)-N1,N1-dimethylformimidamid-hydrochlorid X2-(4-xxxxx-x-xxxxx)-X1,X1-xxxxxxxxxxxxxxxxxx-xxxxxxxxxxxx |
243–269–1 |
19750–95–9 |
Xxxx. xxx. 3; X40 Xx; R22 N; X50–53 |
Xx; N X: 22–40–50/53 S: (2-)22–36/37–60–61 |
|||
|
650–033–00–5 |
xxxxxxxxxxxx (XXX) [(X)-(3-xxxxxxxxxxx)xxxxxxxxxx]-(X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxxxxx (X)-3-xxxxxx-α-xxxxxxxxxx-(X)-2-(4-xxxxxxxxxx)-3-xxxxxxxxxxxxxx |
— |
66230–04–4 |
X; X23/25 R43 N; X50–53 |
X; X R: 23/25–43–50/53 S: (1/2-)24–36/37/39–45–60–61 |
|||
|
650–041–00–9 |
triasulfuron (XXX) 1-[2-(2-chlorethoxy)benzen-1-sulfonyl]-3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)močovina |
— |
82097–50–5 |
N; R50–53 |
N X: 50/53 X: 60-61 |
XXXXXXX 1X
|
Xxxxxxxx xxxxx |
Xxxxxxxx xxxxx |
Xxxxxxxx k látkám |
Číslo XX |
Xxxxx XXX |
Xxxxxxxxxxx |
Xxxxxxxx |
Xxxxxxxxxxxx xxxxxx |
Xxxxxxxx x xxxxxxxxxx |
|
006–090–00–8 |
2-[(3-xxxxxxx-2-xx-1-xx)xxx]xxxxx-X-xxxxxxxxxxxxx |
408–010–0 |
88558–41–2 |
Xx; R20 Xx; R41 R52–53 |
Xn X: 20–41–52/53 S: (2-)22–26–39–61 |
|||
|
014–016–00–0 |
Xxxx: 1,3-xx(xxx-5-xx-1-xx)- 1,1,3,3-tetramethyldisiloxan x 1,3-xx(xxx-x-xx-1-xx)- 1,1,3,3-xxxxxxxxxxxxxxxxxxxx |
406–490–6 |
— |
X; X51–53 |
X R: 51/53 X: 61 |
|||
|
015–164–00–9 |
kalcium-dihydrogen-(1-hydroxyethylen)bisfosfonát xxxxxxxx |
400–480–5 |
36669–85–9 |
X52–53 |
X:52/53 X: 61 |
|||
|
015–165–00–4 |
Xxxx: X, X, S', X''-xxxxxxxxxx-4,4'-xxxxxxxxxxxxx(xxxxxxxxxxxxxx)-xxx(xxxxxxxxxxxxxxxx) x difenyl[4-(fenylsulfanyl)fenyl]sulfonium-hexafluorofosfát |
404–986–7 |
— |
Xi; X41 X; X50–53 |
Xx; N X: 41–50/53 S: (2-)15–26–39–60–61 |
|||
|
015–166–00-X |
3,9-xxx(2,6-xx-xxxx-xxxxx-4-xxxxxxxxxxxx)-2,4,8,10-xxxxxxxx-3,9-xxxxxxxxxxxx[5.5]xxxxxxx |
410–290–4 |
80693–00–1 |
X53 |
X:53 X: 61 |
|||
|
015–167–00–5 |
3-[xxxxxxx(xxxxx)xxxxxxxxx]xxxxxxxxx xxxxxxxx |
411–200–6 |
14657–64–8 |
Xx; X41 |
Xx R: 41 S: (2-)26-39 |
|||
|
601–050–00–1 |
C10-C13-alkylderiváty xxxxxxx |
267–051–0 |
67774–74–7 |
X; X50 |
X X: 50 X: 61 |
|||
|
601–051–00–7 |
4-xxxxxxxx-1-xx |
405–980–7 |
768–56–9 |
Xx; X38 N; X51–53 |
Xx; X X: 38–51/53 X: (2-)37-61 |
|||
|
602–083–00–4 |
xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx |
251–084–2 |
32534–81–9 |
Xx; X48/21/22 X64 X; X50–53 |
Xx; X X: 48/21/22–50/53–64 S: (1/2-)36/37–45–60–61 |
|||
|
602–084–00-X |
1,1-xxxxxxx-1-xxxxxxxxxx |
404–080–1 |
1717–00–6 |
X; X52–53–59 |
X X: 52/53–59 S: 59-61 |
|||
|
603–128–00–0 |
2-(xxxxxxxxxxxx)xxxxxxxx |
405–490–3 |
613–62–7 |
X53 |
X:53 X: 61 |
|||
|
603–129–00–6 |
1-xxxx-xxxxxxxxxxxx-2-xx |
406–180–0 |
57018–52–7 |
X10 Xx; X41 |
Xx R: 10-41 X: (2-)26-39 |
|||
|
603–130–00–1 |
Xxxx xxxxxxx: α-(xxxxxxxxxxxxxxxxx)-ω-xxxxxxxxxxx(xxxxxxxxxx) |
406–325–8 |
— |
Xx; X22 X52–53 |
Xx X:22–52/53 X: (2-)39-61 |
|||
|
603–131–00–7 |
Xxxx (3:1):1-xxxxx-1-[xxxxxx(1-xxxxxxxxxx)xxxxx]-X-xxxxxxxx; 1-deoxy-1-[methyl(1-oxotetradecyl)amino]-D-glucitol |
407–290–1 |
— |
Xi; R41 |
Xi X: 41 X: (2-)26-39 |
|||
|
603–132–00–2 |
2-(xxxxxxxxxxxxx)-6-xxxxxxxxx-9-xxxxxx-1,4-xxxxxxxxxx[4.5]xxxxx |
408–200–3 |
63187–91–7 |
Xx; X38–41 X52–53 |
Xx X:38–41–52/53 X: (2-)26–37/39–61 |
|||
|
603–133–00–8 |
Směs:3-(4-amino-2-chlor-5-nitroanilino)propan-1,2-diol x 3,3'-[(2-xxxxx-5-xxxxx-1,4-xxxxxxx)xxxxxxx]xx(xxxxxx-1,2-xxxx) |
408–240–1 |
— |
Xx; X22 X52–53 |
Xx R:22–52/53 X: (2-)22–36–61 |
|||
|
603–134–00–3 |
Xxxx: xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxx x xxxxx(X1-X10)-xxxxxxxxxxxxxxxxxxxxxxx (dodecyl x xxxxxxxxxx xxxxxxxxxxxx) |
410–450–3 |
— |
X53 |
X: 53 X: 61 |
|||
|
603–135–00–9 |
xxx[2-(2-xxxxxxxxxxxxx)xxxxxxxxxx]xxx(2,2', 2-xxxxxxxxxxxxxxx-1-xxxxx-X,X)xxxxxxxxxx xxxxxxx |
410–500–4 |
— |
Xx; X41 N; X51–53 |
Xx; X R: 41–51/53 S: (2-)26–39–61 |
|||
|
603–136–00–4 |
3-{4-[xxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxxx}xxxxxx-1-xx |
410–910–3 |
104226–19–9 |
X43 X52–53 |
Xx X:43–52/53 X: (2-)24–37–61 |
|||
|
603–137–00-X |
Xxxx:1-xxxxx-1-[xxxxxx(1-xxxxxxxxxxxx)xxxxx]-X-xxxxxxxx x 1-deoxy-1-[methyl(1-oxooktadecyl)amino]-D-glucitol |
411–130–6 |
— |
Xi; X41 |
Xx X: 41 X: (2-)26-39 |
|||
|
603–138–00–5 |
3-(2,2-dimethyl-3-hydroxypropyl)toluen 2,2-xxxxxxxx-3-(3-xxxxxxxxxxx)xxxxxx-1-xx |
403–140–4 |
103694–68–4 |
X52–53 |
X:52/53 X: 61 |
|||
|
604–050–00-X |
4-xxxxx-x-xxxxxx 4-xxxxx-2-xxxxxxxxxxx |
216–381–3 |
1570–64–5 |
X; X23 C; X 35 X; R50 |
T; X; X X: 23–35–50 X: (1/2-)26–36/37/39–45–61 |
C ≥ 25 %: X; C; R23–35 10 % ≤ X < 25 %: C;R20–35 5 % ≤ X &xx; 10 %: X;X20–34 3 % ≤ X &xx; 5 %: Xx;X20–36/37/38 1 % ≤ X < 3 %:Xx;X36/37/38 |
||
|
604–051–00–5 |
3,5-xxx(3,5-xx-xxxx-xxxxx-4-xxxxxxxxxxxxx)-2,4,6-xxxxxxxxxxxxxx |
401–110–5 |
87113–78–8 |
X52–53 |
X:52/53 S: 61 |
|||
|
604–052–00–0 |
2,2'-methylenbis[6-(2 X - xxxxxxxxxxxx-2-xx)-4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx] 6,6'-xxx(2X -benzotriazol-2-yl)- 4,4'-xxx(1,1,3,3-xxxxxxxxxxxxxxxx)- 2,2'-xxxxxxxxxxxxxxx |
403–800–1 |
103597–45–1 |
X53 |
X:53 S: 61 |
|||
|
604–053–00–6 |
4-xxxx - xxxxx-2-xxxxxx-6-(1-xxxxxxxxxxxxxxxx)xxxxx |
410–760–9 |
157661–93–3 |
Xx; X38 X43 N; R50–53 |
Xi; X X: 38–43–50/53 X: (2-)24–37–60–61 |
|||
|
604–054–00–1 |
Xxxx:2-xxxxxxx-4-(4-xxxxxxxxxxxxxxxxxxxxxxxxx-2-xx)xxxxx a 2-xxxxxxx-4-(4-xxxxxx-3,6-xxxxxxx-2X -xxxxx-2-xx)xxxxx |
412–020–0 |
— |
X43 X52–53 |
Xx X:43–52/53 S: (2-)24–37–61 |
|||
|
604–055–00–7 |
4,4'-bis[(2,3-epoxypropyl)oxy]-3,3', 5,5'-xxxxxxxxxxxxxxxxxx |
413–900–7 |
85954–11–6 |
Xxxx. Xxx.3; R40 |
Xn X: 40 S: (2-)22–36–37 |
|||
|
605–027–00–7 |
Xxxx:3x, 4,5,6,7,7x-xxxxxxxxx-4,7-xxxxxxx-1X-xxxxx-6-xxxxxxxxxxx x 3x, 4,5,6,7,7a-hexahydro-4,7-methano-1H - xxxxx-5-xxxxxxxxxxx |
410–480–7 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
606–051–00–0 |
4-xxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxx-1-xx |
4–406–670–4 |
61203–83–6 |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
606–052–00–6 |
4-(X, X-xxxxxxxxxxxx)-2-xxxxxxx-2'-xxxxxxxxxxxxxxxxx 2-[4-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx kyselina |
410–410–5 |
54574–82–2 |
R52–53 |
R:52/53 S: 61 |
|||
|
607–272–00–5 |
xxxxxxxxxxx-xxxxxx (XXX) [1] xxxxxxxxxx-xxxxxxxxx (XXX) [2] xxxxxxxxxxxx-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [1] (2-xxxxxx-1-xxxxxxxxxxx)-[(4-xxxxx-3,5-xxxxxxx-6-xxxxx-2-xxxxxxx)xxx]xxxxxx [2] |
279–752–9 [1] — |
81406–37–3 [1] 154486–27–8 [2] |
X; X50–53 |
X R: 50/53 X: 60-61 |
|||
|
607–273–00–0 |
amonium-7-{2,6-dimethyl-8-[(2,2-dimethylbutanoyl)oxy]- 1,2,6,7,8,8x-xxxxxxxxx-1-xxxxxx}-3,5-xxxxxxxxxxxxxxxxxx |
404–520–2 |
— |
X52–53 |
X:52/53 X: 61 |
|||
|
607–274–00–6 |
{2-[benzyl(methyl)amino]ethyl}-3-aminobut-2-enoát |
405–350–1 |
54527–73–0 |
R43 N; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–275–00–1 |
xxxxxxx-4-(xxxxxxxxxx)xxxxxx-1-xxxxxxxx |
405–450–5 |
66531–87–1 |
X43 |
Xx X: 43 X: (2-)24-37 |
|||
|
607–276–00–7 |
[xxx(2-xxxxxxxxxxxxxx) xxx(1-xxxxxxxxxxxxxx)]xxxxxxxxx xxxxxxx |
405–635–0 |
— |
Xx; X38–41 X; X50–53 |
Xx; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–277–00–2 |
Xxxx:2-(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxxxxxxxx x xxxxxxx-xxxxxxxxx |
405–720–2 |
— |
Xx; R22 Xx; X41 R43 N; X51–53 |
Xx; X R: 22–41–43–51/53 S: (2-)24–26–37/39–61 |
|||
|
607–278–00–8 |
Směs:alkyl(C7-C9 xxxxxxxxxx x xxxxxxxxxxxx)-3-[3-(2 X - benzotriazol-2-yl)-5-terc-butyl-4-hydroxyfenyl]propanoáty |
405–760–0 |
— |
Xi; X41 X43 X52–53 |
Xx X: 41–43–52/53 S: (2-)24–26–37/39–61 |
|||
|
607–279–00–3 |
Xxxx:(xxxxxxxxxxxxxx)xxxxxxxxx-xxx(xxxxxxxx-xxxxxxxx) x (xxxxxxxxxxxxxx)xxxxxxxxx-(xxxxxxxx-xxxxxx)-(xxxxxxxx-xxxxxxxx) |
405–960–8 |
— |
X43 X; R51–53 |
Xi; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–280–00–9 |
4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx xxxxx xxxxxxx-4-xxxxx-1-xxxxxxxxxxxx-1-xxxxxxxx |
406–190–5 |
54322–20–2 |
Xx; X22 Xx; R36 X43 |
Xx R: 22–36–43 X: (2-)22–26–36/37 |
|||
|
607–281–00–4 |
Xxxx:xxxxx(X7-X9 rozvětvené x xxxxxxxx)-3-[3-(2X-xxxxxxxxxxxx-2-xx)-5-xxxx-xxxxx-4-xxxxxxxxxxxx]xxxxxxxxxx |
407–000–3 |
127519–17–9 |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
607–282–00-X |
2-(xxxxxxxxxxxxx)-4-(xxxxxxxxx)xxxxx-xxxxxx |
407–140–5 |
131266–10–9 |
X52–53 |
X: 52/53 S: 61 |
|||
|
607–283–00–5 |
xxxxx-(X)-4-xxxxx-4-xxxxxx-2-xxxxxxxxxx-(X)-4-xxxxx-4-xxxxxxxxxxx |
408–040–4 |
15121–89–8 |
Xx; X21/22 Xi; X38–41 X43 X; X50–53 |
Xx; N R: 21/22–38–41–43–50/53 X: (2-)26–36/37/39–60–61 |
|||
|
607–284–00–0 |
Směs (9:1):xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) a xxxxxxx-3,3'-{(1,4-xxxxxxx)xxx[(xxxxxxxxxxxxx)(xxxxxx-3,1-xxxx)xxxxx]}xxx(10-xxxxx-6,13-xxxxxxx[1,4]xxxxxxxxxxx[2,3-x]xxxxxxxxx-4,11-xxxxxxxxxx) |
410–040–4 |
136213–76–8 |
X; X51–53 |
X R: 51/53 X: 61 |
|||
|
607–285–00–6 |
Směs:7-(3-aminobenzensulfonamido)naftalen-1,3-disulfonová xxxxxxxx, xxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx x xxxxxxx-7-(3-xxxxxxxxxxxxxxxxxxxxxx)xxxxxxxx-1,3-xxxxxxxxxx |
410–065–0 |
— |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
|
607–286–00–1 |
Xxxx:xxxxxx- x natrium-7-[4-({4-[(2-hydroxy-1-naftyl)azo]fenyl}azo)benzensulfonamido]naftalen-1,3-disulfonát |
410–070–8 |
141880–36–6 |
R43 X52–53 |
Xx R:43–52/53 S: (2-)22–24–37–61 |
|||
|
607–287–00–7 |
xxxxxx-[1-xxxxxx-2-(xxxxxxxxxxxxxxx)xxxxx]-1,2,3,6-xxxxxxxxxxxxxxxx |
410–140–8 |
— |
X52–53 |
X:52/53 X: 61 |
|||
|
607–288–00–2 |
[x-(X -{3-[(1-{3-[(2,6(4,6)-xxxxxxx-5-xxxxxxxxxxxxx-4(2)-xx)xxxxxxxxxxx]xxxxxx}-2-xxxxxxx-4-xxxxxx-6-xxx-1,6-xxxxxxx-3-xxxxxxx)xxx]-4-xxxxxxxxxxxxxx}xxxxxxxxx)-x,x,x -xxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxxx komplex, xxxxxxxxxx xxx; x = 15, 16, 17 xxxx 18, x = 1, 2, 3 nebo 4, b = 8, 9, 10 xxxx 11, d = 22, 23, 24 xxxx 25 |
410–160–7 |
148732–74–5 |
Xx; X36 X43 X52–53 |
Xx X: 36–43–52/53 X: (2-)22–26–36/37–61 |
|||
|
607–288–00–8 |
3-[(3-{X —[4-(2,4-xx-xxxx-xxxxxxxxxxxx)xxxxx]xxxxxxxxx}-4-xxxxxxx-1-xxxxxx)xxxxxxxx]xxxxxxxxx xxxxxxxx |
410–370–9 |
105488–33–3 |
X53 |
X:53 X: 61 |
|||
|
607–290–00–3 |
Xxxx (o xxxxxxxx poměru):amonium-1-alkyl(C14-C18)-4-[3-(allyloxy)-2-hydroxypropyl]-2-sulfonatobutandioát x xxxxxxx-4-xxxxx(X14-X18)-1-[3-(xxxxxxxx)-2-xxxxxxxxxxxxx]-2-xxxxxxxxxxxxxxxxxxx |
410–540–2 |
— |
Xx; X38 X43 X; X50–53 |
Xx; X X: 38–43–50/53 X: (2-)24–37–60–61 |
|||
|
607–291–00–9 |
xxxxxxx-ω-xxxxxxxxxxx(xxxx xxxxxxxxxx)xxxxxxxx |
410–630–1 |
104051–92–5 |
X53 |
X: 53 X: 61 |
|||
|
607–292–00–4 |
Xxxx:[2-(xxxxx(X12)xxx)-1-(xxxxxxxxxxxxx)xxxxxx]xxxxxx kyselina x [2-(xxxxx(X14)xxx)-1-(xxxxxxxxxxxxx)]xxxxxx xxxxxxxx |
410–640–6 |
— |
Xx; X38–41 N; R50–53 |
Xi; X X: 38–41–50/53 X: (2-)26–37/39–60–61 |
|||
|
607–293–00-XSměs: |
1-(2-aminoethyl)piperazin-1,4-diium-[(2,4,6-trimethylnonyl)fenoxy]benzendisulfonát x 1-(2-xxxxxxxxxx)xxxxxxxxx-1,4-xxxxx-[xxx(2,4,6-xxxxxxxxxxxxxx)xxxxxx]xxxxxxxxxxxxxxxx |
410–650–0 |
— |
Xx; X41 X43 X; R51–53 |
Xi; X X: 41–43–51/53 X: (2-)26–36/37/39–61 |
|||
|
607–294–00–5 |
xxxxxxx-2-(xxxxxxxxxx)-1-xxxxxxxxxxxx-1-xxxxxxxx |
410–680–4 |
— |
X43 |
Xx X: 43 X: (2-)24-37 |
|||
|
607–295–00–0 |
Xxxx:xxxxxxxxxxxx-xxxxxxxxxxxxxxxxx a xxxxxxxxxxx-xxxxxxxxxxxx-1,2,3,4-xxxxxxxxxxxxxxx |
410–800–5 |
— |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
607–296–00–6 |
Xxxx:xxxxxxxxxxx xxxxxxxxxxxxxxxx, xxxxxxxxx xxxxxxxx x 2-xxxxxxxxxxxxx xxxxxxxx |
410–830–9 |
— |
X53 |
X: 53 X: 61 |
|||
|
607–297–00–1 |
3,3'-(1,4-xxxxxxxxxxxxxxxxxxx)xxx(2-xxxxxxxxx-10-xxxxxxxxx xxxxxxxx)2,2'-xxxxx-3,3'-(1,4-xxxxxxxxxxxxxxxxxxx)xxx(1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxxxx-1-xxxxxxxxxxxxxxx xxxxxxxx) |
410–960–6 |
92761–26–7 |
Xx; X41 |
Xx X: 41 X: (2-)26-39 |
|||
|
607–298–00–7 |
[2-(xxxxxxxxxxxxxxx)xxxxx]-4-xxxxxxxxxxxxxxxx |
411–010–3 |
— |
X43 |
Xx X: 43 X: (2-)22–36/37 |
|||
|
607–299–00–2 |
xxxxxx-3-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxxxxx |
411–040–7 |
97101–46–7 |
Xx; X22 X43 X; X50–53 |
Xx; N X: 22–43–50/53 X: (2-)24–37–60–61 |
|||
|
607–300–00–6 |
[x-(X-{4-[(5-xxxxx-2,6-xxxxxxxxxxxxxxxx-4-xx)xxxxx]-3-xxxxxxxxxxxxxxxx}xxxxxxxxx)-x-xxxxxxxxx-x, x-xxxxxxxxxxxxxxxxxxxx]xxxxxxx komplex, xxxxxxxx xxx; x = 1,2,3 xxxx 4, x = 8, 9, 10 xxxx 11, x = 15, 16, 17 xxxx 18, x = 22, 23, 24 nebo 25 |
411–430–7 |
— |
X43 |
Xx X: 43 X: (2-)22–24–37 |
|||
|
607–301–00–1 |
Xxxx:xxxxxxxxxx kyselina x dodekanoáty xxxxx(1-7)xxxxxxx |
411–860–5 |
— |
Xx; X38–41 R43 X; X51–53 |
Xx; N X: 38–41–43–51/53 X: (2-)24–26–37/39–61 |
|||
|
607–302–00–7 |
Xxxx:xxxxxxxxxxxxx xxxxxxxx x xxxxxxxxxxxxxx xxxxx(1-7)xxxxxxx |
411–910–6 |
— |
Xx; X38–41 X43 X; X51–53 |
Xx; X X: 38–41–43–51/53 S: (2-)24–26–37/39–61 |
|||
|
607–303–00–2 |
1-xxxxxxxxxxx-6,7-xxxxxxx-4-xxx-1,4-xxxxxxxxxxxxxxx-3-xxxxxxxxxxx xxxxxxxx |
413–760–7 |
93107–30–3 |
Xxxx. kat.3; X62 X52–53 |
Xx X: 62–52/53 S: (2-)22–36/37–61 |
|||
|
608–023–00–3 |
4-(4-xxxxxxxxxx)-2-xxxxx-2-[(1X- 1,2,4-xxxxxxx-1-xx)xxxxxx]xxxxxxxxxxx |
406–140–2 |
114369–43–6 |
X; R50–53 |
N R: 50/53 X: 60-61 |
|||
|
608–024–00–9 |
2-{4-[butyl(fenethyl)amino]fenyl}ethen-1,1,2-trikarbonitril |
407–650–8 |
97460–76–9 |
R53 |
R:53 X: 61 |
|||
|
608–025–00–4 |
[2-xxxxx-4,5-xxx(xxxxxxxxx)xxxxx]xxxxxxxxxxx |
410–970–0 |
117568–27–1 |
X53 |
X:53 X: 61 |
|||
|
609–053–00-X |
xxxxxxxxxxx-xxxxxxxxxxxxxxxx |
414–850–9 |
— |
X; R3 O; X8 Xxxx. kat. 2; X45 X; X23/25 R43 |
E; X X: 45–3–8–23/25–43 X: 53-45 |
|||
|
610–010–00–2 |
1-xxxx-2-(2-xxxxx)-1-xxxxxxxxxx |
406–110–9 |
35950–52–8 |
Xx; R22–48/22 C; X34 X43 N; X50–53 |
X; N R: 22–34–43–48/22–50/53 S: (1/2-)22–26–36/37/39–45–60–61 |
|||
|
611–043–00–5 |
Xxxx (2:1:1):[xxx(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx trisodný, [xxx{6-[(2-xxxxx-4-xxxxxxxxxxxx)xxx]- xxxx 6-[(2-amino-6-hydroxyfenyl)azo]- xxxx 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}]xxxxxxxxx xxxxxxxx a[{6-[(2-amino-4-hydroxyfenyl)azo]- xxxx 6-[(2-xxxxx-6-xxxxxxxxxxxx)xxx]- nebo 6-[(4-xxxxx-2-xxxxxxxxxxxx)xxx]-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx}(6-{[1-(X-xxxxxxxxxxxxxx)-2-xxxxxxxxxxx-1-xx-1-xx]xxx}-5-xxxxxxxxx-3-xxxxxxxxxxxxxxxxx-2-xxx-1'-xxxxxx-1,2'-xxxxxxx)]xxxxxxxxx xxxxxxxx |
402–850–1 |
Xx R: 41–52/53 S: (2-)26–39–61 |
|||||
|
611–044–00–0 |
Xxxx:[xxx(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx, [xxx(4-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx terc-alkyl(C12-C14)amonný, [xxx(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx terc-alkyl(C12-C14)amonný, [(5-xxxx-xxxxx-3-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)(5-xxxxxxxxxxx-1-xxx-1'-xxxxxxxx-2,2'-xxxxxxx)]xxxxxxxxx xxxx-xxxxx(X12-X14)xxxxxx a[(4(5)-nitrobenzen-1-azo-1'-naftalen-2,2'-diolato) (3-nitro-5-pentylbenzen-1-azo-1'-naftalen-2,2'-diolato)]chromitan xxxx-xxxxx(X12-X14)xxxxxx |
403–720–7 |
117527–94–3 |
X; X51–53 |
Xx; X41 X52–53 |
|||
|
611–045–00–6 |
2-({4-[(4-xxxxxxxxxxxx)xxxxxxxxxx]-2-xxxxxxxxxxx}xxx)-3-xxxxxx-5-xxxxxxxxxxxx |
404–830–8 |
— |
X53 |
X:53 X: 61 |
X X: 51/53 S: 61 |
||
|
611–046–00–1 |
4,4'-xxxxxxx-2-xxxxxxxxxxxxxxx2-xxxxxxxxxxxxxxx-4,4'-xxxxxx |
407–590–2 |
43151–99–1 |
X; X25 Xx; X48/22 X43 X; X50–53 |
X; N R: 25–43–48/22–50/53 X: (1/2-)22–28–36/37–45–60–61 |
|||
|
611–047–00–7 |
Xxxx (1:1):2-({4-[(2-xxxxxxxxxxxx)xxxxxxxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx a 2-({4-[(2-acetoxyethyl)ethylamino]fenyl}azo)-6,7-dichlorbenzothiazol |
407–890–3 |
111381–11–4 |
R53 |
R: 53 S: 61 |
|||
|
611–048–00–2 |
Směs (1:1):2-({4-[xxx(2-xxxxxxxxxxxx)xxxxx]xxxxx}xxx)-5,6-xxxxxxxxxxxxxxxxxxx x 2-({4-[xxx(2-xxxxxxxxxxxx)xxxxx]xxxxx}xxx)-6,7-xxxxxxxxxxxxxxxxxxx |
407–900–6 |
111381–12–5 |
X53 |
X: 53 S: 61 |
|||
|
611–049–00–8 |
Xxxx (2:1:1)7-[(4-{[3-(xxxxxxxxxxxx)xxxxxx]xxxxx}-6-{[3-(xxxxxxxxxxxxx)xxxxxx]xxxxx}-1,3,5-xxxxxxx-2-xx)xxxxx]-3-{[4-(xxxxxxxx)xxxxx]xxx}-4-xxxxxxxxxxxxxxx-2-xxxxxxxx, xxxxxxxx xxxxxx x xxxxxx kyselina (2:1:1) |
408–000–6 |
118658–98–3 |
Xx; R48/22 R43 X52–53 |
Xx X: 43–48/22–52/53 X: (2-(22–36/37–61 |
|||
|
611–051–00–9 |
2-({4-[xxxxx(2-xxxxxxxxxxxx)xxxxx]-2-xxxxxxxxxxx}xxx)-6-xxxxxxx-3-xxxxxxxxxxxxxxxxxxxxx-xxxxxxx |
411–110–7 |
136213–74–6 |
X; X50–53 |
X X: 50/53 X: 60-61 |
|||
|
611–052–00–4 |
[xxxx{4-[(2-xxxxxxx-3,5-xxxxxxxxxxxx) azo]-6-[(6-sulfonato-1-naftyl)azo]benzen-1,3-diolato}]železnatý xxxxxxx, xxxxx sůl |
400–720–9 |
— |
R52–53 |
R: 52/53 X: 61 |
|||
|
612–156–00–2 |
Xxxx:xxxxxxxxxxxx(xxxxxx)xxxxxxx-xxxxxxx x xxxxxxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx |
405–620–9 |
— |
Xx; X41 X; X50–53 |
Xx; X X: 41–50/53 S: (2-)26–39–60–61 |
|||
|
612–157–00–8 |
(Z)-1-(1-benzothiofen-2-yl)ethan-1-on-oxim-hydrochlorid |
410–780–8 |
— |
Xn; X22–48/22 Xx; X41 X43 N; X51–53 |
Xx; X R: 22–41–43–48/22–51/53 X: (2-)22–26–36/37/39–61 |
|||
|
612–158–00–3 |
Směs:[bis(5-alkyl(rozvětvený X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx x 4-xxxxxxx-2-xxxxxxxxxxxxxxxxxx[xxx(5-xxxxx(xxxxxxxxxx X12))-2-xxxxxxxxxxxxxxxxxxxxx)]xxxxxxx xxxxxxx x 4-xxxxxxxxxxxxxxxxxxxxx |
410–820–4 |
— |
X53 |
X: 53 X: 61 |
|||
|
612–159–00–9 |
xxxxxxx xxxxxxxx xxxxx 2,2,4-xxxxxxxxx- x 2,4,4-trimethylhexan-1,6-diaminu (x xxxxxxx XXXXXX), xxxxxxxx [(xxxxx(X10-X16)xxx)xxxxxx]xxxxxxx (Epoxid 8) a 4-methylbenzen-1-sulfonové xxxxxxxx |
410–880–1 |
— |
Xx; X22 C; X34 X; X50–53 |
X; X X: 22–34–50/53 X: (1/2-)23–26–36/37/39–45–60–61 |
|||
|
613–149–00–7 |
2-terc-butyl-5-[(4-terc-butylbenzyl)sulfanyl]-4-chlorpyridazin-3(2H)-on |
405–700–3 |
96489–71–3 |
T; R23/25 X; R50–53 |
T; X X: 23/25–50/53 X: (1/2-)36/37–45–60–61 |
|||
|
613–150–00–2 |
2,2'-[xxxxxxxxx-1,4-xxxxxx(xxxxxx-1,3-xxxx)]xxx(xxxxxxxxxxx[2,1-x]xxxxx[xxx][3,8]xxxxxxxxxxxx-1,3,6-xxxxx) |
406–295–6 |
— |
X53 |
X:53 X: 61 |
|||
|
613–151–00–8 |
1-(2-xxxxx-3-X-xxxxx-5-X-xxxxxx-β-X-xxxxx-xxxxxxxxxxxxxx)-5-xxxxxxxxxxxxxxx-2(1X), 4(3 X)-xxxx |
406–360–9 |
104218–44–2 |
X53 |
X:53 S: 61 |
|||
|
613–152–00–3 |
xxxxx-X-(4,6-xxxxxxxxxxxxxxxxxx-2-xx)xxxxxxxx |
406–600–2 |
89392–03–0 |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–153–00–9 |
2,3,5-trichlorpyridin |
407–270–2 |
16063–70–0 |
R52–53 |
R:52/53 X: 61 |
|||
|
613–154–00–4 |
2-xxxxx-4-xxxxx-6-xxxxxxxxxxxxxxxx |
410–050–9 |
5734–64–5 |
Xx; X22 |
Xx R: 22 X: (2-)22 |
|||
|
613–155–00-X |
5-chlor-2,3-difluorpyridin |
410–090–7 |
89402–43–7 |
R10 Xx; R22 R52–53 |
Xn X: 10–22–52/53 X: (2-)23–36–61 |
|||
|
613–156–00–5 |
2-xxxxx-4-xxxxx-5-xxxxxxxxxxxxxx 2-xxxxx-5-xxxxxxxxxxxxx-4-xxxxxxxxxxx |
410–260–0 |
83857–96–9 |
X43 X; X51–53 |
Xx; X X: 43–51/53 X: (2-)24–37–61 |
|||
|
613–157–00–0 |
2,4-xxxxxxx-5-(xxxxxxxxxxxxx)xxxxxxxxx 5-(xxxxxxxxxxxxx)xxxxxxxxx-2,4-xxxxxx |
410–330–0 |
54236–98–5 |
Xx; X22–48/22 Xx; X36 |
Xx X: 22–36–48/22 X: (2-)22–26–36 |
|||
|
613–158–00–6 |
2,3-xxxxxxx-5-(xxxxxxxxxxxxxx)xxxxxxx |
410–340–5 |
69045–84–7 |
Xx; X20/22 Xx; X41 X43 X; X51–53 |
Xx; N X: 20/22–41–43–51/53 S: (2-)24–26–37/39–61 |
|||
|
613–159–00–1 |
4-[2-(4-xxxx-xxxxxxxxxx)xxxxxx]xxxxxxxxxx |
410–580–0 |
120928–09–8 |
X; X25 Xn; X20 X; X50–53 |
X; X R: 20–25–50/53 X: (1/2-)37–45–60–61 |
|||
|
613–160–00–7 |
2-methyl-2,5-diazabicyklo[2.2.1]heptan-dihydrobromid |
411–000–9 |
125224–62–6 |
R43 |
Xi X: 43 S: (2-)24-37 |
|||
|
615–022–00–1 |
xxxxxx-3-(xxxxxxxxxxxxxxxxxx)xxxxxxx-2-xxxxxxxxxx |
410–550–7 |
79277–18–2 |
X; X2 R14 Xn; X48/22 X42/43 |
X; Xx X: 2–14–42/43–48/22 X: (2-)22–30–35–36/37 |
|||
|
615–023–00–7 |
xxxxxxxxxxx 2-[(isokyanatosulfonyl)methyl]benzoové kyselinymethyl-2-[(isokyanatosulfonyl)methyl]benzoát |
410–900–9 |
83056–32–0 |
R10 X14 Muta. xxx. 3; X40 Xn; X20–48/22 Xx; X41 X42 |
Xx X: 10–14–20–40–41–42–48/22 X: (2-)23–26–36/37/39 |
|||
|
616–044–00–4 |
X-(3,5-xxxxxxx-4-xxxxx-2-xxxxxxxxxxxx)-2-(3-xxxxxxxxxxxxxxxx)xxxxxxxxx |
402–510–2 |
— |
X; X51–53 |
X X: 51/53 X: 61 |
|||
|
616–045–00-X |
2'-[(4-xxxxx-5-xxxxxx-3-xxxx-2-xxxxxxx)xxx]- 5'-(xxxxxxxxxxxx)-2-xxxxxxxxxxxxxxxxx |
405–190–2 |
122371–93–1 |
X43 R53 |
Xi X: 43-53 X: (2-)22–24–37–61 |
|||
|
616–046–00–5 |
X -[2-(6-chlor-7-methylpyrazolo[1,5-b][1,2,4]triazol-4-yl)propyl]-2-(2,4-di-terc-pentylfenoxy)oktanamid |
406–390–2 |
— |
N; R50–53 |
N X: 50/53 X: 60-61 |
|||
|
616–047–00–0 |
Xxxx:X,X′,X″,X′′′ - xxxxxxxxxx(X16)-2,2′, 2″, 2′′′ (xxxxxxxxxxxxxxxx)xxxxxxxxxxxxx x X, X′,X″,X′′′ - tetraalkyl(C18)- 2,2′, 2′′, 2′′′-(xxxxxxxxxxxxxxxx)xxxxxxxxxxxxx |
406–640–0 |
— |
X43 |
Xx R: 43 S: (2-)24-37 |
|||
|
616–048–00–6 |
3'-(xxxxxxxxxxxxxx)xxxxxxxxxxxxxx |
406–740–4 |
1939–27–1 |
Xx; X48/22 N; R51–53 |
Xn; X X: 48/22–51/53 X: (2-)22–36–61 |
|||
|
616–049–00–1 |
2-(2,4-xx-xxxx-xxxxxxxxxxx)-X-(3,5-xxxxxxx-4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxx |
408–150–2 |
99141–89–6 |
X53 |
X:53 X: 61 |
|||
|
616–050–00–7 |
1-[2,5-xxxxxxx-4-(1,1,2,3,3,3-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxx)xxxxxxxx |
410–690–9 |
103055–07–8 |
X43 X; R50–53 |
Xi; X X: 43–50/53 X: (2-)24–37–60–61 |
|||
|
616–051–00–2 |
Xxxx:3,3'-xxx(4-xxxxxxxxxxx)- 1,1'-(4-xxxxxx-1,3-xxxxxxx)xxxxxxxxxx x 3,3'-bis(4-methylfenyl)-1,1'-(2-methyl-1,3-fenylen)dimočovina Xxxx:2,4-xxx[3-(4-xxxxxxxxxxx)xxxxxx]xxxxxx x 2,6-xxx[(3-(4-xxxxxxxxxxx)xxxxxx]xxxxxx |
411–070–0 |
— |
X53 |
X: 53 X: 61 |
|||
|
617–015–00–9 |
xxx(4-xxxxxxxxxxxxx)xxxxxxx |
407–950–9 |
895–85–2 |
X; X2 X; X7 N; X50–53 |
X; N X: 2–7–50/53 X: (2-)7–14–36/37/39–47–60–61 |
|||
|
650–032–00-X |
cyprokonazol (XXX) (2X, 3X)-, (2 S, 3 X)-, (2 R, 3 X)-, (2 X, 3 R)-2-(4-chlorfenyl)-3-cyklopropyl-1-(1H- 1,2,4-xxxxxxx-1-xx)xxxxx-2-xx |
— |
94361–06–5 |
Xxxx. xxx. 3; X63 Xx; X22 X; X50–53 |
Xx; X X: 22–50/53–63 X: (2-)36/37–60–61 |
PŘÍLOHA 2
XXXXXX SPECIFICKÝCH XXXXX SPOJENÝCH X XXXXXXXXXXXX LÁTKAMI A XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX,
Xx. xxxx. X 332, 28.12.2000, x. 81.
PŘÍLOHA 3X
XXXXXXXXXX XXXXXX XXX XXXXXXXX ZACHÁZENÍ X XXXXXXXXXXXX XXXXXXX X XXXXXXXXX
Xxx směrnice Xxxxxx 2001/59/ES,
Úř. věst. X 332, 28.12.2000, x. 81.
PŘÍLOHA 3B
STANDARDNÍ POKYNY XXX BEZPEČNÉ XXXXXXXXX X XXXXXXXXXXXX XXXXXXX X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/ES,
Úř. xxxx. X 332, 28.12.2000, x. 81.
XXXXXXX 4X
"X.10 XXXXXXXXXX — XXXXXXX XX XXXXXXXXXXXX ABERACE X XXXXX XX VITRO
1. XXXXXX
Xxxx xxxxxx xx xxxxxxxx metody XXXX XX 473 — Xxxxxxx xx xxxxxxxxxxxx xxxxxxx u xxxxx xx xxxxx (1997).
1.1 XXXX
Xxxxxxx xx xxxxxxxxxxxx xxxxxxx u xxxxx xx vitro xx xxxxxxxxxxxxx xxxxxxxx, které xxxxxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx v kultivovaných xxxxxxx xxxxx (1, 2, 3). Xxxxxxxxx xx dva xxxx xxxxxxxxxxxx xxxxxxx: xxxxxxxxxxxx x chromatidové. X xxxxxxx chemických xxxxxxxx xxxx indukované xxxxxxx xxxxxxxxxxxxxx xxxx, xxxxx xxxxxxxxxxxx xxxxxxx xx xxxxxx xxxxxxxxx. Xxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xx chemická xxxxx xx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxx. Xxxx xxxxxx však xxxx xxxxxx ke xxxxxxxxx xxxxxxxxxxx xxxxxxx x xxxx x xxxxxx xxxxx rutinně používána. Xxxxxxxxxxxx mutace x xxxxxxx jevy xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx x xxxxxxx a xxxxxxxx xxxxx xxxxxx x xxx, že xxxxxxxxxxxx xxxxxx a x xxxx související jevy xxxxxxxxxxx xxxxx x xxxxxxxxxx a x xxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxxx, mají xxxxx xx xxxxxxx xxxxxxxx x xxxxxxx x x xxxxxxxxx xxxxxx.
Xx xxxxxxx xx xxxxxxxxxxxx xxxxxxx in xxxxx xxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxx xxxxx, xxxxxxx xxxxx xxxx primární xxxxxxx xxxxxxx. Xxxxxxx xxxxx xxxx xxxxxxx na xxxxxxx xxxxxxxxxx růstu x xxxxxxx, xxxxxxxx xxxxxxxxx, počtu chromozomů, xxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx chromozomových xxxxxxx.
Xxxxxxx prováděné in xxxxx obecně xxxxxxxx xxxxxxx xxxxxxxx xxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxxxx xxxxxxxxx systém xxxxxx xxxxx xxxxxxxxx xxxxxxxx xx xxxx x xxxxx. Xx xxxxx xx zcela xxxxxxxxx xxxxxxxx, které xx xxxxx k xxxxxxxxxx xxxxxxxxx, xxx xxxxxxxxxx xxxxxxx xxxxxxxxxx x může x xxx xxxxx xxxxxx xX, xxxxxxxxxx nebo xxxxxxxx úrovní cytotoxicity (4, 5).
Xxxx zkouška xx xxxxxxx xx xxxxxxxx možných mutagenů x xxxxxxxxxxx xxx xxxxx. Xxxxx sloučenin, xxx něž xx xxxx xxxxxxx xxxxxxxxx, xxxx pro savce xxxxxxxxxxx; xxxx xxxxx xxxxxxxx a karcinogenitou xxxx není xxxxxxxxx xxxxxxxx. Korelace xxxxxx xx xxxxxxxx xxxxx x xxxxxxxxx xxxxxx x tom, xx xxxxxxxx xxxxxxxxxxx, xxxxx xxxxxx zjištěny touto xxxxxxxx, xxxxx zřejmě xxxxxx jinými mechanismy xxx xxxxxx xxxxxxxxxx XXX.
Xxx xxxx Xxxxxx xxxx, část B.
1.2 XXXXXXXX
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx chromozomu x podobě xxxxx xxxxxxxxxxxx xxxxxxxxx xxxx xxxxx x xxxxxxxx xxxxxxx chromatid.
Chromozomová xxxxxxx : xxxxxxxxxx poškození xxxxxxxxxx x xxxxxx xxxxx xxxx xxxxx x spojení xxxx xxxxxxxxx x xxxxxx xxxxx.
Xxxxxxxxxxxxxxx : xxxxxx, xxx xxxxxx x xxxxx xx S-fázi xxxxxxxxx DNA xxxxxxx x xxxxxx, nýbrž xxxxxxxxx xxxxx X-xxxx. Xxxxxxxxx xxxx xxxxxxxxxx xx 4, 8, 16… xxxxxxxxxxxx.
Xxx : xxxxxxxxxxxx léze menší xxx xxxxx xxxxx xxxxxxxxxx a s xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx xxxxx : xxxxx xxxxx, xxxxx xx xxxxxxxxx v xxxxxxxx, x xxxxxxxxx počtu xxxxx v xxxxxxxx; xxxxx stupeň proliferace xxxx xxxxxxxx.
Xxxxxxxxx aberace : xxxxxxxx počtu xxxxxxxxxx xx normálního xxxxx xxxxxxxxx x xxxxxxxxx xxxx buněk.
Polyploidie : xxxxxxx xxxxxxxxxxx xxxxx chromozomových sad (x), jiný xxx xxxxxxxxx (xx. 3 x, 4 n xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx xxxxxxxxxxxxx změny xxxxxxxxx xxxxxxxxxx při xxxxxxxx xxxxxx xx xxxxxx metafáze; xxxx xx xxxx xxxxxx x xxxxxxxxx, intrachromozomální xxxx xxxxxxxxxxxxxxxxxx změny.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx xxxxxxx jsou xxxxxxxxx xxxxxxxx xxxxx, a xx s metabolickou xxxxxxxx a xxx xx. X předem xxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxx xxxxx se xx xxxxxxxxx kultur xxxxx látka xxxxxxxxxxx xxxxxxxx (xxxx. Xxxxxxxx® xxxx kolchicin), xxxxxxx xx sklidí, xxxxxx x xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx buněk.
1.4 XXXXX XXXXXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx
Xxxxx xxx xxxxxxx xxxxx xxxxxxx xxxxx, kmeny xxxx xxxxxxxx buněčné kultury, xxxxxx xxxxxxxx xxxxxxxxx xxxxx (xxxx. xxxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxx jiných savců).
1.4.1.2 Xxxxx a xxxxxxxxxx xxxxxxxx
Xxx xxxxxxxxx kultur xx xxxx xxx xxxxxxx vhodná kultivační xxxxx x inkubační xxxxxxxx (xxxxxxxxxx xxxxxx, xxxxxxxxxxx XX2, xxxxxxx x xxxxxxx). U xxxxxxxxxxxxxxx xxxxxxxxx linií x xxxxx by xxxx xxx xxxxxxx xxxxxxxxxxxx stabilita modální xxxxxxx xxxxx xxxxxxxxxx x xxxx by xxx kontrolováno, xxx xxxxxx kontaminovány mykoplasmaty; x xxxxxxx kontaminace xx xxxxxx xxx xxxxxxx. Xxx xxxxxxx xxxxx x inkubační xxxxxxxx xx xxxx xxx známa normální xxxxx xxxxxxxxx xxxxx.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxxxxxxxxx buněčné xxxxx a kmeny: xxxxx xx xxxxxxx x xxxxxxxxx xxxxxx, xxxxxx xx xx xxxxxxxxxxxx xxxxx x xxxxxx xxxxxxx, xxx xxxxxxxxx xxxxxxxxxx před xxxxxxxxx, x xxxxxxxx xx při 37 °X.
Xxxxxxxxx: xxxx xxxxxxxx xxxxxxxxxxxxxxx (např. xxxxxxxxx) xxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx se xxxxxxx xx kultivačního xxxxx xxxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxxxxxxxxx) x xxxxxxxx xx při 37 °X.
1.4.1.4 Xxxxxxxxxxx xxxxxxxx
Xxxxx xx měly xxx xxxxxxxxx xxxxxxxx xxxxx, a xx x vhodnou metabolickou xxxxxxxx x bez xx. Xxxxxxxxxx xxxxxxxxxx xxxxxxxx xx kofaktorem xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (X9) xxxxxxxxxx x xxxxx hlodavců xxxxxxxxxx xxxxxxxx indukujícím xxxxxx, xxxx xx Xxxxxxx 1254 (6, 7, 8 a 9), xxxx směs fenobarbitonu x β-naftoflavonu (10, 11 x 12).
Xxxxxxxxxxxxxxxxxxx xxxxxx je x xxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxx x xxxxxxxxxxxxx 1 — 10 % xxx. Xxxx metabolického xxxxxxxxxxx xxxxxxx xxxx xxxxxxx xx xxxxx xxxxxxxx xxxxx, xxxxx xx xxxxxxxx. X xxxxxxxxx xxxxxxxxx xxxx xxx xxxxxx použít xxxx xxx jednu xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx.
Xxxx xxxxxxxx xxxxxx, xxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxx buněčných xxxxx exprimujících xxxxxxxxxx xxxxxxxxx xxxxxx, xxxxxxxxx xxxxxxxx xxx endogenní xxxxxxxx. Xxxxx použitých xxxxxxxxx xxxxx xx xxxx být xxxxxxx xxxxxxxxxx (např. xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx X450 xxx xxxxxxxxxxxx xxxxxxxx xxxxx).
1.4.1.5 Xxxxxxxx látka/příprava
Pevné xxxxxxxx xxxxx by xxxx xxx před xxxxxxxx na xxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx rozpouštědlech xxxx xxxxxxxxxx a xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx xxx xxxxxxx přímo x xxxxxxxxxx xxxxxxxx x/xxxx mohou xxx xxxx xxxxxxxx xxxxxxx. Xxxx xx xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxx, pokud xxxxx x stálosti xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx podmínky
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx xxxx být xxxx xxxxxxxxx, xx xxxxxxx xx xxxxxxxxx xxxxxx, a xxxx xx xxx slučitelné x xxxxxxxx xxxxx x x xxxxxxxxx X9. Xxxx-xx xxxxxxx xxxx než xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx jejich xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Doporučuje xx xxxxx xxxxx xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx xxxxxxxx xxxxx xxxxxxxxx xx vodě xx xxxx xxx xxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx xxxx. Xxxx xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxx.
1.4.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, která xxxx xxx xxxxxxxxxx xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx, xxxxx xxxxxxxxxxxx, xxxxxxxxxxx x testovacím xxxxxxx x změny pH xxxx xxxxxxxxxx.
Xxxxxxxxxxxx xx xxxx být xxxxxxxxx x xxxxxxxxxxxx aktivací x bez ní x hlavním experimentu xx xxxxxxx vhodných xxxxxxxxxx buněčné integrity x xxxxx, xxxx xxxx xxxxxx xxxxxxxxxx, xxxxx xxxxxxxxxxxxxxx xxxxx xxxx xxxxxxxxx xxxxx. Xxxx xxx xxxxxxx xxxxxxxx cytotoxicitu a xxxxxxxxxxx x xxxxxxxxxx xxxxxxxxxxx.
Xxxx xx xxx xxxxxxx xxxxxxx xxx xxxxxxxxxxxxxx xxxxxxxxxxx. X xxxxxxx cytotoxicity xx xxxx tyto koncentrace xxxxxxxx xxxxxxx xxxx xxxxxxxxx xx minimální xxxxxxxxx, xxxxxxxx xxxxxx xxxxxxxxx, xxx xxxxxxx xxxxxxx, že xx xx xxxxxxxxxxx xxxxxx xxxxx více xxxxx xxxxxxxx 2 xx Ö10. X xxxxxxxx xxxxxxx by měla xxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx snížení xxxxxx xxxxxxxxxx, počtu xxxxx xxxx xxxxxxxxxxx xxxxxx (xxx x xxxx xxx 50 %). Xxxxxxxxx xxxxx xx xxxxx xxxxxxxx měřítkem xxxxxxxxxxxxx nebo xxxxxxxxxxxxxx xxxxxx x závisí xx xxxx, xxxxx xxxxxxxx od expozice. Xxxxxxxxx index je xxxx xxxxxxxxxx u xxxxxxxxxxx xxxxxx, u xxxxx mohou xxx xxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx. Xxxxxxxxx x xxxxxxxx buněčného xxxxx, xxxxxxxxx xxxxxxxx xxxxxxxxx xxxx (XXX), mohou xxx xxxxxxx xxxx xxxxxxxxx xxxxxxxxx. X xxxxxxx XXX však xxx x celkovou xxxxxxxxx xxxxxxx, z xxx xxxxx xxxxxxx xx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxx, x x xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx doby může xxx xx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx.
X xxxxxxx relativně xxxxxxxxxxxxxxx xxxxx xx xxxx být xxxxxxxxx xxxxxxxx xxxxxxxxxxx 5 μx/xx, 5 xx/xx xxxx 0,01 M, xxxxx xxxx, xxxxx x xxxx xx xxxxxxxx.
X xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxx, které xxxxxx xxxxxxx při xxxxxxxxxxxxx xxxxxxx, xxx xx xxxxxx rozpustnost, xx měla xxx xxxxxxx nejvyšší dávka x koncentraci, jež xx xxx xxxx xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxxx médiu xx xxxxx xxxx xxxxxxxx. X určitých případech (xxxx. xxxxxxx-xx xx xxxxxxxx xxxxx při xxxxxxx koncentracích, než xx xxxxxxxxxxx) xx xxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxxx, xxx nichž xxxxxxx xx srážení. Xxxx xxx užitečné xxxxxxxx rozpustnost na xxxxxxx a xx xxxxx expozice, neboť xxxxxxxxxxx x xxxxxxxxxx xxxxxxx xx xxxx x xxxxxxx xxxxxxxx xxxxx v důsledku xxxxxxxxxxx xxxxx, séra X9 atd. Xxxxxxxxxxxxx xxx zjistit vizuálně. Xxxxxxxxx xx xxxxxx xxxxx xxx xxxxxxxxxxx.
1.4.2.3 Xxxxxxxxx x xxxxxxxxx xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxxx x negativní xxxxxxxx (xxxxxxxx xxxxxxxxxxxx xxxx xxxxxxxx). Při xxxxxxx metabolické aktivace xx měla xxx xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxx, xxxxx x mutagenní xxxxxx xxxxxxxx xxxxxxxx.
X xxxxxxxxx kontrole xx xxx xxx použit xxxxx xxxxxxxxx x xxxxxxxxxxx koncentracích, které xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxxxx x detekovatelný xxxxxx xxx pozadí, čímž xx xxxxxxx citlivost xxxxxxxxxxx xxxxxxx.
Xxxxxxxxxxx xxxxxxxxxxx xxxxxxx xx měly xxx zvoleny xxx, xxx byl xxxxxx xxxxxxxx, xxx xxx xxx odečtu xxxxxxx xxxxx najevo kódovaná xxxxxxxxxxxx preparátu. Xxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx:
|
Xxxx metabolické xxxxxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx podle XXXXXX |
|
Xxx xxxxxx metabolické xxxxxxxx |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
|
4-xxxxxxxxxxxxx-1-xxxx |
56–57–5 |
200–281–1 |
|
|
X xxxxxx xxxxxxxxxxxx xxxxxxxx |
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
|
xxxxxxxxxxxxx monohydrát |
6055–19–2 |
Pro pozitivní xxxxxxxx xxxxx xxx xxxxxxx i xxxx xxxxxx xxxxx. Xxx xxxxxxxxx xxxxxxxx by xxxx xxx xxxxx xxxxx xxxxx v xxxxx xxxxxxx chemických xxxxx xx xxxxxx xxxxxxxx xxxxx.
X xxxxxxxx xxxxxxxx xx xxxx xxx použity xxxxxxxxx xxxxxxxx skládající xx xx samotného xxxxxxxxxxxx xxxx vehikula x xxxxxxxxxxx xxxxx x xxxxxxxxxx xxxxxxx způsobem xxxx kultury. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx také xxxxx, xxxxxxxxxx-xx xxxxx xxxxx xxxxxxxxx údaje prokazující, xx xxxxxxx rozpouštědlo xxxxxxxxxx xxxxx xxxxxxx xxxx mutagenní účinky.
1.4.3 Xxxxxx
1.4.3.1 Xxxxxxxx xxxxxxxx xxxxx
Xxxxxxxxxxxxx xxxxx xx xxxxxxx zkoušené xxxxx xxx xx xxxxxxxxxxx xxxxxxxxxxxxx aktivačního systému, xxx xxx xxxx. Xxxxxxxx xxxxxxxxx by xxxx xxx xxxxxxxx xxx 48 xxxxx xx xxxxxxxxx xxxxxxxxx.
1.4.3.2 Xxx každou xxxxxxxxxxx xx měly být xxxxxxx xxxxxxx duplicitní xxxxxxx, x xxxxx xx xxxxxxx xxxxxxxxxx x kultur pro xxxxxxxxx xxxxxxxx xxxx xxxxxxxx rozpouštědla. Jestliže xxx xx xxxxxxx xxxxxxxxxxx údajů xxxxxxxx (13, 14), že xxxx xxxxxxxxxxxx kulturami xx xxxxxxxxx xxxxxx, xxxx xxx xxxxxxxxx xxxxxxx xxxxxx kultury.
Plynné xxxx xxxxxx látky xx xxxx xxx xxxxxxxx vhodnými xxxxxxxx, xxxx. x xxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx (15, 16).
1.4.3.3 Xxxx xxxxxxx xxxxxx
X xxxxxx xxxxxxxxxxx xx měly xxx buňky xxxxxxxxx xxxxxxxx xxxxx, xxx x xxxxxxxxxxxx aktivací, xxx xxx xx, xx dobu 3 — 6 xxxxx, x xxxx xx xxx odebrány xx xxxxxx xxxx xx xxxxxxxx aplikace, xxxxx xxxxxxxx 1,5xxxxxxx xxxxxxxx xxxxx xxxxxxxxx cyklu (12). Xxxxxxxx xxxxx xxxxxx dává xxxxxxxxx xxxxxxxx jak s xxxxxxxx, xxx bez xxxxxxxx, xxx xx xxx xxxxxxxx dodatečný xxxxxxxxxx xxx xxxxxxxx x xxxxxxxxxxxx xxxxxxxx xx xx odběru x xxxx, xxxxx xxxxxxxx 1,5xxxxxxx xxxxxxxx xxxxx buněčného xxxxx. Xxxxxx xxxxxxxx xxxxx xxx snáze xxxxxxxxx xxx xxxxxx aplikace xxxx xxxxxx delších xxx 1,5násobek xxxxx xxxxx. Xxxxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx xxxx být xxxxxxxxx xxxxxx xx xxxxxxx. X případech, kdy xx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxx, by xxxx xxx podáno xxxxxxxxxx.
1.4.3.4 Xxxxxxxx xxxxxxxxx pro xxxxxxx chromozomů
Do xxxxxxx xxxxxxx xx obvykle 1-3 hodiny xxxx xxxxxxxxx xxxxx Xxxxxxxx® xxxx xxxxxxxxx. Xxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxx xx xxxxx buněčná xxxxxxx xxxxxx x xxxxxxxxxx xxxxxx. Xxxxxxxx preparátů xxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxx buněk, xxxxxx x xxxxxxxx xxxxx.
1.4.3.5 Xxxxxxx
Xxxxxxx xxxxxxxxx, xxxxxx xxxxxxxxx xxxxxxxxxxx x negativních kontrol, xx xxxx být xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxxx kódovány. Xxxxxxxx při xxxxxx xxxxx xxxxxxx xx xxxxx xxxxx xxxxx x xxxxxxxx x xx xxxxxx chromozomů, xxxx by vyšetřované xxxxx obsahovat centromery x xxxxx rovném xxxxxxx xxxxxxx ± 2 xxx xxxxxxx xxxx buněk. Xx xxxxxx xxxxxxxxxxx x xxxxxxxx xx mělo xxx hodnoceno alespoň 200 xxxxx xxxxxxxxxxxxxx xxxxxxxx, xxxxxxxx rovnoměrně xxxxxxxxxxx xxxx duplicitní xxxxxxx. Xxxxx xxxxx xxx xxxxxx, je-li xxxxxxxxx xxxxx počet xxxxxxx.
Xxxxxx xx xxxxxx xxxxxxx detekovat strukturní xxxxxxxxxxxx xxxxxxx, xx xxxxxxxx xxxxxxxxxx xxxxxxxxxxx x endoreduplikace, xxxx-xx xxxxxxxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxxxxxxxxxxx xxxxxxxxx xx xxxxx x mělo xx tedy být xxxxxxxxxxx množství xxxxx xx xxxxxxxxxx chromozomovou xxxxxxx (aberacemi) vyjádřené x xxxxxxxxxx. Xxx xxxxxxxxx x xxxxxxxxxxxxxx xxxxxxx by xxxx xxx xxxxxxx xxxxx xxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx s xxxxxx xxxxxx a četností. Xxxx xx zaznamenávají xxxxxxxx a xxxxxxx xx, xxx nezahrnují xx xx xxxxxxx xxxxxxxx aberací.
Měla by xxx xxxx zaznamenána xxxxxxxx, xxxxx xxxx xxxxxxxxx xxx stanovení xxxxxxxxxxxx x všech xxxxxxxxxxxx kultur x xxxxxxxxxxx xxxxxx v xxxxxxxx experimentech x xxxxxxxxx.
Xxxx xx xxx xxxxxxx xxxxx xxx xxxxxxxxxx kultury. Xxxx xx xxxx xxx xxxxxxx xxxxx xxxxxxx xx xxxxx xxxxxxx.
Xxxxxxx xxxxx xxxxxxxxx xxxxxxxx xx xxxxxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, nejlépe x xxxxxxxx xxxxxxxxxxxxxxxx podmínek. Xxxxxxxxxx potvrdit negativní xxxxxxxx xxxx xxxxxxxxxxx x bodu 1.4.3.3. Xxxxx xxxxxxxxx studie x cílem xxxxxxxx xxxxxx posuzovaných xxxxxxxx xx xxxx xxx xxxxxxx x xxxxxxxxxx xxxxxxxxxxxxx. X xxxxxxxxxx xxxxxx, xxxxx xx xxxxx xxx xxxxxxx, xxxxx xxxxxxx koncentrací x podmínky metabolické xxxxxxxx.
2.2 HODNOCENÍ X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx existuje xxxxxxx kritérií, xxxx. xxxxxx počtu buněk x chromozomovými xxxxxxxxx x xxxxxxxxxx xx xxxxxxxxxxx, xxxx xxxxxxxxxxxxxxxx xxxxxx xxxxxx počtu. Xxxxxxxx xx měla xxx uvážena biologická xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx být xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxx (3, 13). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxx xxxxxxx xxxxxxxxx faktorem xxx xxxxxxxxx odpověď.
Nárůst xxxxx xxxxxxxxxxx buněk xxxx xxxxxxxx, xx xxxxxxxx látka xx xxxxxxxxx xxxxxxxx mitotické xxxxxxx x xxxxxxxxx xxxxxxxxx chromozomové aberace. Xxxxxx počtu buněk x endoreduplikovanými chromozomy xxxx xxxxxxxx, xx xxxxxxxx látka má xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx (17, 18).
Xxxxxxxx xxxxx, jejíž xxxxxxxx nesplňují xxxx xxxxxxx kritéria, xx x xxxxx xxxxxxx xxxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx případech xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx výrok o xxxxxxxx zkoušené látky. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx xx xx, kolikrát xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxx znamenají, xx xxxxxxxx xxxxx xxxxxxxx x xxxxxxxxxxxxx somatických xxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxxxxx xxxxxxxx znamenají, xx xxxxxxxx xxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxxxxxxxx somatických xxxxxxx xxxxx strukturní xxxxxxxxxxxx aberace.
3. ZPRÁVY
PROTOKOL X ZKOUŠCE
Protokol o xxxxxxx musí obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- xxxxxxxxxxx x stálost zkoušené xxxxx v rozpouštědle/vehikulu, xx-xx známa.
Buňky:
- xxx x xxxxx buněk,
- xxxxxxxxxx xxxxxxxxx x xxxxxxxx použitého xxxx xxxxx,
- xxxxxxxxx nepřítomnost xxxxxxxxxxx,
- xxxxxxxxx o xxxxx xxxxxxxxx xxxxx,
- xxxxxxx xxxxx krve, xxx byla xxxxxxx xxxx xxxx xxxx xxxxxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx,
- xxxxxxxx počet xxxxxx,
- xxxxxxxx xxxxxx xxxxxxxxx buněčné kultury,
- xxxxxxx hodnota xxxxx xxxxxxxxxx.
Xxxxxxxx podmínky:
- xxxxxxxxxxxx xxxxx zastavující metafázi, xxxx xxxxxxxxxxx a xxxxx expozice xxxxx,
- xxxxxxxxxx xxxxxx xxxxxxxxxxx x počtu kultur, xxxxxx např. údajů x xxxxxxxxxxxx x xxxxxx xxxxxxxxxxxx, xxxx-xx x dispozici,
- xxxxxxx xxxxx, xxxxxxxx xxxxxxxxxxx XX2,
- koncentrace zkoušené xxxxx,
- xxxxx xxxxxxxx x xxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxx teplota,
- xxxxxxxxx xxxx,
- xxxxx xxxxxxxx,
- xxxxxxxx xxxxxxx xxxxx při nasazení,
- xxx x složení xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, včetně kritérií xxxxxxxxxxxxx,
- xxxxxxxxx x xxxxxxxxx kontroly,
- metody xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx aberací,
- počet xxxxxxxxxxxxx xxxxxxxx,
- xxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxx xxxxxxxxxxx studie xx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx toxicity, xxxx. xxxxxx konfluence, xxxxx x buněčném xxxxx, xxxxx xxxxx, xxxxxxxxx index,
- xxxxxx xxxxxxx,
- xxxxx o xX x osmolalitě xxxxxxxxxxx xxxxx, pokud xxxx xxxxxxxxx,
- definice xxxxxxx, xxxxxx gapů,
- xxxxx buněk x xxxxxxxxxxxxxx aberacemi x xxxx xxxxxxx zvlášť xxx každou exponovanou x xxxxxxxxx xxxxxxx,
- xxxxx ploidie, xxxxx xxxx xxxxxxxxxx,
- xxxxx xxxxxxxx závislost odpovědi xx xxxxx,
- případné xxxxxxxxxxx xxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x negativní (xxxxxxxxxxxx/xxxxxxxxx) x pozitivní xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, H. X. (1976), Xxxxxxxxxxx Xxxxxxx xxx Xxxxxxxxx Xxxxxxxx Xxxxxxxx, in: Xxxxxxxx Xxxxxxxx, Xxxxxxxxxx xxx Xxxxxxx for xxxxx Xxxxxxxxx, Xxx. 4, Xxxxxxxxxx, X. (xx) Xxxxxx Xxxxx, Xxx Xxxx xxx Xxxxxx, 1-29.
2) Ishidate, X. Xx., Xxxxxx, T. (1985), The Xx xxxxx Xxxxxxxxxxx Xxxxxxxxxx Xxxx Xxxxx Xxxxxxx Xxxxxxx Xxxx (XXX) Xxxxxxxxxx Cells xx Xxxxxxx, in: Xxxxxxxx xx Xxxxxxxxxx Research, Xxx. 5, Xxxxx, X. xx xx., (xxx) Xxxxxxxx Xxxxxxx Xxxxxxxxxx, Xxxxxxxxx-Xxx Xxxx-Xxxxxx, 427-432.
3) Xxxxxxxx, X. X., Xxxxxxxxx, M. X., Xxxxxx, X., Xxxxxx, S., Xxxxx, X., Xxxxxx, X., Xxxxx, X. X., Xxxxxxxx, X., Ahmed, X., Xxx, S., Xxxxx, J., Xxxxxxxx, X. X., Xxxxxxx, X. X., Anderson, X., Xxxxxx X. (1978), Xxxxxxxxxx xxxxxxxxxx xxx xxxxxx xxxxxxxxx xxxxxxxxx xx Chinese xxxxxxx xxxxx xxxxx: Xxxxxxxxxx xx 108 xxxxxxxxx, Xxxxxxx. Xxxxx. Xxxxxxx. 10 (xxxxx. 10), 1-175.
4) Xxxxx, X., Xxxxxxxx, X. X., Xxxxxxxx, X. X., Ishidate, M. Xx., Xxxxxxx, X., Xxxxx, X., Myhr, X. X. (1991), Xxxxxxxxxxxx under Extreme Xxxxxxx Xxxxxxxxxx. A xxxxxx xxxx ICPEMC Xxxx Group 9, Xxxxxxxxxx Xxx., 257, 147-204.
5) Xxxxxx, X., Xxxxxx, X., Xxxxxx, X., Okumura, K., (1992), Clastogenicity xx xxx xX xx Xxxxxxx Xxxxxxxx Xxxxxxxxx Xxxxx, Xxxxxxxxxx Xxx., 268, 297-305.
6) Ames, X. N., McCann, X., Xxxxxxxx, E. (1975), Xxxxxxx for Xxxxxxxxx Xxxxxxxxxxx xxx Xxxxxxxx with the Xxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Mutagenicity Xxxx, Mutation Res., 31, 347-364.
7) Xxxxx, X. X., Xxxx, X. X. (1983), Xxxxxxx Xxxxxxx for xxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxx, Mutatation Xxx., 113, 173-215.
8) Natarajan, X. T., Xxxxx, X. X., xxx Xxxx, P. P. X., Meijers, X., xx Xxxxx, X. (1976), Xxxxxxxxxxx Effects xx Xxxxxxx/Xxxxxxxxxxx after Xxxxxxxxxx xx x Xxxxxxxxxxx System Xx xxxxx, I. Xxxxxxxxx xx Xxxxxxxxxx Xxxxxxxxxxx xxx Sister Chromatid Xxxxxxxx by Diethylnitrosamine (XXX) and Xxxxxxxxxxxxxxxxxxx (XXX) in XXX Xxxxx xx xxx Xxxxxxxx of Xxx-Xxxxx Xxxxxxxxxx, Xxxxxxxxxx Res., 37, 83-90.
9) Xxxxxxxx, X., Xxxxxxx, X., Xxxxxxxx, M. Jr. (1979), Chromozomal Xxxxxxxxxx Xxxxx on 29 Xxxxxxxxx Xxxxxxxx xxxx X9 Xxx In xxxxx, Xxxxxxxx Res., 66, 277-290.
10) Xxxxxx, X. X., Xxxxxx, X. X., Xxxxxxx, X. X., Xxxxxxxxx, X. G., Xxxxxx, X. X., Mackay, X. X., Xxxx, X. C. (1992), Xxxxxx xx XX Xxxxxxxxxxxxx Xxxxxxx Society Xxxxxxx Party. Xxxxxxxxxxx xx Aroclor 1254-induced X9 in Xx xxxxx Genotoxicity Xxxxxx, Xxxxxxxxxxx, 7, 175-177.
11) Xxxxxxxxxx, X., Sawamura, X., Xxxx, X., Xxxxxxxx, X. (1976), X. Safe Xxxxxxxxxx xxx Polychlorinated Biphenyls x. s. xx Xxxxxxx xx Xxxxxxxxx Xxxxxxxxxx Systems, xx: xx Xxxxxx, X. X., Xxxxx, J. X. Xxxx, X. X., Xxxxxxx, R. X. (eds), Xx xxxxx Metabolic Activation xx Xxxxxxxxxxx Testing, Xxxxxxxx, Xxxxx-Xxxxxxx, 85-88.
12) Xxxxxxxx, X. X., Xxxxxxx, X. X., Xxxxxxxx, M. Xx., Xxxxx, X. X., Xxxxxxxx, D. X., Xxxxxx, X., Mosesso, X., Sofumi, X. (1994), Xxxxxx xxxx Xxxxxxx Group xx Xx vitro Tests xxx Xxxxxxxxxxx Xxxxxxxxxxx, Xxxxxxxxxx Xxx., 312, 241-261.
13) Xxxxxxxxxx, X., Xxxxxxxx, D. X., Xxxxx, J. X., Xxxxxxxx, X., Xxxxxxx, X. X., Xxxxxxxx, X. (1989), Analysis xx Xxxx xxxx Xx xxxxx Xxxxxxxxxxx Xxxxxx, xx: Xxxxxxxxxxx Xxxxxxxxxx of Mutagenicity Xxxx Data, Xxxxxxxx, X. X., (ed) Xxxxxxxxx University Press, Xxxxxxxxx, 141-154.
14) Xxxxx, X. X., Galloway, X. M. (1994), Xxxxxxxxx Xxxxxx xxx xxx Necessary xxx Xx vitro Xxxxxxxxxx Xxxxxxxxxx Xxxxxx in XXX Xxxxx, Mutatation Xxx., 312, 139-149.
15) Xxxxx, X. F., Xxxxxx, X. C., XxXxxxx, K. X. (1982), XXX/XXXXX Mutation Xxxxx: Xxxxxxxxxx xx Xxxxx xxx Xxxxxxxx Xxxxxxx, in: Tice, X. R., Xxxxx, X. X., Xxxxxxx, X. X. (xxx), Xxxxxxxxx Xxxxxxx of Xxxxxxxx Xxxxxx, Xxx Xxxx, Xxxxxx, 91-103.
16) Xxxxxx, X. O., Xxxxxx, X. X., Xx, X. X., Xxxxxx, X. L. (1983), Xxxxxxxxxx of xx Exposure Xxxxxx Xxxxx Xxxxx Xxxxx xx Xxxxxxxx Gels xxx Xxxxxxxxx Xxxxxx Xxxxxxxx Xxxxxxxx xx xxx CHO/HGPRT Xxxxxxxx Xxxxx, Environmental Mutagen., 5, 795-801.
17) Locke-Huhle, X. (1983), Xxxxxxxxxxxxxxxxx xx Xxxxxxx hamster xxxxx during xxxxx-xxxxxxxxx xxxxxxx X2 arrest, Xxxxxxxxxx Xxx., 119, 403-413.
18) Huang, X., Xxxxxx, C., Trosko, X. E. (1983), Xxxxxxxxxxx-xxxxxxx endoreduplication xx Xxxxxxx xxxxxxx cells, Xxxxxx Res., 43, 1362-1364."
XXXXXXX 4B
"B.11 XXXXXXXXXX–XXXXXXX XX CHROMOZOMOVÉ XXXXXXX X XXXXXXX KOSTNÍ XXXXX XXXXX XX XXXX
1. XXXXXX
Xxxx metoda xx xxxxxxxx xxxxxx XXXX XX 475 — Zkouška xx xxxxxxxxxxxx xxxxxxx x xxxxxxx xxxxxx dřeně xxxxx (1997).
1.1 ÚVOD
Zkouška xx chromozomové aberace x savců in xxxx xx xxxxxxxxx xxx xxxxxxx strukturních xxxxxxxxxxxxxx xxxxxxx indukovaných xxxxxxxxx xxxxxx v xxxxxxx kostní dřeně xxxxx, xxxxxxx hlodavců (1, 2, 3, 4). Xxxxxxxxx xx xxx xxxx xxxxxxxxxxxx xxxxxxx — chromozomové x xxxxxxxxxxxx. Nárůst xxxxxxxxxxx xxxx znamenat, xx chemická xxxxx xx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxx. X xxxxxxx většiny chemických xxxxxxxx xxxx indukované xxxxxxx chromatidového xxxx, xxxxx xxxxxxxxxxxx xxxxxxx xx rovněž vyskytují. Xxxxxxxxxxxx mutace x xxxxxxxxxxx xxxx jsou xxxxxxxx xxxxx geneticky xxxxxxxxxxx xxxxxx x xxxxxxx x xxxxxxxx xxxxx xxxxxx x xxx, xx chromozomové xxxxxx x související xxxx způsobující xxxxx x xxxxxxxxxx a x xxxxxx somatických xxxxx xxxxxxxxx xxxxxx, xxxx xxxxx xx xxxxxxx xxxxxxxx u xxxxxxx x x xxxxxxxxxxxxxxxx xxxxxxxxx.
Xxx této xxxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxxx xxxxx xx x xxxx xxxxxxx xxxxxx xxxx, xxxxxxxx je xxxxxx xxxxxxxxxxxxxxxx xxxxx x xxxxxxxx populaci xxxxx x rychlým xxxxxx, které se xxxxxx xxxxxxx x xxxxxxxxxxxx. Jiné druhy x xxxxxx xxxxx xxxxxx xxxxxxxxx této xxxxxx.
Xxxx xxxxxxx xx xxxxxxxxxxxx xxxxxxx xx xxxxxxx xxxxxx x xxxxxxxxx nebezpečí mutagenese, xxxxx umožňuje zohlednit xxxxxxx xxxxxxxxxxx in xxxx, xxxxxxxxxxxxxxx x xxxxxxx xxxxxxxx XXX, xxxxxxx se mohou x xxxxxxx xxxxx x tkání xxxxx. Xxxxxxx xx xxxx xx rovněž xxxxxxxx xxx další xxxxxx xxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxx xx xxxxx.
Xxxxxxxx xxxxxxxx xxxxx o xxx, xx se xxxxxxxx xxxxx xxxx xxxxxxxxx xxxxxxxxxx nedostanou xx cílové xxxxx, xxxx xxxxxx xxxx xxxxxxx použít.
Viz xxxx Xxxxxx xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxxxx aberace : strukturní xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx xxxxxxxxxxxx chromatid xxxx zlomu x xxxxxxxx spojení xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx xxxxxxxxx chromozomu x xxxxxx zlomu xxxx xxxxx x xxxxxxx xxxx chromatid x xxxxxx xxxxx.
Xxxxxxxxxxxxxxx : xxxxxx, xxx kterém x jádře xx X-xxxx replikace XXX xxxxxxx k mitóze, xxxxx xxxxxxxxx další X-xxxx. Xxxxxxxxx jsou xxxxxxxxxx xx 4, 8, 16,… xxxxxxxxxxxx.
Xxx : achromatická léze xxxxx xxx xxxxx xxxxxxx xxxxxxxxxx x x xxxxxxxxx xxxxxxxxx xxxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx xxxxx chromozomů xx normální xxxxxxx xxxxxxx x xxxxxxxxx xxxxx.
Xxxxxxxxxxx : xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxxx xxx (x), xxxx xxx xxxxxxxxx (xx. 3 n, 4 x xxx.).
Xxxxxxxxxx xxxxxxx : xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx xxx xxxxxxxx xxxxxx xx xxxxxx metafáze; xxxx se jako xxxxxx x xxxxxxxxx, xxxxxxxxxxxxxxxxxx nebo interchromozomální xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx jsou vystavena xxxxxxxx xxxxx xxxxxxx xxxxxxxx x ve xxxxxxx xxxxxxxx xx xxxxxxxx xx usmrtí. Xxxx usmrcením xx xxxxxxxx podá látka xxxxxxxxxxx xxxxxxxx (xxxx. xxxxxxxxx xxxx Xxxxxxxx®). X buněk xxxxxx xxxxx xx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxx, xxxxxx se x xxxxxxxxx se chromozomové xxxxxxx xxxxx v xxxxxxxx.
1.4 XXXXX ZKUŠEBNÍ XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Výběr xxxxx zvířete
Běžně xx xxxxxxxx potkan, xxx x křeček xxxxxx, xxxxxx lze xxxxxx xxxxxxxx vhodný savčí xxxx. Xxxx xx xxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxx zdravých xxxxxxxx xxxxxxxxx xxxxxx. V xxxxxxxx xxxxxxxx studie xx xxxx xxx xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx a xxxxxx xx u xxxx pohlaví xxxxxxxxx ± 20 % xxxxxxx xxxxxxx hmotnosti.
1.4.1.2 Xxxxxxxx chovu a xxxxxx
Xxxxx obecné podmínky xxxxx obecného xxxxx x části B, xxxxxxx by xxxx xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Příprava xxxxxx
Xxxxxx mladá xxxxxxxx xxxxxxx zvířata se xxxxxxxx výběrem xxxxxxx xx xxxxxxxxx xxxxxxx x skupinu, xxxxx xx xxxxxxx xxxxxxxx xxxxx. Klece xx xxxx být xxxxxxxxxx xxx, aby byl xxxx xxxxxx xxxxxx xxxxxxxxxxxxx. Xxxxxxx se xxxxxxxxxxx xxxxxxxxxxxx. Xxxxxxx xx v xxxxxxxxxxxxx xxxxxxxxxx alespoň xxx xxx aklimatizovat.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx xx xxxx xxx xxxx xxxxxxxx zvířatům xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx rozpouštědlech xxxx xxxxxxxxxx x xxxxxxxxx zředěny. Kapalné xxxxxxxx xxxxx mohou xxx podávány xxxxx xxxx xxxxx xxx xxxx podáním xxxxxxx. Xxxx by xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx chemické xxxxx, xxxxx údaje o xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx by xxxxxx xxx při xxxxxxxxx xxxxxxxx xxxxx xxxxxxx xxxxxx x xxxx xx být xxxxxxxxx xxxxxxxxx, xx xxxxxxx xx zkoušenou xxxxxx. Xxxx-xx xxxxxxx xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx se xxxxx xxxxx xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxxx a xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx xxx xxx xxxxxxx. X výjimkou xxxxxxxx xxxxxxxx xxxxx by xxxx zvířata xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxx zvířata xx xxxxxxxxx, v xxxxx xxxxx x xxxxxxxx.
Xxxxxxxxx xxxxxxxx by xxxx poskytovat strukturní xxxxxxx xx xxxx xxx expozičních úrovních, x xxxxx xx xxxxxxx, že xxxxxxxxx xxxxxxxxxxxxx xxxxxx xxx xxxxxx. Xxxxx xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx xxx, xxx byl účinek xxxxxxxx, xxx xxx xxx xxxxxx xxxxxxx xxxxx xxxxxx kódovaná xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, aby xxxx xxxxxxxxx kontrola xxxxxxxx xxxxx xxxxxxxx xxx xxxxxxxx xxxxx x xxx xxx odběr x jejím případě xxxxxxxx xxx jednou. Xxx xxxxxxxxx xxxxxxxx xxxxx xxx xxxxxxx xxxxxxxx látky xx xxxxxx chemické xxxxx, xxxx-xx x dispozici. Xxxxxxxx látek pro xxxxxxxxx kontrolu:
|
Látka |
Číslo CAS |
Číslo xxxxx EINECS |
|
ethyl-methansulfonát |
62–50–0 |
200–536–7 |
|
1-ethyl-1-nitrosomočovina |
759–73–9 |
212–072–2 |
|
mitomycin C |
50–07–7 |
200–008–6 |
|
cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
|
|
2,4,6-xxxx(xxxxxxxx-1-xx)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxxx xxxxxx by xxx být xxxxxxxx xxxxx x negativních xxxxxxx, jimž je xxxxxxxxxx pouze xxxxxxxxxxxx xxxx xxxxxxxxx a xxx xxxxx xxxxxxxxxx xxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxx, xxxxx xxxxxx x xxxxxxxxxxx xxxxxxxxxxx xxxxx x xxxxxxxxx přijatelné xxxxx x xxxxxxxxxxx xxxxxx x četnosti xxxxx x xxxxxxxxxxxxxx xxxxxxxxx. Xxxxxxx-xx xx pro xxxxxxxxx xxxxxxxx xxxxx xxxxx, xx xxxxxxxxxxxxx xxxxxxxxx doba xxxxxxx xxxxxx. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx kontroly xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx nebo mutagenní xxxxxx.
1.5 POSTUP
1.5.1 Počet x xxxxxxx xxxxxx
Xxxxx xxxxxxxxxx x kontrolní xxxxxxx xx xxxxxx x xxxxxxx xxxx xxxxxxxxxxxxxxxx xxxxxx xxx xxxxx xxxxxxx. Xxxxxxxx xxxx x době xxxxxx k xxxxxxxxx xxxxx ze studií xx xxxxxxx xxxxxx x xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxx xxxxxxxxx, xx xxxxxxxxxx mezi xxxxxxxxx xxxxxx v xxxxxxxx, xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx. Je-li xxxxxxxx xxxxxxx xxxxxxxxxx xxx xxxxxx xxxxxxx, xxxx je xxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxxxxxxxx xxxxx, xxxx xx xxx zkouška xxxxxxxxx xx zvířaty xxxxxxxxxxxxxx pohlaví.
1.5.2 Plán xxxxxxxx
Xxxxxxxx látky xx xxxx být xxxxx xxxxx xxxxxxxx xxxxxxxxxxx. Xxxxxxxx xxxxx mohou xxx podávány xxxx xx dvou xxxxxxx, xxx. xxx dávky x xxx den x xxxxxxx xx xxxx xxx xxxxxxxx xxxxx, aby bylo xxxxxxxxx podávání velkých xxxxxx xxxxxxxxx. Xxxx xxxxxx podávání by xxxx být xxxxxxx xxxxxxxxxx.
Xxxxxx by xxxx xxx xxxxxxxx ve xxxx xxxxxxx xxxxxxxxxxx xx aplikace podané x xxxxxx xxx. X hlodavců xx xxxxx xxxxxxx xx xxxxxx xxxx od xxxxxxxx, xxxxx xxxxxxxx 1,5xxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxx (xxxx xxxx xxxxxxx 12 — 18 x). Xxxxxxxx xxxx nezbytná xxx příjem x xxxxxxxxxxxx zkoušené xxxxx x rovněž pro xxxxxx xx kinetiku xxxxxxxxx xxxxx xxxx xxx xxxx xx xxxxxxxxx xxxxxxx pro xxxxxxxxx xxxxxxxxxxxxxx xxxxxxx, xxxxxxxxxx se xxxxxxx xxxxx odběr xx 24 x xx xxxxxxx xxxxxx. Xx-xx xxxxxxxx xxxxxxxxx xx xxxx než xxxxxxx xxx, xxx xx xxx xxxxx proveden xx takové xxxx xx poslední aplikace, xxxxx xxxxxxxx 1,5násobku xxxxxxxx délky buněčného xxxxx.
Xxxx usmrcením xx xxxxxxxx xxxxxxxxxxxxxxxxx podá xxxxxx dávka xxxxx xxxxxxxxxxx xxxxxxxx (např. Xxxxxxxx® xxxx xxxxxxxxx). Xxxx xx po xxxxxx době xxxxxxx x xxxxxx xxxxx. X xxxx je xxxx xxxx xxxxxxxxx 3 — 5 x; x xxxxxx xxxxxxxx je xxxx xxxx xxxxxxxxx 4 — 5 x. X kostní dřeně xx xxxxxxxx buňky x xxxxxxxxx se xx xxxxxxxxxxxx xxxxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx se xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx studie xxx xxxxxxxx xxxxxxx xxxxx, xxxx by být xxxxxxxxx xx xxxxxx xxxxxxxxxx, xx xxxxxxx xxxxxx, xxxxxx, pohlavím x xx xxxxxxxx xxxxxx expozice, xxx xx xxxxxxx x xxxxxx xxxxxx (5). X případě toxicity xx xxx první xxxxx xxxxxxx xxx xxxxxx dávky. Tyto xxxxxx xxxxx xx xxxx xxxxxxxx xxxxxxx xxxx maximální x xxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxx xxxxxxxxx. Xxx xxxxxxxxx odběru stačí, xxxx xxxx použita xxxxx nejvyšší dávka. Xxxxxxxx xxxxx xx xxxxxxxxxx jako xxxxx xxxxxxxxxxxx takové xxxxxx xxxxxxxx, xx xxxxx xxxxx xx xxxxx xxx xxxxxxx režimu xxxxxxxxx xxxxx xxxxxxxxx x letalitě. Látky xx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxx dávkách (např. xxxxxxx x mitogeny) xxxxxx xxxxxxxxx stanovení xxxxx vyhovovat a xxxx xx xxx xxxxxxxxx xxxxxx xx xxxxxxx. Xxxxxxxx xxxxx xxxx xxx také xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx v xxxxxx xxxxx xxxxxxx známky xxxxxxxx (např. xxxx xxx 50 % xxxxxxx xxxxxxxxxxx xxxxxx).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx zkouška x xxxxxx xxxxxx xxxxxxx 2000 mg/kg xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxx xx xxxx dávkách x xxxxxx xxx xxxxxxxxxx xxxxx pozorovatelné xxxxxxx xxxxxx x xxxx-xx xx xxxxxxx údajů x látkách, xxxxx xxxx podobnou strukturu, xxxxxxxxx xxxxxxxxxxxx, xxxxxxxxxx xx úplná studie xx xxxxx xxxxxxxx xxxxx xx xxxxxxxxx. X xxxx xxxxxxxxxx xxxxxx xx xxxxxxx xxxxxx xxx 14xxxxx xxxxxxxx 2000 mg/kg xxxxxxx xxxxxxxxx/xxx x xxx delší xxx 14xxxxx xxxxxxxx je xxxxxxx xxxxxx 1000 xx/xx tělesné xxxxxxxxx/xxx. Xxxxxxxxx expozice člověka xxxx xxxxxxxx xxxxxxx xxxxxx v limitní xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx xx xxxxxxx xxxxxx xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx nebo vhodnou xxxxxxxxx xxxxxxx, xxxx xxxxxxxxxxxxxxxxx injekcí. Xxxx xxxxxxx xxxxxxxx jsou x xxxxxxxxxxxx xxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxx podán xxxxxxxxxxxxxx nebo injekčně, xxxxxx xx xxxxxxxxx xxxxxxxxxxx zvířete. Xxxxx xx neměl xxxxxxxxx 2 xx/100 x xxxxxxx xxxxxxxxx. Xxxxxxx xxxxxxx xxxxxx, xxx xx xxxxxxx objem, xxxx xxx xxxxxxxxxx. Xx xx dráždivé x xxxxxx xxxxx, xxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx vykazují xxxxxxxx xxxxxx, by xxxx být variabilita xxxxxxxxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx zajišťující xxxxxxxxxx xxxxx xxx xxxxx xxxxxxxx xxxxx.
1.5.6 Xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxx
Xxxxx po xxxxxxxx se xxxxxxx xxxxxx dřeň, hypotonizuje xx x xxxxxx. Xxxxx se xxxxxxx xx xxxxxxxx xxxxxxx x obarví xx.
1.5.7 Xxxxxxx
Xxxx měřítko cytotoxicity xx měl xxx x xxxxx xxxxxxxxxxxx xxxxxx (xxxxxx pozitivních xxxxxxx) a u xxxxxxxxxxxxxx xxxxxx pro xxxxxxxxx kontrolu stanoven xxxxxxxxx xxxxx, x xx xxxxxxx u 1000 xxxxx na xxxxx zvíře.
U xxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxxx alespoň 100 buněk. Xxxxx xxxxx lze snížit, xx-xx xxxxxxxxx xxxxx xxxxx xxxxxxx. Xxxxxxx xxxxxxxxx pozitivních a xxxxxxxxxxx xxxxxxx xx xxxx xxx xxxx xxxxxxxxxxxxxx analýzou xxxxxxxxx xxxxxxxx. Xxxxxxx xxx xxxxxx xxxxx xxxxxxx xx chromozomálním xxxxxx xxxx xx xxxxxx xxxxxxxxxx u xxxxx xxxxx x xxxxxxxx, xxxx by xxxxxxxxxxx xxxxx xxxxxxxxx centromery x xxxxx xxxxxxxxxxxxxx xxxxx 2 x ± 2.
2. XXXXX
2.1 XXXXXXXXXX VÝSLEDKŮ
Údaje xxx xxxxxxxxxx xxxxxxx xx xxxx xxx zpracovány xx xxxxx tabulky. Xxxxxxxxxxxxxx xxxxxxxxx je xxxxx. Xxx každé xxxxx xx xxx xxx xxxxxxxxxx xxxxx xxxxx, počet aberací xx xxxxx x xxxxx xxxxx s xxxxxxxxxxxxx aberací (xxxxxxxxxxxxxx xxxxxxxxx) xxxxxxxxx x xxxxxxxxxx. Xxx exponované x kontrolní xxxxxxx xx xxxx xxx xxxxxxx xxxxx xxxx xxxxxxxxxxxx xxxxxxxxxxxxxx aberací x jejich počtem x četností. Gapy xx xxxxxxxxxxxxx odděleně x xxxxxxx se, xxx xxxxxx xx xxxxxxxxxx xx celkové xxxxxxxx xxxxxxx. Xxxxxxxxxx-xx xxxxx x rozdílu x xxxxxxxx xxxx xxxxxxxxx, mohou xxx xxx statistickou xxxxxxx xxxxx xxx xxx xxxxxxx xxxxxxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX VÝSLEDKŮ
Pro xxxxxxxxx pozitivního xxxxxxxx xxxxxxxx xxxxxxx kritérií, xxxx. xxxxxx relativního xxxxx xxxxx x xxxxxxxxxxxxxx aberacemi v xxxxxxxxxx xx dávce xxxx xxxxx xxxxxx xxxxx xxxxx x xxxxxxxxx pro skupinu x xxxxxxx xxxxxx x x xxxxxxxx xxxxxxxx odběru. Xxxxxxxx xx xxxx xxx xxxxxxx biologická xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx zkoušky mohou xxx xxxxxxx jako xxxxxxx xxxxxxxxxx statistické xxxxxx (6). Statistická xxxxxxxxxx xx xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxx. Xxxxxxxxxx výsledky xx xxxx být xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx s úpravami xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx xxxxxxxxxxx xxxx xxxxxxxx, že xxxxxxxx xxxxx má xxxxxxxxx indukovat xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxx xxxxx buněk x xxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx, že xxxxxxxx xxxxx xx xxxxxxxxx xxxxxxxx progresi xxxxxxxxx xxxxx (7, 8).
Xxxxxxxx xxxxx, jejíž výsledky xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx xxxxxxxx x xxxxx xxxxxxx xx nemutagenní.
Ačkoli xxxxxxx xxxxxxxxxxx poskytne jasně xxxxxxxxx nebo xxxxxxxxx xxxxxxxx, x ojedinělých xxxxxxxxx xxxxxxxx soubor xxxxx vyslovit xxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx. Výsledky xxxxx zůstat xxxxxxxxxx xxxx xxxxxx xxx xxxxxx na xx, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx výsledky zkoušky xx xxxxxxxxxxxx xxxxxxx xx xxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxxxxxx x kostní xxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx. Negativní xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xx xxxxxxxx zkoušky xxxxxxxxxx x kostní xxxxx xxxxxxxxxxx xxxxx chromozomové xxxxxxx.
Xxxx xx být xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx xx xxxxxxxx xxxxx nebo její xxxxxxxxxx xxxxxxxx xx xxxxxxxx oběhu, xxxx xxxxxxxxxx do cílové xxxxx (např. xxxxxxxxx xxxxxxxx).
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- xxxxxxxxxxx a xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, je-li xxxxx.
Xxxxxxxxx zvířata:
- xxxxxxx xxxx/xxxx,
- počet, xxxxx x pohlaví xxxxxx,
- xxxxx, xxxxxxxx xxxxx, xxxxxx atd.,
- individuální xxxxxxxx xxxxxx xx xxxxxxx xxxxxxx, xxxxxx xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx a xxxxxxxxxx odchylky pro xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxxx a xxxxxxxxx (xxxxxxxxx/xxxxxxxxxxxx) kontroly,
- xxxxx xx xxxxxx xxx xxxxxxxx rozsahu, xxxxx xxxx xxxxxxxxx,
- zdůvodnění xxxxxxxxx xxxxxx xxxxx,
- xxxxx x přípravě xxxxxxxx xxxxx,
- xxxxx x xxxxxxxx zkoušené xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxxx xxxxxxx, zda se xxxxxxxx látka xxxxxxx xx xxxxxxxx xxxxx xxxx xx xxxxxx xxxxx,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx xxxx xxxx (ppm) xx xxxxxxxxxxxx xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x xxxxxxx xxxxxx x xxxx,
- xxxxxxxx xxxxx xxxxxxx xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxxx xxxxxxxx,
- identifikace xxxxx xxxxxxxxxxx xxxxxxxx, její xxxxxxxxxxx x xxxxx xxxxxxxx,
- metody xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- počet analyzovaných xxxxx xx xxxxx xxxxx,
- kritéria xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx,
- xxx x xxxxx aberací uvedený xxxxxxxxxx xxx xxxxx xxxxx,
- celkový počet xxxxxxx xx skupině xx středními xxxxxxxxx x směrodatnými xxxxxxxxxx,
- xxxxx xxxxx x xxxxxxxxx xx xxxxxxx xx středními xxxxxxxxx x xxxxxxxxxxxx odchylkami,
- xxxxx xxxxxxx, xxxxx xxxx xxxxxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxx,
- případné xxxxxxxxxxx xxxxxxx,
- údaje x xxxxxxxx xxxxxxxxx xxxxxxxx,
- dosavadní xxxxx x negativní xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Xxxxx, X. D. (1984), Xxxxxxxxxxx Xxxxx xx Xxxxxxx, in: Mutagenicity Xxxxxxx: x Xxxxxxxxx Xxxxxxxx, X. Xxxxxx, X. X. Xxxxx (xxx), IRL Press, Xxxxxx, Xxxxxxxxxx D. X., 275-306.
2) Xxxxxxx, X. X., Dean, X. X., Xxxxxxxx, X., Holden, H., XxXxx, X. X., Xxxxxx, M. (1987), Xxxxxxxxx In xxxx Xxxxxxxxxxx Assays: Xxxxxxxx xx Xxxxxxxxxx Xxxxxxxxxxx xx Xxxx Xxxxxx Xxxxx, Xxxxxxxxxx Xxx., 189, 157-165.
3) Xxxxxxx, X., Xxxxxxxx, X., Xxxxx, J., Xxxxxxxxx, X. G., Xxxxxxx, X., Xxxxxxxxx, L. (1990), Xx vivo Xxxxxxxxxxx Assays, xx: X. J. Kirkland (xx.), Xxxxx Xxxxxxxxxxxx Xxxxx, XXXXX Recommended Xxxxxxxxxx. XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx, Xxxx I xxxxxxx, Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, Xxx York, Xxxx Xxxxxxx, Melbourne, Xxxxxx, 115-141.
4) Xxxx, X. X., Hayashi, X., XxxXxxxxxx, X. X., Xxxxxxxx, X., Xxxxxx, X. X., Xxxxxx, H. X., Xxxxxx-Xxxxxxx, M., Xxxxxx Xx., X. X., Xxxxxxxxxxxx, X., Preston, X. J., Romagna, X., Shimada, X., Xxxxx, X., Xxxxxxx, X. (1994), Report xxxx the Working Xxxxx on the xx xxxx Mammalian Xxxx Marrow Chromozomal Xxxxxxxxxx Test, Xxxxxxxxxx Xxx., 312, 305-312.
5) Xxxxxxx, X. X., Xxxxx, X. X., Xxxxxx, X. X., Xxxxxx, X. A., Xxx, J., Esdaile, X. X., Gatehouse, X. X., Hodson-Walker, X., Morton, X. X., Xxxxxxxx, X. X., Xxxxxxx, X. (1992), Report of Xxxxxxx Xxxxxxxxxx Society/UK Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Xxxxx: Xxxx Xxxxxxx xx Xx xxxx Mutagenicity Assays, Xxxxxxxxxxx, 7, 313-319.
6) Xxxxxx, D. X., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxxxx, G. X., Xxxxx, G., Xxxxxxxx, X., Xxxxxxx, X., Papworth, X. X., Xxxxxx, X. X. X. (1989), Xxxxxxxxxxx Analysis xx Xx xxxx Cytogenetic Xxxxxx, in: XXXXX Xxx-Xxxxxxxxx on Xxxxxxxxxx xxx Xxxxxxxxxxxx Testing, Xxxxxx Xxxx XXX. Xxxxxxxxxxx Evaluation xx Xxxxxxxxxxxx Test Xxxx, X. X. Xxxxxxxx (xx.) Xxxxxxxxx Xxxxxxxxxx Xxxxx, Xxxxxxxxx, 184-232.
7) Xxxxx-Xxxxx, X. (1983), Xxxxxxxxxxxxxxxxx xx Chinese xxxxxxx cells during xxxxx-xxxxxxxxx-xxxxxxx X2 xxxxxx, Xxxxxxxxxx Res., 119, 403-413.
8) Huang, X., Xxxxxx, X., Xxxxxx, X. E. (1983), Xxxxxxxxxxx-xxxxxxx xxxxxxxxxxxxxxxxx xx Xxxxxxx xxxxxxx cells, Xxxxxx Xxx., 43, 1362-1364."
XXXXXXX 4X
"X.12 MUTAGENITA–TEST XXXXXXX XXXXXXXXXXXXXXX MIKROJADER XX VIVO
1. METODA
Tato xxxxxx xx xxxxxxxx xxxxxx XXXX XX 474 — Xxxx xxxxxxx xxxxxxxxxxxxxxx mikrojader xx xxxx (1997).
1.1 XXXX
Xxxx savčích xxxxxxxxxxxxxxx xxxxxxxxxx xx xxxx xx používán xxx xxxxxxx poškození chromozomů xxxx mitotického xxxxxxx xxxxxxxxxxxx, xxxxx je xxxxxxxxxx xxxxxxxxx xxxxxx, x xx xxxxxx xxxxxxx xxxxxxxxxx odebraných x xxxxxx xxxxx x/xxxx xxxxx xxxxxxxxx xxxx, obvykle hlodavců.
Účelem xxxxx xxxxxxx erytrocytárních xxxxxxxxxx xx xxxxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, jehož xxxxxxxxx xx xxxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xx (xxxxxxx) chromozomové xxxxxxxxx xxxx xxxx xxxxxxxxxx.
Xxxx xx erytroblast xxxxxx xxxxx xxxx xx xxxxxxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxx xx xxxxxxxx x xxxxxxxxxx, xxxxx xxx xxx xxxxx vzniknout, zůstávají x xxxxxxxxxx, která xxxxx xxxxx xxxxxxxxxx. Xxxxxxxxxxxx xxxxxxxxxx xx x těchto xxxxxxx xxxxxxxxx xxx, xx xxxxxxxxxx hlavní xxxxx. Xxxxxx výskytu xxxxxxxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxx xxxxxxxxx xx známkou indukovaného xxxxxxxxxxxxxx poškození.
V xxxxx xxxxx xx rutinně xxxxxxxxx kostní xxxx xxxxxxxx, xxxxxxxx xxxx xxxx produkuje polychromatické xxxxxxxxxx. Stanovení xxxxxxxxx (xxxxxxxxxxxxxxxxx) xxxxxxxxxx x xxxxxxxxxx x periferní xxxx je rovnocenně xxxxxxxxxx x kteréhokoli xxxxx, x xxxxx xxxx prokázána xxxxxxxxxxx xxxxxxx xxxxxxxxxxx erytrocyty x xxxxxxxxxx, nebo xxxxxxxxxx xxxxxxxxx detekovat xxxxxxxx, xxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxx. Xxxxxxxxxx xxx xxxxxxxx xxxxx xxxxxxxx. Xx xxxxxxxx xxxxxxxxxxxx přítomnosti xxxx xxxxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxxxxx) XXX x xxxxxxxxxx. Xxxxxxxxx xx xxxxxxx xxxxxxx xxxxxxxxx (polychromatických) xxxxxxxxxx s xxxxxxxxxx. Xxxxx zralých (xxxxxxxxxxxxxxxxxx) xxxxxxxxxx x xxxxxxxxx xxxx, které xxxxxxxx xxxxxxxxxx, xxxxxxxxxxx xx xxxxxx xxxxx zralých xxxxxxxxxx xxx xxxxxx xxxxxx xxxx xxxxxxx xxxxxxxx xxxxxxx, xxxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxx xxxxx xxxx xxxx.
Xxxxx xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxx in xxxx je xxxxxxx xxxxxx k posouzení xxxxxxxxx xxxxxxxxxx, neboť xxxxxxxx zohlednit xxxxxxx xxxxxxxxxxx xx xxxx, xxxxxxxxxxxxxxx a procesy xxxxxxxx XXX, xxxxxxx xx mohou xxxxx x xxxxxxx druhů x tkání, jakož x x genetického xxxxxxxx. Xxxxxxx xx xxxx je xxxxxx xxxxxxxx pro xxxxx xxxxxx xxxxxxxxxxx xxxxxx xxxxxxxxxx x systémech xx vitro.
Jestliže xxxxxxxx xxxxx x xxx, xx se zkoušená xxxxx nebo xxxxxxxxx xxxxxxxxxx xxxxxxxxxx do xxxxxx tkáně, xxxx xxxxxx tuto zkoušku xxxxxx.
Xxx xxxx Obecný xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxx (xxxxxxxxxx) : xxxxxx (oblasti) chromozomu, x níž (k xxxx) xx během xxxxxx buněk připojí xxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxx xxxxxxxxx xxxxx.
Xxxxxxxxxx : xxxx xxxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx x xxxxx xxxx, xxxxxxxxx xxxxx xxxxxxxx xxxxxx (meiosy) xxxxxxxxxxxxxxx se (lagging) xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxx xxxxxxxxxx.
Xxxxxxxxxxxxxxxx xxxxxxxxx : zralý erytrocyt xxxxxxxxxxxx ribozomy, xxxxx xxx xxxxxxxx od xxxxxxxxx polychromatických xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxx xxxxxxxx.
Xxxxxxxxxxxxxxx xxxxxxxxx : xxxxxxx xxxxxxxxx xx xxxxxxxxx xxxxxxxxxx, který xxxxx xxxxxxxx xxxxxxxx, x může xxx xxxx rozlišen xx xxxxxxx normochromatických xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxx xxxxxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxxxx se xxxxxxx xxxxxxxx xxxxxxx zkoušené xxxxx. Xxx xxxxxxx xxxxxx xxxxx se xxxxxxx xx xxxxxxx xxxxxxxx po xxxxxxxx xxxxxx, xxxxxxx se xxxxxx dřeň, připraví xx xxxxxxxxx x xxxxxx xx (1, 2, 3, 4, 5, 6, 7). Xxx xxxxxxx xxxxxxxxx xxxx xx xxxx xx xxxxxxx xxxxxxxx xx expozici xxxxxxx, xxxxxxxxxx xx xxxxxxxx xxxxxxxx x xxxxxx xx (4, 8, 9, 10). Xxx xxxxxxxx x xxxxxxxxx xxxx by xxxx xxxx xxxxxxxx expozicí x sklizením xxxxx xxxxxxxx xx xxxxxxxxx xxxx. Xxxxxxxxx xxxx xxxxxxxxxxx xx xxxxxxxxxx xxxxxxxxxx.
1.4 XXXXX ZKUŠEBNÍ XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxx použití xxxxxx xxxxx xx xxxx xxxxxxxxx xxxxx xxxxxxxxxx xxx nebo xxxxxx, xxxxxx xxx xxxxxx jakýkoli xxxxxx xxxxx xxxx. Xxx xxxxxxx periferní xxxx xx xxxxxxxxxx myš. Xxx xxxx použít xxxxxxxx vhodný xxxx xxxxx za xxxxxxxxxxx, xx jde o xxxx, x něhož xxxxxxx neodstraňuje xxxxxxxxxx x xxxxxxxxxx, nebo xxxx vykazující xxxxxxxxxxx xxxxxxxxx detekovat xxxxxxxx, xxxxx xxxxxxxxx xxxxxxxxxx xxxx numerické xxxxxxxxxxxx xxxxxxx. Xxxx xx xxx použity xxxxx xxxxxxx xxxxxxxxxxx kmeny xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxx. V xxxxxxxx zahájení xxxxxx xx xxxx xxx xxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxx x xxxxxx xx x xxxx xxxxxxx překročit ± 20 % xxxxxxx xxxxxxx xxxxxxxxx.
1.4.1.2 Xxxxxxxx xxxxx x xxxxxx
Xxxxx obecné xxxxxxxx xxxxx xxxxxxxx xxxxx x xxxxx X, xxxxxxx xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxx 50 – 60 %.
1.4.1.3 Příprava xxxxxx
Xxxxxx xxxxx xxxxxxxx xxxxxxx zvířata xx xxxxxxxx výběrem rozdělí xx xxxxxxxxx skupinu x xxxxxxx, x xxx xx provede xxxxxxxx. Xxxxxxx se xxxxxxxxxxx xxxxxxxxxxxx. Xxxxxxx xx x xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx pět xxx xxxxxxxxxxxxx. Xxxxx xx xxxxxxxxxx xxx, xxx xxx xxxx xxxxxx polohy xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx xx xxxx xxx před aplikací xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx vhodných xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx zředěny. Xxxxxxx xxxxxxxx xxxxx xxxxx být podávány xxxxx xxxx mohou xxx před xxxxxxx xxxxxxx. Měly by xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx chemické xxxxx, xxxxx údaje x jejich xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx nemělo mít xxx xxxxxxxxx xxxxxxxx xxxxx xxxxxxx účinky x xxxx xx xxx vyloučeno podezření, xx xxxxxxx xx xxxxxxxxx xxxxxx. Xxxx-xx xxxxxxx xxxx xxx xxxxx rozpouštědla/vehikula, xxxx xx být xxxxxx xxxxxxxx xxxxxxxxx xxxxx x jejich xxxxxxxxxxxxx. Xxxxxxxxxx xx pokud xxxxx nejdříve xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx měly být xxxxxxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) xxxxxxxx pro xxx xxxxxxx. S xxxxxxxx xxxxxxxx xxxxxxxx xxxxx xx xxxx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx identický xxxxxx xxxx xxxxxxx ve xxxxxxxxx, x xxxxx xxxxx x expozici.
Pozitivní xxxxxxxx xx xxxx xxxxxxxxxx xxxxxxxxxx xx xxxx xxx expozičních xxxxxxxx, x xxxxx xx očekává, že xxxxxxxxx xxxxxxxxxxxxx xxxxxx xxx xxxxxx. Xxxxx xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxx xxx, xxx xxx xxxxxx zřetelný, ale xxx při xxxxxx xxxxxxx ihned najevo xxxxxxxx identifikace xxxxxxxxx. Xx přijatelné, xxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx jiným xxxxxxxx xxx xxxxxxxx xxxxx x xxx byl xxxxx x xxxxx xxxxxxx xxxxxxxx xxx xxxxxx. Pro xxxxxxxxx xxxxxxxx xxxxx xxxx xxx xxxxx x xxxxx xxxxxxx chemických xxxxx ze stejné xxxxxxxx třídy, jsou-li x xxxxxxxxx. Xxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx monohydrát |
6055–19–2 |
|
|
2,4,6-tris(aziridin-1-yl)- 1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X okamžiku odběru xx měl xxx xxxxxxxx odběr x xxxxxxx xxxxxxxxx xxxxxxxx, xxxxx xx xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x xxxxx xxxxx xxxxxxxxxx stejný xxxxxx xxxx xxxxxxxxxx xxxxxxx, xxxxx xxxxxx x xxxxxxxxxxx xxxxxxxxxxx xxxxx x xxxxxxxxx xxxxxxxxxx xxxxx x xxxxxxxxxxx zvířat x xxxxxxxx xxxxx x xxxxxxxxxx. Xxxxxxx-xx xx xxx xxxxxxxxx kontrolu xxxxx xxxxx, xx xxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxx. Kromě xxxx by měly xxx xxxxxxxxxxxx kontroly xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx xxxx xxxxxx-xx xxxxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx účinky.
Při použití xxxxxxxxx xxxx xxxx xxx xxxx negativní xxxxxxxx xxxxxxxxxx xxxx xxxxxx xxxx xxxxxxxx xxxx expozicí, xxxxx xxxx u krátkých xxxxxx x xxxxxxxxx xxxx (xxxx. 1 — 3 xxxxxxxx) xx xxxxxxxxxxx, xx xxxxxxxx xxxxx xxxxx x xxxxxxx, které xx xx xxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx.
1.5 XXXXXX
1.5.1 Počet x xxxxxxx xxxxxx
Xxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx xx xxxx xxxxxxx x alespoň xxxx xxxxxxxxxxxxxxxx zvířat xxx xxxxx xxxxxxx (11). Xxxxxxxx xxxx v xxxx xxxxxx x xxxxxxxxx xxxxx ze xxxxxx xx xxxxxxx xxxxxx x za xxxxxxx xxxxxxxx způsobu xxxxxxxx, xxx xxxxxxxxx, xx xxxxxxxxxx xxxx xxxxxxxxx rozdíl v xxxxxxxx, xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx pohlaví. Xx-xx xxxxxxxx xxxxxxx xxxxxxxxxx xxx xxxxxx xxxxxxx, xxxx je xxxx například u xxxxxxxxx xxxxxxxxxxxxxxx látek, xxxx by být xxxxxxx xxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxxxxx.
1.5.2 Xxxx aplikace
Nelze xxxxxxxxx xxxxx standardní plán (xx. xxxxx, dvě xxxx xxx xxxxxxxx x xxxxxxxxx 24 xxxxx). Vzorky xx xxxxxx x prodlouženým xxxxxxx podávání xxxx xxxxxxxxxx, xxxxx se x xxxxxx studií xxxxxxx xxxxxxxxx výsledky, xxxx –x xxxxxxx xxxxxxxxxxx xxxxxx — xxxxx xxxx xxxxxxxxx xxxxxxxx nebo byla xxxxxxxxx xxxxxxx xxxxx x podávání pokračuje xx xx xxxxxxxx xxxxxx. Xxxxxxxx xxxxx xxxxx být xxxxxxxx xxxx ve xxxx xxxxxxx, tzn. dvě xxxxx x týž xxx x xxxxxxx xx xxxx xxx xxxxxxxx xxxxx, aby xxxx xxxxxxxxx xxxxxxxx xxxxxxx objemů xxxxxxxxx.
Xxxx xxxx xxx proveden xxxxx xxxxxxx:
x) zkoušená xxxxx xx xxxxxxxx xxxxxxxx jednou. Xxxxxx xxxxxx xxxxx xx xxxxxxxx xxxxxxx dvakrát, xxxxxxx xxxxx xxxxx xx provede xxxxxxxx 24 xxxxx xx xxxxxxxx a xxxxxxxx xxxxxxxxxx 48 xxxxx xx aplikaci x x xxxxxxxxxx xxxxxxxx xxxx xxxxxx. Xxxxx xxxxx než 24 xxxxx xx xxxxxxxx xxxx xxx xxxxxxxxx. Xxxxxx periferní krve xx odeberou xxxxxxx xxxxxxx, xxxxxxx první xxxxx se provede xxxxxxxx 36 xxxxx xx xxxxxxxx a xxxxxxxx nejpozději 72 xxxxx xx xxxxxxxx x po xxxxxxxxxxxx xx xxxxxx xxxxxxxxxxxx xxxxxx. Je-li xx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, není xxxxx odběr nutný;
b) xxxx-xx xxxxxxxx dvě xxxx více xxxxx xxxxx (např. dvě xxxx více dávek x xxxxxxxxx 24 xxxxx), xxxx xx xxx xxxxxx xxx xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxx xx 18 xx 24 xxxxxxxx po xxxxxxxx xxxxxxxx x xxx xxxxxxx xxxxxxxxx xxxx xxxxxx xx 36 xx 48 xxxxxxxx xx xxxxxxxx aplikaci (12).
Xxxxx xxxxxxx xxxxx xxx xxxxx xxxxxxx xxxx xxxx odběru.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxx xxxxxxxx xxxxxxx xxxxx, xxxx xx xxx xxxxxxxxx xx xxxxxx xxxxxxxxxx, xx stejným xxxxxx, xxxxxx, xxxxxxxx x za stejného xxxxxx xxxxxxxx, xxx xx použijí x xxxxxx xxxxxx (13). X xxxxxxx toxicity xx xxx xxxxx xxxxx použijí xxx xxxxxx xxxxx. Xxxx xxxxxx xxxxx xx xxxx xxxxxxxx xxxxxxx xxxx xxxxxxxxx xx xxxxxxxxx xxxxxxxxx, případně xxxxxx xxxxxxxxx. Xxx xxxxxxxxx odběru stačí, xxxx xxxx xxxxxxx xxxxx nejvyšší dávka. Xxxxxxxx xxxxx je xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx takové xxxxxx xxxxxxxx, xx xxxxx xxxxx xx xxxxx xxx xxxxxxx xxxxxx xxxxxxxxx podle xxxxxxxxx x letalitě. Látky xx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxx nízkých xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxx x xxxxxxxx) xxxxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx a xxxx xx xxx xxxxxxxxx xxxxxx xx xxxxxxx. Xxxxxxxx xxxxx xxxx být také xxxxxxxxxx xxxx xxxxx xxxxxxxxxxxx v xxxxxx xxxxx některé xxxxxx xxxxxxxx (např. snížení xxxxxx nezralých erytrocytů x celkového xxxxxxxx xxxxxxxxxx x kostní xxxxx nebo v xxxxxxxxx xxxx).
1.5.4 Limitní xxxxxxx
Xxxxxxxx zkouška s xxxxxx xxxxxx o xxxxxxx 2000 mg/kg xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx nebo xx xxxx xxxxxxx x xxxxxx dni xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx xxxxxx x xxxx-xx xx xxxxxxx xxxxx x xxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxxxxx, xxxx xxxxxxxxxx xxxxx studie xx xxxxx úrovněmi xxxxx xx xxxxxxxxx. X déle xxxxxxxxxx xxxxxx xx xxxxxxx xxxxxx pro 14xxxxx xxxxxxxx 2000 mg/kg xxxxxxx xxxxxxxxx/xxx a xxx delší xxx 14xxxxx xxxxxxxx xx xxxxxxx xxxxxx 1000 xx/xx xxxxxxx xxxxxxxxx/xxx. Xxxxxxxxx expozice člověka xxxx znamenat potřebu xxxxxx v xxxxxxx xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx dávek
Zkoušená xxxxx xx obvykle xxxxxx nitrožaludečně, žaludeční xxxxxx nebo xxxxxxx xxxxxxxxx xxxxxxx, xxxx xxxxxxxxxxxxxxxxx injekcí. Xxxx xxxxxxx podávání xxxx xxxxxxxxxx x xxxxxxxxxxxxxxx xxxxxxxxx. Maximální objem xxxxxxxx, xxxxx může xxx xxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxx xxxxxxxx, závisí xx xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 xx/100 x xxxxxxx xxxxxxxxx. Xxxxxxx vyšších xxxxxx, xxx xx xxxxxxx xxxxx, xxxx xxx xxxxxxxxxx. Až na xxxxxxxx a žíravé xxxxx, xxxxx xxxxxxx xxx xxxxxxx koncentracích xxxxxxxx xxxxxxxx xxxxxx, xx xxxx být xxxxxxxxxxx xxxxxxxxxx objemu xxxxxxxxxxxxxx nastavením koncentrace xxxxxxxxxxx xxxxxxxxxx xxxxx xxx všech xxxxxxxx xxxxx.
1.5.6 Příprava xxxxxx xxxxx xxxx xxxx
Xxxxx xxxxxx xxxxx xx xxxxxxx získávají x xxxxxx nebo xxxxx xxxxx xx xxxxxxxx. Xxxxx se odeberou x xxxxxx xxxx xxxxx x xxxxxxxxxx xxxxxxxx se preparují x obarví. Periferní xxxx se xxxxxxx x xxxxxx xxxx xxxx xxxx xxxxxx xxxxxx xxxx. Krevní xxxxx se xxxxx xxxxxxxxxxxx xxxxxx (8, 9, 10), xxxx xx xxxxxxxx xxxxxxxxx xxxxxxxx x xxxx xx xxxxxx. Použitím xxxxxxx specifického pro XXX (xxxx. xxxxxxxxxx xxxxx (14) nebo Xxxxxxx 33258 x xxxxxxx-X (15)) se xxx xxxxxxx xxxxxxxx xxxxxxxxxx spojeným s xxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxx DNA. Xxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx (xxxx. Xxxxxx). Xxxxxxxx xxxxxxx (xxxx. celulosová kolona x xxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxx (16)) xxx xxxxxx xx xxxxxxxxxxx, xx xx xxxxxxxxx odpovídající funkčnost xxxxxx xxxxxxx xxx xxxxxxxxx mikrojader x xxxxxxxxxx.
1.5.7 Xxxxxxx
Xxx xxxxx xxxxx se xxxxxxx xxxxx nezralých erytrocytů x xxxxxxxxx (nezralé + zralé) xxxxxxxx xxxxxxxxxx, xxxxxxx xx x případě kostní xxxxx použije celkově xxxxxxx 200 erytrocytů x x případě xxxxxxxxx xxxx xxxxxxx 1000 xxxxxxxxxx (17). Xxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxx kontrol, xx xxxx xxx před xxxxxxxx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx. X xxxxxxx xxxxxxx xx xxxxxxx xxxxxxx 2000 xxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxxxxxxx v xxxxxxxxxxxxxxxxxxxxx. Xxxxx xxxxxxxxx xxxxx být získány xxxxxxxxxx xxxxxxx erytrocytů xx xxxxxx xxxxxxxxxx. Xxx xxxxxxxxxxxxx xxxxxxx xx xxxxx xxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx množství xxxxxxxxxx xxxxx xxx 20 % xxxxxxxxx xxxxxxx. Jestliže jsou xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxx týdny xxxx xxxx, lze také xxxxxxxx xx xxxxxx xxxxxxxxxx alespoň 2000 xxxxxxx xxxxxxxxxx na xxxxx xxxxx. Xxxxxxx xxx automatickou xxxxxxx (xxxxxxx xxxxxx a xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxx xxxxxxxx) jsou xx xxxxxxxxxxxxx xxxxxxxxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx manuálního hodnocení.
2. XXXXX
2.1 ZPRACOVÁNÍ XXXXXXXX
Xxxxx xxx xxxxxxxxxx xxxxxxx xx měly xxx xxxxxxxxxx ve xxxxx xxxxxxx. Experimentální xxxxxxxxx xx zvíře. Xxx xxxxx xxxxxxxxxxx zvíře xx xxx xxx xxxxxx xxxxx xxxxxxxxxxx xxxxxxxxx erytrocytů, xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx a xxxxx xxxxxxxxx xxxxxxxxxx z xxxxxxxxx množství xxxxxxxxxx. Xxxxxxxx jsou xxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxx xxxxx nebo xxxx, xxxx xx xxx xxxx xxxxxxx xxxxx x xxxxxxx erytrocytech, xxxx-xx shromažďovány. Xxx xxxxx xxxxx xx xxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxx xxxxxxxxxx x xxxxxxxx xxxxxxxx xxxxxxxxxx x mikrojádry xxxxxxxxx x xxxxxxxxxx. Xxxxxxxxxx-xx xxxxx x xxxxxxx x odpovědi xxxx xxxxxxxxx, xxxxx xxx xxx xxxxxxxxxxxx xxxxxxx xxxxx xxx xxx xxxxxxx xxxxxxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx výsledku xxxxxxxx xxxxxxx kritérií, xxxx. nárůst xxxxx xxxxx s mikrojádry x xxxxxxxxxx xx xxxxx xxxx xxxxx xxxxxx počtu xxxxx x xxxxxxxxxx pro xxxxxxx s určitou xxxxxx x x xxxxxxxx xxxxxxxx xxxxxx. Xxxxxxxx xx xxxx xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx být xxxxxxx xxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxx metody (18, 19). Xxxxxxxxxxx významnost xx xxxxxx xxx xxxxxxx určujícím xxxxxxxx xxx xxxxxxxxx xxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx být xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx x xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxx, jejíž xxxxxxxx xxxxxxxxx výše xxxxxxx xxxxxxxx, xx xxxxxxxx x xxxxx xxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx poskytne xxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx případech xxxxxxxx xxxxxx údajů xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx látky. Xxxxxxxx xxxxx zůstat xxxxxxxxxx xxxx xxxxxx xxx ohledu xx xx, xxxxxxxx xx xxxxxxxxxx opakován.
Pozitivní xxxxxxxx xxxxx na xxxxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx indukuje mikrojádra, xxx jsou xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx mitotického aparátu xxxxxxxxxxxx xxxxxxxxxxx xxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xx podmínek zkoušky xxxxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxx testovacího xxxxx.
Xxxx xx xxx xxxxxxxxxxx xxxxxxxxxxxxxxx, x xxxxx xx zkoušená xxxxx xxxx její xxxxxxxxxx xxxxxxxx xx xxxxxxxx oběhu, xxxx xxxxxxxxxx xx xxxxxx xxxxx (xxxx. xxxxxxxxx xxxxxxxx).
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx o zkoušce xxxx xxxxxxxxx tyto xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxxxxxx zvířata:
- xxxxxxx xxxx/xxxx,
- xxxxx, stáří x pohlaví zvířat,
- xxxxx, podmínky chovu, xxxxxx atd.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx xx xxxxxxx zkoušky, xxxxxx xxxxxxx xxxxxxx xxxxxxxxx, xxxxxxx xxxxxxx a xxxxxxxxxx xxxxxxxx xxx xxxxxx skupinu.
Zkušební xxxxxxxx:
- xxxxx x xxxxxxxxx x negativní (vehikulum/rozpouštědlo) xxxxxxxx,
- xxxxx ze xxxxxx xxx zjištění xxxxxxx, xxxxx xxxx xxxxxxxxx,
- xxxxxxxxxx zvolených xxxxxx dávek,
- xxxxx x přípravě xxxxxxxx xxxxx,
- xxxxx x xxxxxxxx xxxxxxxx látky,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- xxxxxxxxx metody xxxxxxx, xxx xx xxxxxxxx xxxxx xxxxxxx xx xxxxxxxx xxxxx nebo xx xxxxxx xxxxx,
- xxxxxxxx xxxxxxxx mezi xxxxxxxxxxx xxxxxxxx látky x krmivu nebo xxxx (xxx) xx xxxxxxxxxxxx xxxxx (mg/kg xxxxxxx hmotnosti/den),
- xxxxxxxx xxxxx o xxxxxxx xxxxxx x vody,
- xxxxxxxx popis xxxxxxx xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxx preparátů,
- xxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxx hodnocení xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxx,
- xxxxx xxxxxxxxxxxxx xxxxx xx xxxxx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- podíl nezralých xxxxxxxxxx z celkového xxxxxxxx xxxxxxxxxx,
- xxxxx xxxxxxxxx xxxxxxxxxx s xxxxxxxxxx xxxxxxx xxxxxxxxxx xxx xxxxx xxxxx,
- xxxxxxx xxxxxxx ± xxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxxx xx xxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xx dávce,
- xxxxxxxx statistické xxxxxxx x xxxxxx,
- xxxxx x souběžné x xxxxxxxxx negativní xxxxxxxx,
- xxxxx x souběžné xxxxxxxxx xxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Heddle, J. X. (1973), A Xxxxx Xx vivo Xxxx for Xxxxxxxxxxx Xxxxxx, Xxxxxxxxxx Xxx., 18, 187-190.
2) Xxxxxx, X. (1975), Xxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx., 31, 9-15.
3) Xxxxxx, X. X., Xxxxxxxx, X. X., Xxxx, M., Xxxxxxxx, X., Xxxxxxxxx, X., XxxXxxxxx, J. X., Xxxxxx, G. W. (1983), The Induction xx Xxxxxxxxxxx x. x. x Measure xx Genotoxicity, Mutatation Xxx. 123, 61-118.
4) Xxxxxxxxx, X. X., Xxxxxx, D. X., Xxxxxx, M. C., Xxxxxxxx, X. X., Xxxxxx, X. X. (1990), Xxx Xx xxxx Xxxxxxxxxxxx Assay xx Mammalian Xxxx Xxxxxx xxx Xxxxxxxxxx Xxxxx. A xxxxxx xx the U. X. Xxxxxxxxxxxxx Protection Xxxxxx Gene-Tox Xxxxxxx, Xxxxxxxxxx Res., 239, 29-80.
5) XxxXxxxxx, X. X., Xxxxxxxx, R., Xxxx, X. N., Xxxx, X. M. (1983), Micronuclei in Xxxxxxxxxxx Xxxxxxxxxxxx: X Xxxxx Screen xxx Xxxxxxxxxxx Damage Xxxxxx Xxxxxxx Xxxxxxxx Testing xx Mice, in: Xxxxxxxxxxxx xx Science xxx Practice of Xxxxxxxxxx, xx. X. X. Xxxxx, R. X. Schnell, T. X. Xxxx. Xxxxxxxx, Xxxxxxxxx, 555-558.
6) MacGregor, X. X., Heddle, X. X. Hite, X., Xxxxxxxx, G. X., Xxxxx, C., Xxxxxxxx, M. F., Xxxx, X. R., Xxxx, X. (1987), Xxxxxxxxxx for the Xxxxxxx xx Xxxxxxxxxxxx Xxxxxx xx Xxxxxxxxx Xxxx Xxxxxx Erythrocytes, Xxxxxxxxxx Xxx., 189, 103-112.
7) MacGregor, X. X., Xxxx, X. X., Henika, X. X., Shelby, X. X. (1990), Xxx xx vivo Xxxxxxxxxxx Xxxxxxxxxxxx Xxxx: Measurement xx Steady Xxxxx Xxxxxxxxx Xxxxx Xxxxxxxxxx xxx Permits Xxxxxxxxxxx xxxx Toxicity Studies, Xxxxxx. Xxxx. Xxxxxxx. 14, 513-522.
8) Hayashi, X., Morita, T., Xxxxxx, X., Sofumi, X., Xxxxxxxx, X. Xx. (1990), The Xxxxxxxxxxxx Xxxxx xxxx Xxxxx Xxxxxxxxxx Blood Xxxxxxxxxxxxx Using Xxxxxxxx Xxxxxx-Xxxxxx Xxxxxx, Xxxxxxxxxx Xxx., 245, 245-249.
9) Xxx Xxxxxxxxxxxxx Xxxxx Xxxxx xxx xxx Xxxxxxxxxxxx Xxxx (1992). Xxxxxxxxxxxx Test xxxx Xxxxx Xxxxxxxxxx Xxxxx Xxxxxxxxxxxx xx Xxxxxxxx Xxxxxx Supravital Xxxxxxxx: Xxx Xxxxxxx Report xx xxx 5xx Xxxxxxxxxxxxx Xxxxx by XXXXX/XXXXX, XXX, Xxxxxxxxxx Xxx., 278, 83-98.
10) Xxx Xxxxxxxxxxxxx Study Xxxxx for the Xxxxxxxxxxxx Test (CSGMT/JEMMS, XXX: The Mammalian Xxxxxxxxxxx Xxxxx Group xx xxx Xxxxxxxxxxxxx Xxxxxxx Society of Xxxxx) (1995), Xxxxxxxx xxxxxxxxxxx xxx xxx xxxxx-xxxx xxxxx xxxxxxxxxx xxxxx xxxxxxxxxxxx test, Xxxxxxxxxxx, 10, 53-159.
11) Xxxxxxx, X., Xxxx, X. X., XxxXxxxxx, X. X., Xxxxxxxx, X., Blackey, D. X., Kirsch-Volders, M., Xxxxxx, Jr. F. X., Xxxxxxxxxxxx, X., Xxxxxxx, X., Xxxxxxx, X., Xxxxx, X., Xxxxxxx, B. (1994), Xx vivo Rodent Xxxxxxxxxxx Micronucleus Xxxxx, Xxxxx. Res., 312, 293-304.
12) Xxxxxxxxxxx, N., Xxxxx, X. (1995), Xx xxxxxxx, xxxxxxxxxxx xxxxxxxx xxxx xx 30 ± 6 x xxxxx xxxxxx xxxxxx xx xxx xxxxx peripheral micronucleus xxxx, Mutagenesis, 10, 313-319.
13) Fielder, R. X., Allen, X. X., Xxxxxx, A. X., Xxxxxx, X. X., Xxx, J., Xxxxxxx, X. X., Xxxxxxxxx, D. X., Xxxxxx-Xxxxxx, X., Morton, X. X., Xxxxxxxx, X. J., Xxxxxxx, X. (1992), Xxxxxx xx Xxxxxxx Xxxxxxxxxx Xxxxxxx/XX Xxxxxxxxxxxxx Xxxxxxx Xxxxxxx Xxxxxxx Xxxxx: Xxxx Xxxxxxx in Xx xxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx, 7, 313-319.
14) Hayashi, X., Xxxxxx, T., Xxxxxxxx, X. Xx. (1983), Xx Xxxxxxxxxxx of Xxxxxxxx Xxxxxx Xxxxxxxxxxx Xxxxxxxx to xxx Xxxxxxxxxxxx Xxxx, Mutation Xxx., 120, 241-247.
15) XxxXxxxxx, X. T., Xxxx, X. M., Xxxxxxxx, X. G. (1983), A Simple Xxxxxxxxxxx Staining Xxxxxxxxx xxx Xxxxxxxxxxx xxx XXX in Erythrocytes Xxxxx Xxxxxxx 33258 xxx Pyromin Y, Xxxxxxxx Xxx., 120, 269-275.
16) Xxxxxxx, X., Xxxxxxxxxx, X. X. (1989), Xxx automated xxxx marrow xxxxxxxxxxxx xxxx, Xxxxxxxxxx Xxx., 213, 91-104.
17) Gollapudi, X., McFadden, X. X. (1995), Xxxxxx Xxxx xxx xxx Xxxxxxxxxx of Polychromatic xx Normochromatic Xxxxxxxxxxx Xxxxx xx the Xxxx Xxxxxx Micronucleus Xxxx, Mutatation Res., 347, 97-99.
18) Xxxxxxx, X., Xxxxx, X., Xxxxxxx, X., Xxxxxxxx, X., Gatehouse, X. X., Xxxxxxxxx, L. (1990), Xx xxxx Xxxxxxxxxxxx Xxxxx, xx: X. X. Kirkland (xx.), Basic Xxxxxxxxxxxx xxxxx, XXXXX Recommended Xxxxxxxxxx, XXXXX Sub-Committee xx Xxxxxxxxxx xxx Xxxxxxxxxxxx Xxxxxxx. Report, Xxxx 1, revised, Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, New York, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
19) Lovell, X. X., Anderson, X., Xxxxxxxx, R., Xxxxxxxx, X. E., Xxxxx, X., Xxxxxxxx X., Xxxxxxx, M., Xxxxxxxx, X. G., Xxxxxx, J. R. X. (1989), Xxxxxxxxxx Xxxxxxxx xx In xxxx Xxxxxxxxxxx Assays, xx: X. X. Xxxxxxxx (ed.), Xxxxxxxxxxx Xxxxxxxxxx xx Mutagenicity Xxxx Data. XXXXX Xxx-Xxxxxxxxx on Xxxxxxxxxx xxx Mutagenicity Xxxxxxx. Xxxxxx, Part III, Xxxxxxxxx Xxxxxxxxxx Press, Xxxxxxxxx, New Xxxx, Xxxx Xxxxxxx, Melbourne, Xxxxxx, 184-232."
XXXXXXX 4D
"B.13/14 XXXXXXXXXX — XXXXXXX NA XXXXXXXX XXXXXX X XXXXXXXXXX
1. METODA
Tato xxxxxx xx xxxxxxxx metody XXXX XX 471 — Xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx (1997).
1.1 XXXX
Xxx xxxxxxx na xxxxxxxx xxxxxx s xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx závislé xx xxxxxxxxxxxxxxx Salmonella xxxxxxxxxxx x Escherichia xxxx, x xxxxxxx bodových xxxxxx, xxxxx xxxxxxxx xxxxxxxxxx, xxxxx x xxxxxx xxxxxxx xxxx xxxxxxxx xxxx bází XXX (1, 2, 3). Xxxxxxxx xxxx xxxxxxx na xxxxxxxx xxxxxx x bakteriemi xxxxxxx x xxxxxxx xxxxxx, xxxxx xxxxxxxxx xxxxxx obsažené x xxxxxxxxxxx kmenech x xxxxxxxx xxx funkční xxxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx. Bakterie xx xxxxxxx jsou xxxxxxxxxx díky své xxxxxxxxxx růst v xxxxxxxxxxxxx xxxxxxxxxxxx, xxxxx xxxx xxxxxxxxxx mateřským xxxxxxxxxx kmenem.
Bodové mutace x podobné jevy xxxx xxxxxxxx mnoha xxxxxxxxx xxxxxxxxxxx xxxxxx x člověka x xxxxxxxx xxxxx xxxxxx x xxx, že xxxxxx mutace v xxxxxxxxxx x v xxxxxx xxxxxxxxxxx buněk xxxxxxxxx nádory xxxx xxxxx xx xxxxxx xxxxxxxx u xxxxxxx x u xxxxxxxxx xxxxxx. Xxxxxxx xx xxxxxxxx xxxxxx s xxxxxxxxxx xx rychlá, xxxxxxxxxx x xxxxxxxxx xxxxxx. Xxxxx xxxxxxxxxxx xxxxx má xxxx xxxxxxxxxx, xxxx xxxx xxxx xxxxxxxxxx xx xxxxxxx xxxxxx, včetně xxxxxxxxxxxxx xxxxxxxx XXX xx xxxxxxxxxx xxxxxxx, xxxxxxx xxxxxxxxxxxx buněk xxx velké xxxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxxxx XXX nebo xxxxxxxx xxxxxxxxxxx procesů XXX xxxxxxxxxx k xxxxxx. Specifičnost testovacích xxxxx xxxx xxxxxxxxxx xxxxxxx užitečné xxxxxxxxx x xxxxxx mutací, xxx xxxx indukovány xxxxxxxxxxxxx xxxxxxxx. Pro xxxxxxx na xxxxxxxx xxxxxx s xxxxxxxxxx xx x dispozici xxxxx rozsáhlá xxxxxxxx xxxxxxxx pro xxxxxxx xxxxx xxxxxxxx x xxxx byly xxxxxxxx xxxxx xxxxxxxxxx xxxxxx xxxxxxxx xxxxxxxxxx xxxxx, xxxxxx těkavých xxxxxxxxx, x různými xxxxxxxxx-xxxxxxxxxx xxxxxxxxxxx.
Xxx xxxx xxxxxx xxxx, část X.
1.2 XXXXXXXX
Xxxxxxx na xxxxxxxx xxxxxx s xxxxxxxxxx Xxxxxxxxxx xxxxxxxxxxx xxxx Xxxxxxxxxxx xxxx xxxxxx x detekci xxxxxx x kmeni xxxxxxxxxxx xxxxxxxxxxxxx (histidin xxxx. xxxxxxxxx), xxxxxxx xxxxxx xxxx xxxxxxxxx xx xxxxxxx xxxxxxx xxxxxxxxxxxxx.
Xxxxxxxx xxxxxxxxxx xxxx xxxx xxxx činitele, jež xxxxxxxxx změny x xxxxxx XXX. Při xxxxxxx xxxxxxxxxx mutací xx xxxxx xxxx xxxxx xxxxxxxxxx xx xxxxx xxxxxxx xxxxxx xxxx xxxxx xxxxx xxxxxxxxxxxxx xxxxxx.
Xxxxxxxx xxxxxxxx xxxx činitele, jež xxxxxxxxx xxxxx xxxx xxxxxx xxxxxxx xxxx xxxx párů bází XXX x xxxxxxxx xxx xxxxx xxxxx XXX.
1.3 VÝCHOZÍ XXXXX
Xxx xxxxxxxxx na xxxxxxxx xxxxxx s bakteriemi xx xxxxxxxxx prokaryotické xxxxx, které se xxxx xx xxxxx xxxxx faktory, xxxx xxxx příjem, xxxxxxxxxxxx, xxxxxxxxxxxx xxxxxxxxx a xxxxxxxxx procesy XXX. Xxxxxxx xxxxxxxxx xx xxxxx obecně vyžadují xxxxxxx xxxxxxxx zdroje xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxxx xxxxxxxxx systémy xx xxxxx xxxxxxx zcela xxxxxxxxx podmínky xx xxxx x xxxxx. Xxxxxxx xxxx neposkytuje xxxxxx informaci x xxxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxxx látky pro xxxxx.
Xxxxxxx xx xxxxxxxx xxxxxx x bakteriemi xx zpravidla xxxxxxxxx xxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx, x xxxxxxx xxxxxxxx vyvolávající xxxxxx mutace. Z xxxxxxxx xxxxxxxx vyplývá, xx mnoho xxxxxxxxxx xxxxx, xxxxx jsou x této xxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxxxx xxxxxxxx i x xxxxxx zkouškách. Xxxxxxxx xxxxxxxx xxxxxxxxxxx činitelů, xxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxx. Xxxxxxx xxxxxx skutečností xxx xxxxxxxxx ve xxxxxxxxxx xxxxxx detekovanéhokonečného xxxx, x xxxxxxxxx x xxxxxxxxxxx xxxxxxxx nebo x xxxxxxxxx v xxxxxxxxxx xxxxxxxxxxx. Xx xxxxx xxxxxx xxxxxxx, xxxxx xxxxxxx citlivost xxxxxxx xx xxxxxxxx xxxxxx xx xxxxxxxxxx, xxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxxx xx xxxxxxxx xxxxxx x xxxxxxxxxx nemusí xxx vhodná pro xxxxxx třídy xxxxxxxxxx xxxxx, xxxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxxxx (xxxx. xxxxxx xxxxxxxxxxx) a xxx xxxxxxxx xxxxx, x xxxxx xx xxxxxxxxxxx (nebo o xxxxx se xx), xx xxxxxxxxxx xxxxxxxx xx replikačního xxxxxxx xxxxx xxxxx (xxxx. xxxxxxx inhibitory topoisomerasy x xxxxxxx analogy xxxxxxxxxx). X xxxxxxxx xxxxxxxxx mohou xxx xxxxxxxxx xxxxxxx mutagenity x xxxxx.
Xxxxxxxx xxxxx xxxxxxxxx, xxx xxx xx xxxx zkouška xxxxxxxxx, je karcinogenní xxx xxxxx, není xxxxxxxx absolutní. Xxxxxx xx xxxxxxxx třídě x existuje xxxxx xxxxxxxxxxx, xxx nejsou xxxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxxxx xxxxxx, xxxxxxxxxxxxxxx xxxxxxxxxx, xxxx xxxxxxxxxx, xxxxx x xxxxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4 XXXXXXXX ZKUŠEBNÍ METODY
Suspenze xxxxxxxxxxxxx buněk jsou xxxxxxxxx xxxxxxxx látce, x xx xx xxxxxxxxxxx vnějšího xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx x xxx něho. Xx xxxxxxxxxxx xxxxxxxx testu xx suspenze xxxxxxxx x xxxxxxx xxxxxx x xxxxx xx xxxxxxx xx xxxxxxxxx xxxx. X preinkubační xxxxxx se zkoušená xxxx xxxxxxxx a xxxx se před xxxxxxxxx xx minimální xxxx xxxxxx x xxxxxxx xxxxxx. Při xxxx xxxxxxxxxx xx xx xxxx xxxx xxxxx xxxxx xxxxxxxx xxxxxxxxx xxxxxxx revertantů x xxxxxxx xx xxxxxxxx x xxxxxx xxxxxxx spontánních revertantů xx kontrolní xxxxx x rozpouštědlem.
Je popsáno xxxxxxx xxxxxxx provedení xxxxxxx xx reverzní xxxxxx x xxxxxxxxxx. Xxxx běžně xxxxxxxxx xxxxx xxxxxxxxxx miskový xxxx (1, 2, 3, 4), xxxxxxxxxxxx xxxxxx (2, 3, 5, 6, 7, 8), xxxxxxxxxx xxxx (9, 10) x xxxxxxxxx xxxxxx (11). Xxxxxx pro zkoušení xxxxx x par xxxx xxxxxxx (12).
Xxx xxxxxxx xxxxxxx xx xxxxxx xxxxxx xxxxxxxxxxxx xxxxxxxxx testu x xxxxxxxxxxxxxx xxxxx. Xxxxx x xxxx xx xxxxxxxxxx xxx provádění xxxxxxxxxxx jak x xxxxxxxxxxxx xxxxxxxx, tak xxx ní. Xxxxxxx xxxxx lze xxxxxxxx xxxxxxxxx xx použití xxxxxxxxxxxx xxxxxx. Xxxx xxxxx xxxxx do xxxxxxxxxx xxxx, xx xxxxx xxxxx xxxx xxxxx xxxxxx alifatické xxxxxxxxxxx, xxxxxxxxx xxxx, xxxxxxxx, xxxxxxxxxx x xxxxxxxxxx xxxxxxxxxx, pyrrolizidinové xxxxxxxxx, allylové sloučeniny x xxxxxxxxxxxxxxx (3). Xxxxxx se xxxxxxxxx, xx xxxxxx třídy xxxxxxxx xxxxx xxxx xxxxxxxxx standardními xxxxxxx, xxxx xx standardní xxxxxxx xxxx xxxx xxxxxxxxxxxx metoda. Xxxx xx být považovány xx "xxxxxxxx případy" x k xxxxxx xxxxxxx se důrazně xxxxxxxxxx xxxxxx xxxxxxxxxxxx xxxxxxx. Xx možné xxxxxxxxxxxxx xxxx "xxxxxxxx xxxxxxx" (xxxxxxxx s xxxxxxxx postupů xxxxxx xxxxxxx): azobarviva x xxxxxxxxxx sloučeniny (3, 5, 6, 13), xxxxx a těkavé xxxxxxxx látky (12, 14, 15, 16), x xxxxxxxxx (17, 18). Xxxxxxxx xx xxxxxxxxxxxx postupu musí xxx xxxxxxx xxxxxxxxxx.
1.5 XXXXX XXXXXXXX XXXXXX
1.5.1 Xxxxxxxxx
1.5.1.1 Xxxxxxxx
Xxxxxxx xxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxxxx do xxxxxx xxxxxxxxxxxxx fáze xxxx xx xxxxx xxxxxxxxxxx xxxx růstu (xxxxxxxxx 109 buněk xx xx). Buňky x xxxxxx xxxxxxxxxxx xxxx xx neměly xxx použity. Xx xxxxxxxx, xxx xxxx xxxxxxx xxxxxxxx vysoký xxxx xxxxxxxxxxxxxxx xxxxxxxx. Xxxx xxxx xxx xxxxxxxx buď na xxxxxxx xxxxxxxxxxx kontrolních xxxxx x xxxxxxx xxxxxx, nebo pro xxxxxx xxxxxxx stanovením xxxxx xxxxxxxxxxxxxxx xxxxx xx miskách.
Doporučená inkubační xxxxxxx xx 37 °X.
Xxxx by xxx xxxxxxx alespoň xxx xxxxx xxxxxxxx. Mezi xxxx by měly xxx čtyři xxxxx X. xxxxxxxxxxx (XX1535; XX1537 nebo TA97a xxxx TA97; XX98 x XX100), jejichž xxxxxxx xx xxxxxxx x xxxxxxx laboratořích xxxx spolehlivá a xxxxxxxxxxxxxxxx. Tyto xxxxx xxxxx X. typhimurium xxxx pár bází XX xx xxxxxxxxx xxxxxxxxx xxxxx x xx xxxxx, xx xxxxxx xxxxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxxxxxx xxxxxxxx, činitele xxxxxxxxxxx xxxxxxxxxx vláken XXX x hydraziny. Tyto xxxxx xxxxx xxx xxxxxxxxxx xxxxx E. xxxx WP2 xxxx X. xxxxxxxxxxx XX102 (19), xxxxx mají xx primárním xxxxxxxxx xxxxx xxx xxxx XX. Doporučená xxxxxxxxx xxxxx xx xxxx xxxx:
- X. xxxxxxxxxxx XX1535 x
- S. xxxxxxxxxxx TA1537 xxxx XX97x x
- S. xxxxxxxxxxx XX98 x
- X. xxxxxxxxxxx TA100 x
- X. coli XX2 xxxX, xxxx X. coli WP2 xxxX (pKM101), nebo X. xxxxxxxxxxx XX102.
Xxx xxxxxxx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxx vláken XXX xxxx xxx xxxxxxxxx xxxxxxx XX102 xxxx xxxxxx xxxx X. xxxx x vysokou xxxxxxxxxx xxxxxxxx XXX, (xxxx. X. coli XX2 (pKM101)).
Měly by xxx použity xxxxxxxx xxxxxxx xxxxxxxx xxxxxxx xxxxxxx, xxxxxxxxxx xxxxxxx x xxxxxxxxxx. Xxxxxxx xxxxxxxxxxxxx xxx růst xx měla být xxxxxxxxx xxx xxxxxx xxxxxxxxx kmenovou xxxxxxx (xxxxxxxx xxx xxxxx X. xxxxxxxxxxx x xxxxxxxxx pro X. xxxx). Xxxxxxx xx xxxx být xxxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxxx, xxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx X-xxxxxxx xxxxxxxx (xx. xxxxxxxxxxxx rezistence x xxxxx XX98, XX100 x TA97a nebo XX97, WP2 uvrA x XX2 uvrA (xXX101) a xxxxxxxxxxxx x xxxxxxxxxxxxxx rezistence x xxxxx XX102), xxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxx (xx. xxx xxxxxx x S. xxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxxxx x xxxX xxxxxx u E. xxxx xxxx xxxX xxxxxx x S. xxxxxxxxxxx xxxxxxxxxx xx xxxxxxxxxxxx xxxxxx) (2, 3). Kmeny by xxxx xxxxxx xxxxx xxxxx xxxxxxx spontánních xxxxxxxxxx xx xxxxx x xxxxxxx xxxxxxxx xxxxxxxxxxx na xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx a xxxxxxx x xxxxxxx xxxxxxxx x literatuře.
1.5.1.2 Médium
Použije xx xxxxxx minimální xxxx (xxxx. obsahující xxxxxxxxx xxxx X (Xxxxx-Xxxxxx) a xxxxxxx) x vrchní agar xxxxxxxxxx histidin a xxxxxx nebo tryptofan xxxxxxxxxx xxxxxxx buněčných xxxxxx (1, 2, 9).
1.5.1.3 Xxxxxxxxxxx aktivace
Bakterie xx xxxx xxx xxxxxxxxx xxxxxxxx xxxxx, x xx s xxxxxxx xxxxxxxx metabolické xxxxxxxx x xxx xxxx. Nejčastěji xxxxxxxxxx xxxxxxxx je xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx (X9) připravená x xxxxx hlodavců ošetřených xxxxxxxxxxx indukujícím xxxxxx, xxxx je Xxxxxxx 1254 (1, 2) xxxx xxxxxxxxxxxxx a β-xxxxxxxxxxxx (18, 20, 21). Xxxxxxxxxxxxxxxxxxx xxxxxx xx xxxxxxx používána x xxxxxxxxxxxxx v xxxxxxx 5 až 30 % xxx. xx xxxxx X9. Xxxxx a xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx systému xxxx xxxxxxx xx xxxxx xxxxxxxx chemické xxxxx. V xxxxxxxxx xxxxxxxxx xxxx být xxxxxx xxxxxx xxxx xxx xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx xxxxxx. U xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxx může xxx xxxxxxxxx použití xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx (6, 13).
1.5.1.4 Zkoušená xxxxx nebo přípravek
Pevné xxxxxxxx xxxxx by xxxx xxx xxxx xxxxxxxx xx bakterie xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx rozpouštědlech xxxx vehikulech x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx mohou xxx přidány přímo x xxxxxxxxxx xxxxxxxx x/xxxx xxxxx xxx xxxx aplikací xxxxxxx. Xxxx by být xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
Xxxxxxxxxxxx/xxxxxxxxx xx xxxx xxx xxxx xxxxxxxxx, xx xxxxxxx se xxxxxxxxx látkou, x xxxx xx xxx xxxxxxxxxx s přežitím xxxxxxxx x x xxxxxxxxx X9 (22). Xxxx-xx použita jiná xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx by xxx xxxxxx zařazení xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx možno xxxxxxxx xxxxxx xxxxxxx xxxxxxx xxxxxxxxxxxx/xxxxxxx. Xxx xxxxxxxx xxxxx xxxxxxxxx ve xxxx xx měla xxx použita xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx xxxx.
1.5.2 Xxxxxxxx xxxxxxxx
1.5.2.1 Zkušební xxxxx (viz 1.5.1.1)
1.5.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxxxx při xxxxxxxxx xxxxxxxxxx xxxxxxxx zkoušené xxxxx xxxxx xxxxxxxxxxxx x xxxxxxxxxxx x xxxxxxx xxxxx xxx xxxxxxxx.
Xxxx xxx užitečné xxxxxxxx xxxxxxxx x xxxxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxxx. Xxxxxxxxxxxx xxxx xxx xxxxxxxxxx snížením xxxxx xxxxxxx revertantů, xxxxxxxxx xxxx zeslabením xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx stupně xxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxxxxxxx xxxxx xx xxxx xxxxxx v xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxxxxxxxxxx by xxxx xxx xxxxxxxxx xx xxxxxxx viditelného xxxxxxx x xxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxx rozpustné xxxxxxxxxxxxx xxxxx xx 5 xx/xxxxx xxxx 5 μx/xxxxx. X xxxxxxxxxxxxxxx látek xxxxxxxxxxxxx xxx koncentracích 5 xx/xxxxx nebo 5 μx/xxxxx xx xxxx xxx xxxxx xxxx xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxx, xxx látky xxxx v konečné xxxxx xxx xxxxxxxx xxxxxxxxxxx. Xxxxxxxx xxxxx, xxxxx xxxx xxxxxxxxxxx xxx xxx koncentracích xxxxxxx xxx 5 xx/xxxxx nebo 5 μx/xxxxx, by měly xxx zkoušeny xx xx xxxxxxxxxxx xxxxxxxxxxx. Xxxxxxxxx xx xxxxxx xxxxx při xxxxxxxxxxx.
Xxxx xx xxx xxxxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx, xxxxxxx xxx xxxxxx xxxxxxxxxxx xx xxxx být xxxxxxxxx xxxx xxxxxxxxxx xxxx xxxxx přibližně polovině xxxxx xxxxxxxxxxxx xxxxxxxx (xx. Ö10). Menší xxxxxxxxx xxxx xxxxxx x xxxxxxx, xxx xx xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx. Xxxxxxxx koncentrací xxxxxxx xxx 5 xx/xxxxx xxxx 5 μx/xxxxx xxxx xxx xxxxxxx xxx xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxx.
1.5.2.3 Xxxxxxxxx x xxxxxxxxx xxxxxxxx
Xxxxxxxx každého xxxxxxxxx xx měly xxx kmenově xxxxxxxxxx xxxxxxxxx a negativní (xxxxxxxxxxxx xxxx vehikulum) xxxxxxxx x metabolickou xxxxxxxx x xxx xx. Xxx pozitivní xxxxxxxx xx xxxx xxx vybrány xxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxx.
X xxxxxxx xxxxxxx x xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx systému by xxxx být xxxxx (xxxxx) xxx xxxxxxxxx xxxxxxxx xxxxxxx (vybrány) xx xxxxxxx typu xxxxxxxxx xxxxx xxxxxxxx.
Xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxx x xxxxxxx s xxxxxxxxxxxx aktivací jsou xxxx látky:
|
Látka |
Číslo XXX |
Xxxxx xxxxx XXXXXX |
|
9,10-xxxxxxxxxxxxxxxxx |
781–43–1 |
212–308–4 |
|
7,12-xxxxxxxxxxxxx[x]xxxxxxxxx |
57–97–6 |
200–359–5 |
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
|
2-xxxxxxxxxxxxxx |
613–13–8 |
210–330–9 |
|
Xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
xxxxxxxxxxxxx monohydrát |
6055–19–2 |
Tato xxxxx xx vhodnou xxxxxxxxx xxxxxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
|
XX Xxxxxx Xxx 28 |
573–58–0 |
209–358–4 |
2-xxxxxxxxxxxxxx by xxxxx xxx použit jako xxxxxx xxxxxxxxx účinnosti xxxxx S9. Xxx xxxxxxx 2-aminoanthracenu xx xxxx být xxxxx xxxxx X9 xxxxxxxxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxxxxx aktivaci mikrosomálními xxxxxx, xxxxxxxxx xxxxx[x]xxxxx xxxx 7,12-xxxxxxxxxxxxx[x]xxxxxxxxx.
Xxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxx u xxxxxxx xxx xxxxxx xxxxxxxxxxx aktivace xxxx xxxx xxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx XXXXXX |
Xxxx |
|
xxxx sodný |
26628–22–8 |
247–852–1 |
TA1535 x TA100 |
|
2-nitrofluoren |
607–57–8 |
210–138–5 |
TA98 |
|
9-aminoakridin |
90–45–9 |
201–995–6 |
TA1537, XX97 x TA97a |
|
ICR 191 |
17070–45–0 |
241–129–4 |
TA1537, XX97 x XX97x |
|
Xxxxxxxxxxxxxxxxx |
80–15–9 |
201–254–7 |
XX102 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
XX2xxxX x XX102 |
|
1-xxxxxx-3-xxxxx-1-xxxxxxxxxxxxxxx |
70–25–7 |
200–730–1 |
XX2, XX2 uvrA x XX2 xxxX (pKM101) |
|
4-nitrochinolin-1-oxid |
56–57–5 |
200–281–1 |
WP2, XX2 xxxX x XX2 xxxX (xXX101) |
|
α-[(5-xxxxx-2-xxxxx)xxxxxxxxxx]xxxxx-2-xxxxxxxx (XX2) |
3688–53–7 |
xxxxx obsahující xxxxxxxx |
Xxx xxxxxxxxx xxxxxxxx xxxxx xxx použity jiné xxxxxx xxxxxxxxxx látky. Xxx pozitivní xxxxxxxx xx xxxx xxx xxxxx x xxxxx xxxxxxx chemických xxxxx xx xxxxxx chemické xxxxx, jsou xx x dispozici.
Měly by xxx použity xxxxxxxxx xxxxxxxx xxxxxxxxxx xx xx xxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxxx, xxx xxxxxxxx xxxxx, xxxxxxxxxx xxxxx xxxxxxx způsobem xxxx exponované xxxxxxx. Xxxxx toho xx xxxx být xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, neexistují-li xxxxx xxxxxxxxx údaje xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx žádné xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.5.3 Xxxxxx
X xxxxxxxxxx miskové xxxxxx (1, 2, 3, 4) xxx xxxxxxxxxxx xxxxxxxx xx xxxxxxx xxxxxx 0,05 xx xxxx 0,1 xx xxxxxxxxxx roztoků, 0,1 xx xxxxxxx xxxxxxxxxxx xxxxxxx (xxxxxxxxxx xxxxxxxxx 108 xxxxxxxxxxxxxxx xxxxx) x 0,5 xx xxxxxxxxxx xxxxx x 2,0 xx xxxxxxxx agaru. X xxxxxxx zkoušky x xxxxxxxxxxxx xxxxxxxx xx xxxxxxx xxxxxx 0,5 xx xxxxxxxxxxx aktivační xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxxxxxx frakce (x xxxxxxx 5 xx 30 % xxx. x metabolické xxxxxxxxx xxxxx) x xxxxxxx xxxxxx (2,0 xx) x xxxxxxx x xxxxxxxxxx x xxxxxxxxx xxxxxx nebo xxxxxxxxx xxxxxxxx. Xxxxx xxxxx xxxxxxxx se xxxxxxxx x přelije xxxx povrch xxxxxxxxxxx xxxxx xx xxxxx. Xxxx xxxxxxxx xx xxxxx xxxxxx agar xxxxxxxx.
X preinkubační xxxxxx (2, 3, 5, 6) xx xxxxxxxx xxxxx xxxx xxxxxxxx xxxxxx xxxx smícháním x xxxxxxx xxxxxx x přelitím xxxx xxxxxx minimálního agaru xx xxxxx xxxxxxx 20 xxxxx xxxx xxxx xxxxxxxxxxx x xxxxxxxxxx kmenem (xxxxxxxxxxx xxxxxxxxx 108 xxxxxxxxxxxxxxx xxxxx) x sterilním xxxxxx xxxx metabolickým xxxxxxxxxx xxxxxxxx (0,5 xx) xxx 30 — 37 °C. Xxxxxxx se xxxxxx 0,05 xxxx 0,1 xx xxxxxxxx xxxxx xxxx xxxxxxxxxx xxxxxxx, 0,1 ml xxxxxxxx x 0,5 xx xxxxx S9 xxxx xxxxxxxxxx pufru s 2,0 ml vrchního xxxxx. Zkumavky xx xxxx xxx xxxxx xxxxxxxx xxxxxxxxxxxxxx xx xxxxxxxx.
X xxxxxxxxxxxx xxxxxx xxxxxxxx xx měly xxx xxx každé xxxxxx xxxxx xxxxxxx 3 xxxxx. Xxxxxxx xxxx xxxxx xx xxxxxxxxxx xx vědeckém xxxxxxxxxx. Xxxxxxxx ztráta xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxx.
Xxxxxx nebo xxxxxx xxxxx xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxxx, xxxx. x xxxxx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx (12, 14, 15, 16).
1.5.4 Xxxxxxxx
Xxxxxxx xxxxx x xxxx zkoušce xx xxxx xxx inkubovány xxx 37 °X xx 48 –72 xxxxxxxx. Xx xxxxxxxx xxxxxxxxx xxxx xx xxxxxx xxxxx kolonií xxxxxxxxxx xx xxxxx.
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxxxxxxxxxx xxxxx xx xxxx xxx xxxxx kolonií xxxxxxxxxx xxxxxxxxxxx na xxxxx. Měl by xxx xxxxxx xxxxxx xxxxx xxxxxxx xxxxxxxxxx xxx xx xxxxxxx x negativní kontrolou (xxxxxxxx xxxxxxxxxxxx a xxxxxxxx xxxxxxxxxxxx kontrola), xxx xx xxxxxxx x xxxxxxxxx kontrolou. Xxxxx na xxxxxxxxxxxx xxxxxxx, xxxxxxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxx xx misku x xxxxxxxxxx xxxxxxxx xx xxxx xxx předloženy xxx zkoušenou xxxxx x xxxxxxxxx x xxxxxxxxx kontrolu (neexponovanou xxxxxxxx a/nebo xxxxxxxx xxxxxxxxxxxx).
Xxxxxxx jasně pozitivní xxxxxxxx se nepožaduje. Xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, nejlépe x úpravou xxxxxxxxxxxxxxxx xxxxxxxx. Negativní xxxxxxxx xxxx xxx xxxxxxxxx xxxxxx od xxxxxxx. Xxxxxxxx se xxxxxxxxx xxxxxxxxxxx výsledků xxxxxxxxxx xx xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxxxx. Xxxxx parametrů xxxxxx s cílem xxxxxxxx xxxxxx posuzovaných xxxxxxxx xx měla xxx xxxxxxx x xxxxxxxxxx xxxxxxxxxxxxx. X xxxxxxxxxx xxxxxx, xxxxx xx mohly být xxxxxxx, xxxxx xxxxxxx xxxxxxxxxxx, xxxxxx xxxxxxxxxx (xxxxxxxxxx xxxxxxx xxxxxx xxxx xxxxxxxxxxx v xxxxxxxx xxxxx) x xxxxxxxx xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX A XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxx kolonií xxxxxxxxxx xx xxxxx xxx xxxxxxxxx rozsah u xxxxxxx xxxxxxx xxxxx x xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx nebo xxx xxxx, x xx x xxxxxxxxxx na xxxxxxxxxxx, nebo xxxxxxxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx xxxxx xxxx xxxx xxxxxxxxxxx (23). Xxxxxxxx xx xxxx xxx uvážena xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx výsledků xxxxxxx xxxxx být xxxxxxx xxxx xxxxxxx prostředek xxxxxxxxxxx metody (24). Xxxxxxxxxxx významnost xx xxxxxx být xxxxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx odpověď.
Zkoušená xxxxx, xxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx xxxxxxxx v xxxxx xxxxxxx za xxxxxxxxxxx.
Xxxxxx většina experimentů xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx xxxxxxxx, x ojedinělých xxxxxxxxx xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxx xxxxx. Xxxxxxxx mohou xxxxxx xxxxxxxxxx xxxx xxxxxx xxx xxxxxx xx to, xxxxxxxx xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx zkoušky na xxxxxxxx xxxxxx x xxxxxxxxxx xxxxxxxxx, že xxxxxxxx látka xxxxxxxx x genomu xxxxx Xxxxxxxxxx typhimurium x/xxxx Xxxxxxxxxxx coli bodové xxxxxx xxxxxxxxxx xxxx xxxx xxxxxxx xxxxxxx xxxxx. Negativní xxxxxxxx xxxxxxxxx, xx xxxxxxxx xxxxx xxxx xx xxxxxxxx xxxxxxx pro xxxxxxxxx xxxxx xxxxxxxxx.
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x zkoušce xxxx xxxxxxxxx xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx volby xxxxxxxxxxxx/xxxxxxxx,
- xxxxxxxxxxx a xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, je-li xxxxx.
Xxxxx:
- xxxxxxx xxxxx,
- počet xxxxx x xxxxxxx,
- xxxxxxxxxxxxxxx kmene.
Zkušební podmínky:
- xxxxxxxx zkoušené xxxxx xx xxxxx (xx/xxxxx xxxx μl/misku) x xxxxxxxxxxx výběru xxxxx x počtu xxxxx xx xxxxxxxxxxx,
- xxxxxxx xxxxx,
- typ x xxxxxxx metabolického xxxxxxxxxxx xxxxxxx, včetně xxxxxxxx xxxxxxxxxxxxx,
- xxxxxx xxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxx xxxxxxx,
- počty na xxxxxxxxxxxx miskách,
- xxxxxxx xxxxxxx xxxxx xxxxxxx xxxxxxxxxx na xxxxx x xxxxxxxxxx xxxxxxxx,
- xxxxx možnosti xxxxxxxxx xxxxxxxx xx xxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxxx,
- xxxxx o souběžné xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) a xxxxxxxxx xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx x směrodatnými odchylkami,
- xxxxxxxxx údaje o xxxxxxxxx (rozpouštědlo/vehikulum) a xxxxxxxxx xxxxxxxx s xxxxxxxxx, xxxxxxxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Xxxx, X. X., XxXxxx, X., Xxxxxxxx X. (1975), Xxxxxxx xx Xxxxxxxxx Carcinogens xxx Xxxxxxxx with the Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Mutagenicity Xxxx, Xxxxxxxxxx Res., 31, 347-364.
2) Xxxxx, X. X., Xxxx, X. X. (1983), Xxxxxxx Xxxxxxx xxx xxx Xxxxxxxxxx Mutagenicity Xxxx, Xxxxxxxxxx Xxx., 113, 173-215.
3) Xxxxxxxxx, X., Xxxxxxx, X., Xxxxxx, X., Gocke, X., Xxxx, X., Xxxxxxxxxx, X., Xxxxxxx, X., Xxxxx, X., Venitt, X., Xxxxxx, E. (1994), Xxxxxxxxxxxxxxx xxx xxx Xxxxxxxxxxx xx Xxxxxxxxx Xxxxxxxx Assays, Xxxxxxxxxx Res., 312, 217-233.
4) Xxxx, X. X., Xxxxxxx X. X., Auletta, X. X., Von Xxxxx, X. X., Xxxxx, X. M., Xxxxxx, X. F., Dunkel, X., McCann, X., Xxxxxxxxxx, X., Xxxxxx, X., Xxx, X. X., Ray X. (1986), The Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxxx Xxxxx: X Report xx xxx X. X. Xxxxxxxxxxxxx Xxxxxxxxxx Xxxxxx Xxxx-Xxx Xxxxxxx, Mutatation Xxx., 168, 69-240.
5) Xxxxxx, X., Xxxxxx, X., Xxxxx, X. X., Xxxxxxxxxx, X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxxx, Y. (1975), Xxxxxxxxxxxx xx Xxxxxxxxxx Azo Xxxx xxx xxxxx Derivatives, Xxxxxx Lett. 1, 91-96.
6) Xxxxxxxxxx, X., Xxxxxxxx, T., Xxxxx, X., Yahagi, X., Xxxxxx, X., Xxxxxxxx, X. (1980), Xxxxxxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxx, in: Xxxxx-xxxx Xxxx Xxxxxxx xxx Xxxxxxxxx Xxxxxxxxxxx, ed. Xxxxxxx K. H., Xxxxxx, X. C., Xxxxxxxx, Xxxxxx-Xxxxxxxxxx-Xxx York, 273-285.
7) Gatehouse, X. X., Rowland, I. X., Xxxxxx, X., Xxxxxxxxx, R. X., Xxxxxx, R. (1980), Xxxxxxxxx Xxxxxxxx Xxxxxx, xx: Xxxxx Mutagenicity Xxxxx: UKEMS Part 1 Revised, ed. X. X. Xxxxxxxx, Xxxxxxxxx Xxxxxxxxxx Press, 13-61.
8) Xxxxxxxxxx, X. X., Xxxxxx, U., Xxxxxxx, L. (1987), Xxxxxx Xxxxxxxxxxxxx Xxxxxxxxxxxx Xxxx for Foods, X. Food Xxxxxx., 8, 167-177.
9) Xxxxx, X. X. X., Xxxxxx, X. X., Xxxxxxx, X. X. (1976), Xxx xx x xxxxxxxxxx fluctuation xxxx to detect xxx xxxxxx of xxxxxxxx, Xxxxxxxxxx Xxx., 38, 33-42.
10) Xxxxxxx, X. X., Xxxxx, X. X. X., Xxxxxxxxx, D., Xxxxxxx, X. X. (1984), Xxx Xxxxxxxxxxx Xxxx xx Bacteria, xx: Xxxxxxxx xx Mutagenicity Xxxx Procedures, 2. xxx., Kilbey, B. X., Xxxxxxx, X., Xxxxxxx, W., Xxxxx, X. (xxx.), Elsevier, Xxxxxxxxx-Xxx Xxxx-Xxxxxx, 141-161.
11) Xxxxxxxx, X. D., Xxxxxxx, X. X. (1981), Xx Xxxxxxxxxxx xx xxx Quantitative Xxxxxxxxxx Assay for Xxxxxxxxxxx xxxx Xxxxxxx xx Salmonella xxxxxxxxxxx, Xxxxxxxxxxxxx Mutagenesis, 3, 453-465.
12) Araki, A., Xxxxxxx, X., Xxxx, X., Xxxxxxxxxx, X. (1994), Xxxxxxxx Method xxx Xxxxxxxxxxxx Xxxxxxx xx Xxxxxxx Xxxxxxxxx xx Xxxxx x Xxx Xxxxxxxx Xxx, Xxxxxxxxxx Xxx., 307, 335-344.
13) Xxxxxx, X. X., Bell, X. X., Xxxxxxxx, X. X., Xxxxxxx, X. X., Vaughan, X. X. (1984), Mutagenicity xx Benzidine xxx Xxxxxxxxx-Xxxxxxxx Dyes and Xxxxxxxx Xxxxxxx Dyes xx x Xxxxxxxx Xxxxxxxxxx Assay, Xxxxxxxxxx Xxx., 136, 33-47.
14) Xxxxxx, X., Xxxxxxxx, X. X., Xxxxxxx, X., Xxxxxx, X., Xxxxxxxxxx, X. (1992), Xxxxxxxxxx Xxxxxxxxxxxx Xxxxx. X. Xxxxxxx xxxx xxx Xxxxxxx xx 311 Xxxxxxxxx, Environ. Xxx. Xxxxxxx., 19, 2-141.
15) Simmon, X., Xxxxxxxx, X., Tardiff, X. G. (1977), Xxxxxxxxx Xxxxxxxx xx Xxxxxxxxx Xxxxxxxxxx xx Xxxxxxxx Xxxxx, xx Xxxxxxxx xx Genetic Xxxxxxxxxx, D. Xxxxx, X. Xxxxxxx, X. Xxxxxx (xxx.) Xxxxxxxx, Xxxxxxxxx, 249-258.
16) Xxxxxx, X. X., Simmons, X. X., Monteith, X. G., Xxxxxxx, X. X. (1987), Xxxxxxxxxxxx Xxxxxxxxx to Xxxxxxx Xxxxxxxxx Xxxxxxxx xx Volatile Xxxxxxx Xxxxxxxxx xx xxx Xxxx/Xxxxxxxxxx Xxxxx, Xxxxxxxxxxxxx Xxxxxxxxxxx, 9, 421-441.
17) Xxxxxxxxxx, T., Xxxxxxxxx, X., Xxxxxx, X., Xxxxxxxx, M., Sugimura, X. (1979), Xxxxxxxxxxxx xx xxx Xxxxxxxxx Xxxxxxxxx Xxxxxxxxxx Xxxxxxx xxx Xxxxxxxxx Methylazoxy Xxxxxxx Xxxxxxxxxx xx Xxxxxxxxxx xxxxxxxxxxx, Xxxxxx Xxx., 39, 3780-3782.
18) Xxxxxx, X., Gold, X., Xxxxx-Xxxxx, A., Xxxx, B. N. (1980), Xxxxxxxx: X Xxxxx xxx Xxxxxxxxxx xx Xxxxxxx Xxxxxxxxxx xx Mutagens by Xxxxxxxxxx Xxxxx, Xxxx. Xxxx. Acad. Xxx. X. S. X, 77, 4961-4965.
19) Xxxxxx, X., Xxxxxx, X., Xxxx, D. J., Xxxxxxxxx, D. X. (1990), Xxxxxxxxxx of Xxxxxxxxxx xxxxxxxxxxx XX 102 with Xxxxxxxxxxx xxxx WP2 Xxxxxx xxxxxxx, Xxxxxxxxxxx, 5, 285-291.
20) Xxxxxxxxxx, X., Xxxxxxxx, X., Xxxx, X., Sugimura, T. (1976), X Xxxx Xxxxxxxxxx for Xxxxxxxxxxxxxxx Xxxxxxxxx x. x. xx Xxxxxxx xx Xxxxxxxxx Xxxxxxxxxx Xxxxxxx, xx: Xx xxxxx Xxxxxxxxx Activation xx Xxxxxxxxxxx Testing, eds. X. J. de Xxxxxx xx al. Xxxxxxxx, North Xxxxxxx, 85-88.
21) Xxxxxx, X. X., Combes, X. X., Xxxxxxx, C. X., Xxxxxxxxx, X. X., Gibson, X. X., Xxxxxx, J. X., Wolf, R. X. (1992), Xxxxxxxxxxxx xx Xxxxxxx 1254-induced X9 xx xx xxxxx Xxxxxxxxxxxx Assays, Xxxxxxxxxxx, 7, 175-177.
22) Xxxxx, X., Katzenellenbogen, X., Ames, X. X. (1981), Xxxxxxxxxxxxx xx Xxxxxxx Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx Xxxx, Mutatation Xxx., 88, 343-350.
23) Claxton, X. X., Xxxxx, X., Auletta, X., Xxxxxxxxxx, K., Xxxxxxxx, X., Xxxxxx, E. (1987), Guide for xxx Xxxxxxxxxx xxxxxxxxxxx/Xxxxxxxxx Xxxxxxxxx Xxxxx xxx Xxxxxxxxx Xxxxxxxxxxxx, Xxxxxxxxxx Xxx., 189, 83-91.
24) Xxxxx, X. X. X., Xxxxx, X. X. X., Xxxxxxxxx, X., Xxxxxxx, X., Xxxxxxxx, W. D., Xxxxxx, X. X. (1989), Analysis of Xxxx xxxx Microbial Xxxxxx Assays, xx: XXXXX Xxx-Xxxxxxxxx xx Xxxxxxxxxx for Xxxxxxxxxxxx Xxxxxxx, Xxxx II. Xxxxxxxxxxx Evaluation xx Xxxxxxxxxxxx Test Data, xx. Kirkland, X. X., Cambridge Xxxxxxxxxx Xxxxx, 28-65."
PŘÍLOHA 4X
"X.17 XXXXXXXXXX — XXXXXXX XX XXXXXX XXXXXX V XXXXXXX XXXXX XX XXXXX
1. METODA
Tato metoda xx replikou metody XXXX TG 476 — Xxxxxxx xx xxxxxx xxxxxx x xxxxxxx xxxxx xx xxxxx (1997).
1.1 ÚVOD
Zkoušku xx genové xxxxxx x buňkách xxxxx xx vitro xxx xxxxxx xxx xxxxxxx xxxxxxxx mutací indukovaných xxxxxxxxxx látkami. Xxxx xxxxxx buněčné xxxxx xxxxx buňky xxxxxxx X5178X xxxx, xxxxxxx xxxxx XXX, XXX-XX52 x V79 xxxxxx xxxxxxxx x xxxxxxxxxxxxxxx xxxxx XX6 xxxxxxx (1). X těchto xxxxxxxxx xxxxx jsou xxxxxxxxxxxxxxx mírou genetických xxxxxx mutace xxxx xxx thymidinkinasu (XX) x xxxxxxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (HPRT) x xxxxxxxx xxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXX). Xxxxxxx xx xxxxxx XX, XXXX x XXXX xxxxxxxx xxxxx xxxxxxxx genetických xxxxxxxx. Xxxxxxxxxxx xxxxxx XX x XPRT xxxx umožnit detekci xxxxxxxxxxx xxxxxxxx (xxxx. xxxxxxxx delece), které xxxxx xxxxxxxxx v XXXX xxxxxx xx X xxxxxxxxxxxx (2, 3, 4, 5, 6).
Xx zkoušce xx xxxxxx mutace x xxxxxxx savců xx xxxxx xxx použít xxxxxxx xxxxxxxxxx linií xxxxx nebo xxxxxxx xxxxx. Xxxxx se xxxxxxxx podle schopnosti xxxxx x xxxxxxx x xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.
Xxxxxxx prováděné xx vitro obecně xxxxxxxx xxxxxxx vnějšího xxxxxx metabolické xxxxxxxx. Xxxxx xxxxxxxxxxx xxxxxxxxx xxxxxx nemůže xxxxx xxxxxxxxx xxxxxxxx in xxxx x xxxxx. Xx xxxxx se xxxxx xxxxxxxxx xxxxxxxx, xxxxx by xxxxx x xxxxxxxxxx xxxxxxxxx, xxx neodrážejí vlastní xxxxxxxxxx. X pozitivním xxxxxxxxx, xxx xxxxxxxxxx xxxxxxx xxxxxxxxxx, xxxx xxxxx xxxxxx xX, xxxxxxxxxx xxxx vysokých xxxxxx xxxxxxxxxxxx (7).
Tato xxxxxxx se xxxxxxx xx xxxxxxxx možných xxxxxxxx a xxxxxxxxxxx xxxxx. Mnoho xxxxxxxxx, xxx xxx xx xxxx xxxxxxx pozitivní, xxxx karcinogeny savců; xxxx xxxxx xxxxxxxx x xxxxxxxxxxxxxx však xxxx xxxxxxxxx xxxxxxxx. Xxxxxxxx závisí xx xxxxxxxx xxxxx a xxxxxxxxx důkazy x xxx, xx xxxxxxxx xxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx touto xxxxxxxx, xxxxx xxxxxx xxxxxx xxxxxx, negenotoxickými mechanismy, xxxx mechanismy, xxxxx x xxxxxxxxxxxxx buňkách xxxxxxxxxx (6).
Xxx také xxxxxx xxxx, část X.
1.2 DEFINICE
Přímá mutace : genová xxxxxx xxxxxxxxx xxxx mutované xxxxx, xxxxx xxxxxxxxx xxxxx xxxx ztrátu xxxxxxxxxxx aktivity xxxxxxxxxx xxxxxxxx.
Xxxxxxxx substituce xxxx xxxx : látky, xxxxx xxxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxx xxxx xxxx x XXX.
Xxxxxxxx mutageny : xxxxx, které xxxxxxxxx xxxxx nebo deleci xxxxxxx xxxx xxxx xxxx xxxx v xxxxxxxx DNA.
Doba xxxxxxx xxxxxxxx : xxxx, xxxxx xxx xxxxxx x nově xxxxxxxxxx xxxxx xxxxxxxxx genové xxxxxxxx.
Xxxxxxx xxxxxxx : xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx dělený xxxxxx xxxxxxxxxxxxxxx xxxxx.
Xxxxxxxxx celkový xxxx : nárůst xxxxx xxxxx v xxxx xx xxxxxxxx x xxxxxxxxx populací xxxxx; xxxxxxx se xxxx součin poměru xxxxxxxxx růstu x xxxxxxxx x v xxxxxxxxx kontrole x xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxx x xxxxxxxx : xxxxxx xxxxx xxxxx x xxxxxxx xxxxxxx xxxxxxxx x negativní kontrole.
Životaschopnost : xxxxxxxx klonování xxxxx x okamžiku xxxxxxxx xx xxxxx xx selektivních xxxxxxxx xx xxxxxxx.
Xxxxxxx : xxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxx na xxxxx xx konci xxxxxx xxxxxxxx; přežití xx xxxxxxx vyjádřeno x xxxxxx k xxxxxxx xxxxxxxxx populace xxxxx.
1.3 XXXXXXXX XXXXXXXX XXXXXX
Xxxxx, xxxxx x xxxxxxxx xxxxxx TK+/-® XX— /- xxxxxxxxxx xxxxxxxxxxxxxx (TK) jsou xxxxxxxxxxx x xxxxxxxxxxxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxxxxxxxxx (TFT). Xxxxx xxxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxx na XXX, xxx způsobuje inhibici xxxxxxxxx xxxxxxxxxxx a xxxxxxxxx xxxxx xxxxxxx xxxxxx. Xxxxxxxx buňky xxxx xxxx xxxxxxx xxxxxxxxxxx za xxxxxxxxxxx XXX, xxxxxxx normální xxxxx, xxxxx obsahují xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx. Podobně lze x buněk s xxxxxxxxxxxx XXXX xxxx XXXX xxxxxxx selekci xxxxxxxxxxxxxxx rezistence x 6-xxxxxxxxxxx (XX) xxxx 8-xxxxxxxxxx (XX). Vlastnosti xxxxxxxx xxxxx xx xxxx xxx pečlivě xxxxxxx, xxxxxxxx xx xx xxxxxxx xx xxxxxx mutace v xxxxxxx savců xxxxxxx xxxxxx báze nebo xxxxxxxxxx podobná xxxxxxxxxx xxxxxxx. Xxxx xx xxx xxxxxxxxx xxxxxxxxx xxxxxxxx podezření xx xxxxxxxxxx xxxxxxxx zkoušené xxxxx xxx xxxxxxxx xxxx nemutantní buňky. Xxx xxxxxxxx xxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx strukturu xxxx xxxxxxxx xxxxxxx, musí xxxx xxx xxxxxxxxx xxxxxxxx systému xxxx xxxxxxx xxx xxxxxxx (8).
Xxxxx x suspenzní xxxx xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxx dobu xxxxxxxxx zkoušené xxxxx xxx s xxxxxxxxxxxx xxxxxxxx, xxx xxx xx, a subkultivovány xx účelem stanovení xxxxxxxxxxxx a za xxxxxx xxxxxxx fenotypu xxxx xxxxxxx xxxxxxx (9, 10, 11, 12, 13). Xxxxxxxxxxxx xx obvykle zjistí xxxxxxxxxx relativní účinnosti xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxx xxxxxx po xxxxxxxx xxxx expozice. Xxxxxxxxxx xxxxxxx xx xxxxxxx v xxxxxxxx xxxxx po xxxxxxx xxxx xxxxxxxxxxxxxxxxx xxx xxxxx xxxxxxx xxxxx x xxx xxxxx, xxx xxxxxxx xxxxxxxxx xxxxxxxxx fenotypová exprese xxxxxxxxxxxx xxxxxx. Četnost xxxxxxx xx xxxxxxx xxx, xx se xxxxxx xxxxx počet xxxxx xx média xxxxxxxxxxxx xxxxxxxx činidlo xxx detekci xxxxxxxxxx xxxxx a do xxxxx xxx xxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx (xxxxxxxxxxxxxxx). Po xxxxxx xxxxxxxxx xxxx xx xxxxxxxxx xxxxxxx. Četnost xxxxxxx se xxxxxxx x xxxxx mutantních xxxxxxx x xxxxxxxxx xxxxx x xxxxx xxxxxxx x xxxxx xxx xxxxxxxxxx xxxxxxx.
1.4 XXXXX XXXXXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Buňky
Pro xxxxxxx x xxxx xxxxxxx xxxx x xxxxxxxxx xxxxx typy xxxxx, xxxxxx subklonů buněk X5171X, CHO, CHO-AS52, X79 xxxx XX6. Xxxx xxxxx v xxxx zkoušce by xxxx xxxxxxxxx xxxxxxxxx x xxxxxxxxx mutagenům, xxxxxxx xxxxxxxxx xxxxxxxxx x stabilní frekvenci xxxxxxxxxxx xxxxxx. Xxxxx xx xxxx xxx xxxxxxxxxxxx, zda xxxxxx xxxxxxxxxxxxx xxxxxxxxxxxx, x x xxxxxxx kontaminace xx xxxxxx xxx xxxxxxx.
Xxxxxxx by xxxx xxx xxxxxxxx xxx, xxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx x xxxx. Xxxxx použitých xxxxx, xxxxxx a xxxxxxxxxxx xxxxxxxx látky xx xxx tyto xxxxxxxxxx xxxxxxxxx xxxxxxx (14). Xxxxxxxxx počet xxxxx, které xxxxxxx xxxxxxxx x xxxxx xxxxx použity x xxxxxx stadiu xxxxxxx, xx xxx být xxxxxxx na xxxxxxxx xxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxxxx je, aby xxx použit xxxxx xxxxx, xxxxx je xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx spontánních mutací. Xx xxxx xxxxxxxxxx, xxx xxxx xxxxxxx xxxxxxx 106 xxxxx. Xxxx by být x dispozici xxxxxxxxxx xxxxxxxxx xxxxx o xxxxxxxx xxxxxxxx systému, xxx xxxx xxxxxxxx xxxxxxxxxxxx výpovědní hodnota xxxxxxx.
1.4.1.2 Xxxxx x xxxxxxxxxx xxxxxxxx
Xxx xxxxxxxxx xxxxxx xx xxxx xxx xxxxxxx xxxxxx xxxxxxxxxx média x xxxxxxxxx xxxxxxxx (xxxxxxxxxx xxxxxx, xxxxxxxxxxx CO2, xxxxxxx a vlhkost). Xxxxx by měla xxx zvolena podle xxxxxxxxxx xxxxxxx a xxxx xxxxx xxxxxxxxx xxx xxxxxxx. Xx xxxxxxx důležité, xxx xxxxxxxxxx xxxxxxxx xxxx xxxxxxx tak, xxx xxxx xxxxxxxxx xxxxxxxxx xxxx xxxxx během xxxxxx xxxxxxx a xxxxxxxxx jak mutovaných, xxx xxxxxxxxxxxx xxxxx xxxxxx kolonie.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxx xx měly xxx xxxxxxxxx x xxxxxxxxx kultur, xxxxxxxx xx xxxxxxxxxxxx xxxxx x xxxxxxxxxx xxx 37 °X. Před xxxxxxxx x xxxx xxxxxxx může xxx xxxxxxxx xxxxxxxxx x xxxxxxx xxx přítomné xxxxxxxx xxxxx.
1.4.1.4 Xxxxxxxxxxx xxxxxxxx
Xxxxx xx xxxx xxx xxxxxxxxx xxxxxxxx xxxxx, x xx x xxxxxxx systémem xxxxxxxxxxx xxxxxxxx x xxx xxxx. Xxxxxxxxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxx dotovaná postmitochondriální xxxxxx (X9) xxxxxxxxxx x jater xxxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx, xxxx xx Xxxxxxx 1254 (15, 16, 17 x 18), nebo xxxx xxxxxxxxxxxxx x β-naftoflavonu (19, 20).
Postmitochondriální xxxxxx xx x xxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxxxxxxx v xxxxxxxxxxxxx 1 — 10 % xxx. Xxxxx x xxxx metabolického xxxxxxxxxxx xxxxxxx může xxxxxxx xx xxxxx xxxxxxxx xxxxx, která xx zkoušena. X xxxxxxxxx případech xxxx xxx xxxxxx xxxxxx xxxx xxx xxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxx frakce.
Řada xxxxxxxx vývoje, včetně xxxxxxxx geneticky modifikovaných xxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx, xxxxxxxxx možnosti pro xxxxxxxxx xxxxxxxx. Xxxxx xxxxxxxxx xxxxxxxxx xxxxx xx xxxx být xxxxxxx zdůvodněna (xxxx. xxxxxxxxxxx isoenzymu xxxxxxxxxx X450 xxx xxxxxxxxxxxx xxxxxxxx látky).
1.4.1.5 Xxxxxxxx xxxxxxxx látky
Pevné xxxxxxxx xxxxx by xxxx xxx xxxx aplikací xx xxxxx rozpuštěny xxxx xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx nebo xxxxxxxxxx a popřípadě xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx být xxxxxxx přímo x xxxxxxxxxx xxxxxxxx x/xxxx xxxxx xxx xxxx xxxxxxxx xxxxxxx. Xxxx xx být xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx látky, xxxxx xxxxx x stálosti xxxxxxxxxxx xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Rozpouštědlo/vehikulum
Rozpouštědlo/vehikulum xx xxxx být xxxx podezření, že xxxxxxx se xxxxxxxxx xxxxxx, a xxxx xx být xxxxxxxxxx x xxxxxxxx xxxxx x s xxxxxxxxx X9. Xxxx-xx použita xxxx než xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx jejich zařazení xxxxxxxxx xxxxx o xxxxxx kompatibilitě. Doporučuje xx xxxxx xxxxx xxxxxxxx xxxxxx xxxxxxx xxxxxxx rozpouštědel/vehikul. Při xxxxxxxx xxxxx nestálých xx xxxx by xxxx xxx použitá xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxx xxxx. Xxxx lze xxxxxxxxx přidáním xxxxxxxxxxxx xxxx.
1.4.2.2 Xxxxxxxxx xxxxxxxxxxx
Xxxx xxxxxxxx, která mají xxx zohledněna xxx xxxxxxxxx xxxxxxxx koncentrace, xxxxx xxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx xxxxxxx x změny xX xxxx xxxxxxxxxx.
Xxxxxxxxxxxx by xxxx xxx stanovena x xxxxxxxxxxxx xxxxxxxx x xxx ní x hlavním xxxxxxxxxxx xx použití xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx x růstu, xxxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxx xxxxxxx xxxx. Xxxx být xxxxxxx xxxxxxxx cytotoxicitu x xxxxxxxxxxx x předběžném xxxxxxxxxxx.
Xxxx xx xxx xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxxx koncentrace. V xxxxxxx xxxxxxxx by xxxx xxxx xxxxxxxxxxx xxxxxxxx rozmezí dané xxxxxxxxx a xxxxxxxxx xxxxxxxxx, xxxxxxxx žádnou xxxxxxxxx, xxx bude xxxxxxx xxxxxxxx, xx xx se koncentrace xxxx xxxxx xxxxxxxx 2 xx Ö10. Xx-xx xxxxxxxxx xxxxxxxxxxx xxxxxxxx od xxxxxxxxxxxx, xxxx xx být xxxxxxxxx xxxxxxxxx 10 — 20 % (xxx nejméně 10 %) přežití (relativní xxxxxxxx xxxxxxxxx) nebo xxxxxxxxx xxxxxxx xxxx. X xxxxxxx xxxxxxxxx xxxxxxxxxxxxxxx látek xx xxxx xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx 5 μx/xx, 5 mg/ml xxxx 0,01 X, xxxxx xxxx, xxxxx x nich xx xxxxxxxx.
Xxxxxxxxx nerozpustné xxxxx xx měly xxx xxxxxxxx xx x xxxx xxxxxxxxxxxx xx xxxxxxxxxxxx xxxxxxxx, xxxx xx xx xxxx xxx. Měla xx xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxx x konečném xxxxx, xx kterému xxxx xxxxx exponovány. Xxxx xxx xxxxxxx xxxxxxxx xxxxxxxxxxx xx xxxxxxx x na xxxxx aplikace, neboť xxxxxxxxxxx xx může x průběhu expozice x xxxxxxxxxx xxxxxxx xxxxx x xxxxxxxx xxxxxxxxxxx buněk, X9 xxxx, xxx. Xxxxxxxxxxxxx xxx zjistit xxxxxxxx. Xxxxxxxxx xx xxxxxx xxxxx xxx xxxxxxxxxxx.
1.4.2.3 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx měly xxx xxxxxxxxx a xxxxxxxxx (xxxxxxxxxxxx xxxx xxxxxxxxx) xxxxxxxx xxx s xxxxxxxxxxxx xxxxxxxx, xxx xxx xx. Při xxxxxxx metabolické xxxxxxxx xx xxxx být xxxxxxxxx kontrolou chemická xxxxx, která x xxxxxxxxx odpovědi vyžaduje xxxxxxxx.
Xxxxxxxxx pozitivní kontroly xxxxx xxx xxxx xxxxx:
|
Xxxx xxxxxxxxxxx xxxxxxxx |
Xxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx podle Xxxxxx |
|
Xxx xxxxxx metabolické xxxxxxxx |
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
XX (xxxx a velké xxxxxxx) |
xxxxxx-xxxxxxxxxxxxxx |
66–27–3 |
200–625–0 |
|
|
XXXX |
xxxxx-xxxxxxxxxxxxxx |
62–50–0 |
200–536–7 |
|
|
1-xxxxx-1-xxxxxxxxxxxxxxx |
759–73–9 |
212–072–2 |
||
|
X vnější xxxxxxxxxxxx xxxxxxxx |
XXXX |
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–4 |
|
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–549–8 |
||
|
7,12-xxxxxxxxxxxxxxxxxxxxxx |
57–97–6 |
200–359–5 |
||
|
XX (xxxx x xxxxx xxxxxxx) |
xxxxxxxxxxxxx |
50–18–0 |
200–015–4 |
|
|
xxxxxxxxxxxxx xxxxxxxxxx |
6055–19–2 |
|||
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
||
|
3-xxxxxxxxxxxxxxxxx |
56–49–5 |
200–276–5 |
||
|
XXXX |
X-xxxxxxxxxxxxxxxxxxx (xxx xxxxxx xxxxxx X9) |
62–75–9 |
200–549–8 |
|
|
xxxxx[x]xxxxx |
50–32–8 |
200–028–5 |
Xxxxx být xxxxxxx xxxx xxxx referenční xxxxx xxx xxxxxxxxx xxxxxxxx, xxxx. xx-xx xxxxxxxxx xxxxxxxx dosavadních xxxxx o 5-xxxx-2′-xxxxxxxxxxxx (XXX 59–14–3, XXXXXX 200–415–9), xxxx xxx xxxx xxxxxxxxxx xxxxx xxxxxx použita. Pro xxxxxxxxx xxxxxxxx by xxxx xxx xxxxx x úvahu xxxxxxx xxxxxxxxxx xxxxx pokud xxxxx ze xxxxxx xxxxxxxx xxxxx.
Xxxx xx xxx xxxxxxx negativní xxxxxxxx xxxxxxx médiem xxxxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxx xxxxx stejným xxxxxxxx xxxx xxxxxxxxxx xxxxxxx. Xxxxx xxxx xx xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx xxxxx, xxxxxxxxxx-xx xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.4.3 Xxxxxx
1.4.3.1 Xxxxxxxx xxxxxxxx xxxxx
Xxxxxxxxxxxxx buňky xx xxxx xxx xxxxxxxxx zkoušené xxxxx xxx za přítomnosti xxxxxxxxxxxxx aktivačního xxxxxxx, xxx xxx xxxx. Xxxxxxxx xx měla xxxxx vhodnou xxxx (xxxxxxx xx účinná xxxx 3 xx 6 hodin). Xxxxxxxxx xxxx může být xxxxxxxxxxx na jeden xxxx xxxx xxxxxxxxx xxxxx.
Xxx xxxxxx xxxxxxxx xxxxxxxxxxx xxxxx xxx xxxxxxx duplicitní xxxxxxx xxxx jedna exponovaná xxxxxxx. Je-li xxxxxxx xxxxx xxxxxxx, xxx xx xxx xxxxx xxxxxxxxxxx zvýšen xxx, xxx xxx xxxxxxxx xxxxxxxxxxxx xxxxx kultur xxx xxxxxxx (xxxx. xxxxxxx xxx xxxxxxxxxxxxxxxx xxxxxxxxxxx). Xxxx xx xxx xxxxxxx duplicitní xxxxxxxxx kontrolní kultury (xxxxxxxx xxxxxxxxxxxx).
Xxxxxx xxxx xxxxxx látky xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxxx, xxxx. x xxxxx uzavřených xxxxxxxxxxxx nádobách (21, 22).
1.4.3.2 Stanovení přežití, xxxxxxxxxxxxxxxx a xxxxxxxx xxxxxx
Xx konci expoziční xxxx xx xxxxx xxxxxxx x kultivují xx xxxxxx stanovení xxxxxxx x za xxxxxx xxxxxxxx xxxxxxx xxxxxxxx xxxxxxx. Xx xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx (xxxxxxx) xxxx xxxxxxxxxxx xxxxxxxxx růstu xxxxxx se xxxxxxx xxxxxxx xx expoziční xxxx.
Xxxxx xxxxx xx xxxxxxxxxx minimální časové xxxxxx, xxx xxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxx nově xxxxxxxxxxxx xxxxxxx (XXXX a XXXX xxxxxxxx xxxxxxx 6 xx 8 xxx, XX xxxxxxx xxx dny). Buňky xxxx kultivovány x xxxxx se xxxxxxxxx xxxxxxxx (xxxxxxxxxx činidly) x xxx něho (xxx nich) xx xxxxxx stanovení počtu xxxxxxx x xxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx xxxxxxxxxxxxxxxx (xxxxxxx pro xxxxxxx xxxxxxxx xxxxxxx) xx započne xx xxxxx xxxx xxxxxxx xxxxxxxxx xx misku xxx selekčního xxxxxxx.
Xx-xx xxxxxxxx látka xxxxxxxxx xx xxxxxxx L5178Y XX+/-, xxxx by xxx xxxxxxxxx xxxxxxx xx xxxxx ze xxxxxxxxxx xxxxxx (x xxxxxxxx pozitivní koncentrací) x xx xxxxxxxxxxx x pozitivních kontrolách xxxxxxxxx xxxxxxx podle xxxxxxxxx xxxxxxx. Xx-xx xxxxxxxx látka xx xxxxxxx X5178X TK+/- xxxxxxxxx, mělo xx xxx rozdělení xxxxxxx xxxxx xxxxxxxxx xxxxxxx xxxxxxxxx xx xxxxxxxxxxx x pozitivních xxxxxxxxxx. Xxx xxxxxxxx xx xxxxxxx TK6 XX+/- xxxx xxx také xxxxxxxxx xxxxxxxxx kultury xxxxx xxxxxxxxx kolonií.
2. XXXXX
2.1 XXXXXXXXXX VÝSLEDKŮ
Údaje xx měly xxxxxxxxx xxxxxxxxx xxxxxxxxxxxx a xxxxxxxxxxxxxxxx, xxxxx xxxxxxx x xxxxxxxx xxxxxxx xxx exponované a xxxxxxxxx kultury. X xxxxxxx pozitivní xxxxxxxx xx xxxxxxx X5178X XX+/- se kolonie xxxxxxxxx xxxxxxx u xxxxx xxxxxxxxxxx xxxxxxxx xxxxx (xxxxxxxx pozitivní xxxxxxxxxxx) x u xxxxxxxxx a xxxxxxxxx xxxxxxxx xx xxxxxxx xxxxxxxx xxxx xxxxxxx — xxxxx kolonie. Xxxxxxxxxxx x cytogenetická xxxxxx xxx xxxxxxx xxxxxxxxx velké xxxxxxx, xxx xxxxxxx xxxxxxxxx xxxx kolonie xxxx xxxxxxxx xxxxxxxx (23, 24). Xx xxxxxxx XX+/- xxxx xxxxxxx xxxxxxxxxxx xx použití xxxxxxxx kolonie x xxxxxxxxx xxxxxx (xxxxx) x kolonie x xxxxxxx xxxxxx (xxxx) (25). X xxxxxxxxxx xxxxx, které xxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx, xx prodloužily doby xxxxxxxx, x xxxxx xxxx malé xxxxxxx. Xxxxxxxxx xx xxxxxxx xxxxxx xx xxxxx xxxxxx xxxx xx xx xxxxxxxxxxxx viditelné xxxxxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxx tvořících xxxx xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxxxxx, xxxxx indukují xxxxx xxxxxxxxxxxx aberace (26). Xxxx závažně xxxxxxxxx xxxxx xxxxxxx xxxxxx xxxxxxxx xxxxxx xxxx xxxxxxxx xxxxx a xxxxx xxxxx xxxxxxx.
Xxxx xx xxx xxxxx xxxxxxx (xxxxxxxxx xxxxxxxx xxxxxxxxx) nebo xxxxxxxxx xxxxxxx růst. Xxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxx xxxx xxxxx xxxxxxx k xxxxx xxxxxxxxxx xxxxx.
Xxxx xx být uvedeny xxxxx xxx xxxxxxxxxx xxxxxxx. Dále xx xxxx xxx xxxxxxx xxxxx xxxxxxx ve xxxxx xxxxxxx.
Xxxxxxx jasně xxxxxxxxx odpovědi xx xxxxxxxxxx. Xxxxxxxxxx výsledky xx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx s xxxxxxx xxxxxxxxxxxxxxxx podmínek. Negativní xxxxxxxx xxxx xxx xxxxxxxxx případ od xxxxxxx. Xxx, kde xxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xx xxxxx, xx xxxxx xxxxx zdůvodnění. Xxxxx xxxxxxxxx xxxxxx x xxxxx rozšířit rozsah xxxxxxxxxxxx podmínek xx xxxx xxx zvážena x xxxxxxxxxx xxxxxxxxxxxxx xxx xxx xxxxxxxxxx xxxxxxxx, xxx xxx xxxxxxxxx xxxxxxxx. X xxxxxxxxxx xxxxxx, xxxxx xx xxxxx xxx xxxxxxx, xxxxx xxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxxxx xxxxxxxx.
2.2 XXXXXXXXX X XXXXXXXXXXXX XXXXXXXX
Xxx xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx několik xxxxxxxx, xxxx. xxxxxx xxxxxxxx xxxxxxx v xxxxxxxxxx xx koncentraci, nebo xxxxxxxxxxxxxxxx nárůst xxxx xxxxxxxx. Xxxxxxxx by xxxx xxx uvážena xxxxxxxxxx relevance xxxxxxxx. Xxx hodnocení výsledků xxxxxxx mohou xxx xxxxxxx xxxx pomocný xxxxxxxxxx xxxxxxxxxxx xxxxxx. Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxx jediným xxxxxxxxx faktorem xxx xxxxxxxxx xxxxxxx.
Xxxxxxxx látka, xxxxx výsledky xxxxxxxxx xxxx uvedená xxxxxxxx, xx v xxxxx xxxxxxx xxxxxxxx za xxxxxxxxxxx.
Xxxxxx většina experimentů xxxxxxxx jasně xxxxxxxxx xxxx xxxxxxxxx výsledky, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx soubor údajů xxxxxxxx konečný xxxxx x xxxxxxxx zkoušené xxxxx. Xxxxxxxx mohou xxxxxx xxxxxxxxxx xxxx xxxxxx xxx ohledu xx to, kolikrát xx xxxxxxxxxx opakován.
Pozitivní xxxxxxxx zkoušky xx xxxxxx xxxxxx v xxxxxxx xxxxx in xxxxx xxxxxxxxx, xx xxxxxxxx látka indukuje x xxxxxxxxx xxxxxxxxxxxxx xxxxxxx xxxxx xxxxxx xxxxxx. Reprodukovatelná pozitivní xxxxxxxxx xxxxxxxx na xxxxxxxxxxx xx xxxxx xxxxxxxx. Xxxxxxxxx výsledky xxxxxxxxx, xx xxxxxxxx xxxxx za xxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxxxx kultivovaných xxxxxxx xxxxx xxxxxx mutace.
3. XXXXXX
XXXXXXXX O XXXXXXX
Xxxxxxxx x zkoušce xxxx xxxxxxxxx tyto xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx rozpouštědla/vehikula,
- xxxxxxxxxxx x stálost xxxxxxxx látky x xxxxxxxxxxxx/xxxxxxxx, xx-xx xxxxx.
Xxxxx:
- xxx x xxxxx xxxxx,
- počet xxxxxxxxx xxxxxx,
- xxxxxxxx počet xxxxxx,
- xxxxxxxx metody xxxxxxxxx xxxxxxx xxxxxxx,
- xxxxxxxxxxxx mykoplasmat.
Zkušební xxxxxxxx:
- xxxxxxxxxx výběru koncentrací x xxxxx xxxxxx, xxxxxx xxxx. xxxxx x xxxxxxxxxxxx x xxxxxx rozpustnosti, xxxx-xx x dispozici,
- xxxxxxx xxxxx, xxxxxxxx xxxxxxxxxxx XX2,
- xxxxxxxxxxx zkoušené xxxxx,
- xxxxx xxxxxxxx x xxxxxxx zkoušené xxxxx,
- xxxxxxxxx teplota,
- xxxxxxxxx xxxx,
- xxxxx xxxxxxxx,
- případně xxxxxxx xxxxx během expozice,
- xxx x xxxxxxx xxxxxxxxx metabolického xxxxxxxxxxx xxxxxxx, xxxxxx kritérií xxxxxxxxxxxxx,
- pozitivní x xxxxxxxxx kontroly,
- délka xxxx xxxxxxx (xxxxxxxx xxxxxx xxxxx xxxxxxxxxx xxxxx, xxxxxxxxx x xxxxxx xxxxx),
- xxxxxxxx xxxxxxx,
- kritéria klasifikace xxxxxxx xx pozitivní, xxxxxxxxx xxxx dvojznačnou,
- xxxxxx xxxxxxx x xxxxxxxx životaschopných a xxxxxxxxxx xxxxx,
- definice xxxxxxx podle xxxxxxxxx x xxxx (xxxxxxxx xxxxxx xxxxxxxx pro "xxxx" a "xxxxx" xxxxxxx).
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxx xxxxxxx,
- xxxxx x xX a xxxxxxxxxx během xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxx xxxxxxxxx,
- velikost xxxxxxx, xxxx-xx xxxxxxxxxxx, xxxxxxx xxx negativní x pozitivní xxxxxxxx,
- xxxxxxxxx xxxxxxxxxxx laboratoře xxxxxxxxx xxxxxxx xxxxxxx xxxx xxxxxxx xxxxxxxx X5178X TK+/-,
- podle xxxxxxxx xxxxxxxxx odpovědi xx xxxxx,
- xxxxxxxx xxxxxxxxxxx analýzy,
- údaje x souběžné xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) x xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx x xxxxxxxxx (rozpouštědlo/vehikulum) x pozitivní xxxxxxxx x xxxxxxxxx, středními xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxx,
- xxxxxxx xxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. LITERATURA
1) Xxxxx, X. M., DeMarini, X. X., DeSerres, X. X., Xxxxxx, X. R. (eds.) (1987), Xxxxxxx Xxxxxx 28; Xxxxxxxxx Xxxx Xxxxxxxxxxx, Xxxx Xxxxxx Xxxxxx Xxxxxxxxxx, New Xxxx.
2) Xxx, X. X. X., Xxxxxxx X. X. (1968), Xxxxxxxxx Xxxx Xxxxxxxx. XX. Chemical Xxxxxxxxx xx Specific Xxxxx Xxxxxxxxx xx Chinese Xxxxxxx Xxxxx Xx xxxxx, Xxxx. Xxxx. Xxxx. Xxx. U. X. X, 61, 1306-1312.
3) Liber, X. X., Xxxxxx, X. X. (1982), Xxxxxxxx Xxxxx at xxx Xxxxxxxxx Xxxxxx Xxxxx xx Diploid Xxxxx Xxxxxxxxxxxx, Mutation Xxx. 94, 467-485.
4) Xxxxx, X. X., Xxxxxxxxx-Xxxxx, X., Doerr, C. X., Xxxxxxxxx, X. X. (1989), Differential Xxxxxx Quantitation xx xxx Xxxxx Xxxxxxxx XX xxx XXX XXXXX Xxxx, Xxxxxxxxxxx, 4, 394-403.
5) Xxxxx, X. S., Xxxxxxxxxx, Xx. L. X., (1989), Comparison xx xxx XX52/XXXX xxx xxx XXX/XXXX Assays: Xxxxxxxxxx of Xxx Xxxx Xxxxxxxxxx, Mutatation Xxx. 223, 121-128.
6) Xxxxx, X. X., Xxxxxxxxxx, G., Glatt, X. R., Xxxxx, X., Xxxxx, X., Xxxxxxxxxx, Xx. X. X., Theiss, J., Xxxxxxxx, E. (1994), Xxxxxxxxx Xxxx Gene Xxxxxxxx Xxxxxx Working Xxxxx Xxxxxx. Xxxxxx xx xxx Xxxxxxxxxxxxx Xxxxxxxx xx Xxxxxxxxxxxxxxx xx Genotoxicity Xxxx Xxxxxxxxxx. Xxxxxxxx Xxx. 312, 235-239.
7) Scott, X., Galloway, X. X., Xxxxxxxx, X. X., Xxxxxxxx, X., Xxxxxxx, X., Xxxxx, X., Xxxx, X. X. (1991), Genotoxicity Xxxxx Extreme Xxxxxxx Xxxxxxxxxx. X report xxxx XXXXXX Xxxx Xxxxx 9, Xxxxxxxx Xxx. 257, 147-204.
8) Xxxxx, D., McCuen, X., Xxxxxxx, J. X. X., Piper, X., Mavournin, K. X. (1983), Xxxxxxxx Xxxx Xxxxxxxxx in X5178X Xxxxx xx Xxxxxxx. A Xxxxxx xx xxx X. X. Xxxxxxxxxxxxx Protection Xxxxxx Gene-Tox Xxxxxxx, Xxxxxxxxxx Res., 115, 225-251.
9) Xx, X. X., Gupta, X. X., Xxxxxxx, R. X., Wasson, X. X. (1988), X Xxxxxx and Xxxxxxxx xx xxx Xxxxxxx Xxxxxxx Xxxxx/Xxxxxxxxxxxx Xxxxxxx Xxxxxxxxxxxxxx Transferase Xxxxxx xx Determine the Xxxxxxxxxxxx of Xxxxxxxx Xxxxxx: X Report xx Xxxxx III xx xxx U. X. Xxxxxxxxxxxxx Protections Xxxxxx Xxxx-Xxx Program, Xxxxxxxxxx Xxx., 196, 17-36.
10) Li, X. X., Xxxxxx, X. X., Xxxx, W. X., Xxxx, A. X., Gupta, X. X., Loveday, K. X., X'Νxxxx, X. X., Xxxxxx, X. X., Stankowski, X. X. Jr., Yang, X. X. (1987), X Guide xxx xxx Performance xx xxx Xxxxxxx Hamster Xxxxx Xxxx/Xxxxxxxxxxxx-Xxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx Xxxx Xxxxxxxx Xxxxx, Xxxxxxxxxx Xxx., 189, 135-141.
11) Xxxxx, X. L., Xxxxxxx, X. X., Xxxxxx, X. B. (1989), X Comparison xx Xxxxxxxx Induction at xxx TK xxx XXXX Xxxx in Xxxxx Xxxxxxxxxxxxxx Xxxxx: Xxxxxxxxxxxx Xxxxxxxxxxx xxx Xxx to xx Xxxxxxxxxx Xxxxx xx Xxxxxxxxx xx xxx Xxxxxxxxx TK Xxxxx, Xxxxxxxxxx Res., 216, 9-17.
12) Xxxxxxxxxx, X. X. Xx., Tindal, X. X., Xxxx, X. X. (1986), Xxxxxxxxxxxx xxx Xxxxxxxxx Xxxxxxxx xx Ethyl Xxxxxxxxxxxxxxxxx xxx XXX 191-Xxxxxxx Xxxxxxxxx Xxxxxxxx xx Xxxxx Xxxxxxxxxxxxxxxxx xxx XXX 191 Xxxxxxx Xxxxxxxx in XX52 Cells, Xxxxxxxxxx Xxx., 160, 133-147.
13) Xxxxxx, X. T., Xxxxxx, X. X., Xxxxx, D. (1984), Xxxxxxxxx xxx xxx X5178X/XX+/--XX+/- Xxxxx Lymphoma Xxxx Mutagenicity Xxxxx, xx: Xxxxxx, X. X. xx xx (xxx.) Handbook xx Xxxxxxxxxxxx Xxxx Xxxxxxxxxx, Xxxxxxxx Xxxxxxx Publishers, Xxx Xxxx, 239-268.
14) Xxxxxx, X. F., Xxxxx, X. X., Xxxxxx, G. M., Xxxxx, X. X. X., Xxxx, J., XxXxxxxx, X. B., Xxxxxxx S. X. (1989), Mammalian Cell Xxxx Xxxxxxxx Xxxxxx Xxxxx xxxx Xxxxxx Xxxxxxxxx, xx: Statistical Xxxxxxxxxx xx Xxxxxxxxxxxx Xxxx Xxxx, Xxxxxxxx, X. J., xx., Xxxxxxxxx Xxxxxxxxxx Press, 66-101.
15) Abbondandolo, A., Xxxxxxx, X., Xxxxx, X., Xxxxxx, X., Xxxxxxxx, X., Xxxxxxxxxx, X. (1977), Xxxxxxxxx xx 6-Thioguanine-Resistant Mutants xx V79 Xxxxxxx Xxxxxxx Xxxxx by Xxxxx-Xxxxx Microsome-Activated Dimethylnitrosamine, Xxxxxxxxxx Res. 46, 365-373.
16) Ames, X. X., XxXxxx, X., Xxxxxxxx, E. (1975), Xxxxxxx xxx Detecting Xxxxxxxxxxx and Xxxxxxxx xxxx xxx Xxxxxxxxxx/Xxxxxxxxx-Xxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx. 31, 347-364.
17) Xxxxx, X., Johnson, X. X., Spector, X. X. X., Xxxxxx X. X., Xxxxx X. X. X. (1979), Xxxxxxxxxx xxx Xxxxxxxxxxxxxxxx xx xxx X5178X/XX+/--Xxxxx Lymphoma Xxxxxxx Xxxxx Xxxxxx, Xxxxx. Res. 59, 61-108.
18) Xxxxx, X. X., Xxxx, X. X. (1983), Xxxxxxx Xxxxxxx xxx xxx Xxxxxxxxxx Xxxxxxxxxxxx Xxxx, Xxxxxxxxxx Xxx. 113, 173-215.
19) Elliott, X. X., Combes, R. X., Elcombe, X. X., Xxxxxxxxx, X. X., Xxxxxx, X. X., Mackay, X. X., Wolf, X. X. (1992), Xxxxxxxxxxxx xx Xxxxxxx 1254-Induced X9 xx: Xx xxxxx Xxxxxxxxxxxx Xxxxxx, Xxxxxxxxxxx 7, 175-177.
20) Xxxxxxxxxx, T., Sawamura, X., Xxxx, X., Xxxxxxxx, T. (1976), X Xxxx Xxxxxxxxxx xxx Xxxxxxxxxxxxxxx Xxxxxxxxx x. s. xx Xxxxxxx xx Xxxxxxxxx Xxxxxxxxxx Systems, V: Xx vitro Metabolic Xxxxxxxxxx xx Mutagenesis Xxxxxxx, xx Serres, X. X., Xxxxx, X. R., Bend, X. R., Xxxxxxx, X. X. (xxx), Xxxxxxxx, North-Holland, 85-88.
21) Xxxxx, X. X., Xxxxxx, X. X., XxXxxxx, K. T. (1982), XXX/XXXXX Mutation Xxxxx: Xxxxxxxxxx of Xxxxx xxx Xxxxxxxx Xxxxxxx, in: Ticc, X. R., Costa, X. X., Schaich, X. X. (eds), Xxxxxxxxx Xxxxxxx of Xxxxxxxx Agents, Xxx Xxxx, Xxxxxx, 91-103.
22) Xxxxxx, X. X., Xxxxxx, X. X., Xx, X. X., Xxxxxx, A. L. (1983), Xxxxxxxxxx of xx Xxxxxxxx System Xxxxx Xxxxx Xxxxx xx Collagen Xxxx xxx Detecting Xxxxxx Xxxxxxxx Mutagens in xxx XXX/XXXXX Xxxxxxxx Xxxxx, Xxxxxxx. Xxxxxxxxxxx, 5, 795-801.
23) Xxxxxxxxx, X. X., Xxxxx, X. M., Xxxxxx, X. X., Xxxxxxx, X., Hozier, X. X. (1990), Xxxxxxxxx Xxxxxxxxxx of Mutations xx xxx Heterozygous Xxxxxxxxx Xxxxxx Xxxxx xx Xxxxx Lymphoma Xxxxx, Xxxx. Natl. Xxxx. Xxx. X. X. X, 87, 51-55.
24) Xxxxx, X. X., Xxxxx, X., Xxxxxx, J. X., Xxxxxx, X. X., Xxxxxx, X. X., Xxxxxx, X. X., Xxxxxx, X. (1985), Xxxxxxxx of Trifluorothymidine, Xxxxxxxxx (XXX+) Xxxxxxx xx X5178X/XX+/--Xxxxx Lymphoma Xxxxx, Xxxxxxxxxx Xxx. 151, 161-174.
25) Yandell, X. X., Dryja, X. X., Xxxxxx, X. X. (1990), Xxxxxxxxx Genetic Analysis xx Recessive Mutations xx x Heterozygous Xxxxxxxxx Xxxxx xx Xxxxx Cells, Xxxxxxxxxx Xxx. 229, 89-102.
26) Xxxxx, M. M., Xxxxx, X. X. (1990), Xxxxxxxxxx of Xxxxxxxxxx Xxxxxxxxxx Xxxxxxxxx xxx Small Xxxxxx XX-Xxxxxxxxx Xxxxxx Frequency xx X5178X/XX+/- 3.7.2X Xxxxx Lymphoma Xxxxx, Xxxxxxxxxxx, 5, 609-614."
PŘÍLOHA 4X
"X.23 XXXXXXX XX CHROMOZOMOVÉ ABERACE XX XXXXXXXXXXXXXXX XXXXX
1. XXXXXX
Xxxx metoda xx xxxxxxxx xxxxxx XXXX XX 483 — Xxxxxxx na xxxxxxxxxxxx xxxxxxx xx xxxxxxxxxxxxxxx xxxxx (1997).
1.1 ÚVOD
Účelem xxxxxxx na xxxxxxxxxxxx xxxxxxx ve xxxxxxxxxxxxxxx xxxxx xx xxxx xx xxxxxxxxxxxxx takové xxxxx, xxxxx způsobují xxxxxxxxxx chromozomové xxxxxxx xx xxxxxxxxxxxxxxx xxxxx (1, 2, 3, 4, 5). Xxxxxxxxx xx xxx typy xxxxxxxxxxxx aberací: chromozomové x chromatidové. U xxxxxxx xxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx typu, xxxxx xxxxxxxxxxxx aberace xx xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxx xxxxxx xx xxxxxxxxx numerických xxxxxxx x není x xxxxxx účelu xxxxxxx xxxxxxxxx. Chromozomové xxxxxx x xxxxxxx xxxx xxxx xxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxxx xxxxxx x xxxxxxx.
Xxxxx xxxxxxxx se stanovují xxxxxxxxxxxx změny xx xxxxxxxxxxxxxxx a předpokládá xx xxxx, xx xxxx xxxxxxx poskytne xxxxxxxxx indukce xxxxxxxxx xxxxxx x xxxxxxxxxxxx xxxxxxx.
X této xxxxxxx xxxx xxxxxxx používáni xxxxxxxx. Touto xxxxxxxxxxxxxx xxxxxxxx xx xxxx xx xxxxxxxx xxxxxxxxxxxx xxxxxxx xxx mitose xxxxxxxxxxxxx. Xxxx xxxxxx xxxxx xxxxxx xxxxxxxxx xxxx zkoušky.
Pro xxxxxxx xxxxxxx xxxxxxxxxxxxxx typu xx xxxxxxxxxxxxxxx by xxxx xxx — xxxxx xxx dojde xx ztrátě xxxx — vyšetřeno xxxxx xxxxxxxxx buněčné dělení, xxxxx xxxxxxxxx po xxxxxxxx. Xxxxx xxxxxxxxx x xxxxxxxxxxxx spermatogoniálních xxxxxxxxx xxxxx xxx xxxxxx meiotickou xxxxxxxxxxxxx xxxxxxxx aberací chromozomového xxxx x xxxxxxxxx-xxxxxxxx X, kdy se xxxxxxxxxx xxxxx stávají xxxxxxxxxxxx.
Xxxx xxxxxxx in xxxx xx xxxxxxxx xxx xxxxxxxxx, zda xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxxxxx také x xxxxxxxxxxxx xxxxxxx. Xxxxx je xxxx xxxxxxx xx spermatogoniemi xxxxxxxx xxx posouzení xxxxxxxxx xxxxxxxxxx, xxxxx xxxxxxxx xxxxxxxxx faktory xxxxxxxxxxx xx vivo, xxxxxxxxxxxxxxx x procesy xxxxxxxx XXX.
Xx xxxxxxxxx xx xxxxxxxx řada xxxxxxxx spermatogonií x xxxxxx citlivostí xx xxxxxxxx chemické látce. Xxxxxxxxxx xxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxx x xxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx. X xxxxxxxxxx xx své poloze xx xxxxxxxxx, xxxxx xxxx xxxxxx být xxxxx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxx v xxxxxxxx xxxxxxxxx x fyziologické xxxxxxx Sertoliho xxxxx x xxxxxxx xxxx xxxxxxx oběhem x xxxxxxx.
Xxxxxxxx xxxxxxxx xxxxx x tom, xx xx xxxxxxxx látka xxxx reaktivní metabolity xxxxxxxxxx xx xxxxxx xxxxx, xxxx xxxxxx xxxx xxxxxxx xxxxxx.
Xxx xxxx obecný xxxx, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxxxx xxxxxxx : strukturní xxxxxxxxx xxxxxxxxxx v xxxxxx zlomu jednotlivých xxxxxxxxx xxxx xxxxx x xxxxxxxx xxxxxxx xxxxxxxxx.
Xxxxxxxxxxxx xxxxxxx : xxxxxxxxxx poškození chromozomu x podobě zlomu xxxx xxxxx x xxxxxxx obou chromatid x xxxxxx xxxxx.
Xxx : achromatická xxxx xxxxx xxx xxxxx xxxxx xxxxxxxxxx x x xxxxxxxxx odchylkou xxxxxxxxx.
Xxxxxxxxx xxxxxxx : xxxxxxxx xxxxx xxxxxxxxxx xx xxxxxxxx xxxxxxx x použitých xxxxx.
Xxxxxxxxxxx : xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxxxx sad (x), xxxx xxx xxxxxxxxx (xx. 3 x, 4 x xxx.).
Xxxxxxxxxx aberace : xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxxx při xxxxxxxx xxxxxx xx xxxxxx metafáze pod xxxxxxxxxxx, jeví xx xxxx xxxxxx x xxxxxxxxx, intrachromozomální nebo xxxxxxxxxxxxxxxxxx změny.
1.3 PODSTATA XXXXXXXX METODY
Zvířata xxxx xxxxxxx způsobem exponována xxxxxxxx xxxxx x xx vhodné xxxx xx xxxxxxxx xxxxxxxx. Xxxx usmrcením xx xxxxxxxx podá xxxxx xxxxxxxxxxx xxxxxxxx (xxxx. xxxxxxxxx xxxx Xxxxxxxx®). X germinálních xxxxx xx xxxx připraví xxxxxxxxx chromozomů, obarví xx x xxxxxxxxx xx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxx.
1.4 XXXXX XXXXXXXX METODY
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxxxx xxxx používáni samci xxxxxx čínského a xxxx; xxx xxxx xxxxxx xxxxx jakéhokoli xxxxxx vhodného xxxxx xxxxx. Xxxx xx xxx použity xxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx xxxxxxxx xxxxxx xx xxxx xxx xxxxxxxx v hmotnosti xxxxxx xxxxxxxxx a xxxxxx by překročit ± 20 % xxxxxxx xxxxxxx xxxxxxxxx.
1.4.1.2 Xxxxxxxx chovu x xxxxxx
Xxxxx xxxxxx podmínky xxxxx xxxxxxxx xxxxx x xxxxx X, xxxxxxx xx mělo xxx xxxxxxxx vlhkosti xxxxxxx 50 – 60 %.
1.4.1.3 Příprava xxxxxx
Xxxxxx mladí xxxxxxxx xxxxxxx samci xx xxxxxxxx xxxxxxx xxxxxxx xx xxxxxxxxx skupinu x xxxxxxx, xxxxx xx exponuje. Klece xx měly xxx xxxxxxxxxx tak, xxx xxx vliv xxxxxx xxxxxx xxxxxxxxxxxxx. Xxxxxxx xx xxxxxxxxxxx xxxxxxxxxxxx. Xxxx započetím xxxxxx xx nechají x xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxx xxxxxxxxxxxxx.
1.4.1.4 Xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx xx xxxx xxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx nebo xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx x xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx xxxxx být podávány xxxxx xxxx xxxxx xxx xxxx xxxxxxx xxxxxxx. Měly by xxx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx, pokud xxxxx x stálosti neprokazují xxxxxxx xxxxxxxxxx.
1.4.2 Xxxxxxxx xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx xx xxxxxx xxx xxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxx xxxxxx a xxxx xx xxx xxxxxxxxx podezření, xx xxxxxxx xx xxxxxxxxx xxxxxx. Xxxx-xx xxxxxxx xxxx xxx známá xxxxxxxxxxxx/xxxxxxxx, mělo xx xxx jejich zařazení xxxxxxxxx xxxxx x xxxxxx xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxx možno xxxxxxxx xxxxxx použití xxxxxxx rozpouštědel/vehikul.
1.4.2.2 Xxxxxxxx
Xxxxxxxx xxxxxxx xxxxxxxxxxx xx xxxx xxx xxxxxxxx xxxxxxxxx a xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) kontroly. X xxxxxxxx xxxxxxxx xxxxxxxx xxxxx by xxxx xxxxxxx kontrolní skupiny xxxxxxxxxx xxxxxxxxx xxxxxx xxxx xxxxxxx ve xxxxxxxxx, x xxxxx xxxxx x expozici.
Pozitivní xxxxxxxx by xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx xx spermatogoniích xx xxxx xxx xxxxxxxxxxx xxxxxxxx, x xxxxx xx předpokládá, že xxxxxxxxx xxxxxxxxxxxxx xxxxxx xxx pozadí.
Dávky xxxxxxxxx xxxxxxxx xx měly xxx zvoleny xxx, xxx xxx účinek xxxxxxxx, xxx xxx xxx odečtu nevyšla xxxxx najevo xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Xx xxxxxxxxxx, xxx xxxx xxxxxxxxx xxxxxxxx xxxxxxxx xxxxx způsobem xxx xxxxxxxx xxxxx x xxx xxx odběr x xxxxx xxxxxxx xxxxxxxx xxx jednou. Xxx xxxxxxxxx kontrolu xxxx xxx xxxxx xxxxx x úvahu xxxxxxx xxxxxxxxxx látek xx stejné xxxxxxxx xxxxx, jsou-li k xxxxxxxxx. Xxxxxxxx xxxxx xxx xxxxxxxxx xxxxxxxx:
|
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx Einecs |
|
cyklofosfamid |
50–18–0 |
200–015–4 |
|
cyklofosfamid xxxxxxxxxx |
6055–19–2 |
|
|
xxxxxxxxxxxxxx |
108–91–8 |
203–629–0 |
|
xxxxxxxxx X |
50–07–7 |
200–008–6 |
|
xxxxxxxxx (xxxxxxx) |
79–06–1 |
201–173–7 |
|
2,4,6-xxxx(xxxxxxxx-1-xx)-1,3,5-xxxxxxx |
51–18–3 |
200–083–5 |
X xxxxxxxx xxxxxxx xxxxxx xx xxx xxx xxxxxxxx xxxxx x xxxxxxx negativní xxxxxxxx, xxxxx je xxxxxxxxxx xxxxx rozpouštědlo xxxx xxxxxxxxx x xxxxx xxxxx xxxxxxxxxx xxxxxx xxxxxx jako xxxxxxxxxx xxxxxxx, xxxxx xxxxxx x dosavadních kontrolních xxxxx x xxxxxxxxx xxxxxxxxxx xxxxx x xxxxxxxxxxx zvířat a xxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxxx. Xxxxx xxxx by xxxx xxx xxxxxxxxxxxx xxxxxxxx xxxxxxx xxxx tehdy, xxxxxxxxxx-xx xxxxx xxxxxxxxx xxxxx xxxxxxxxxxx, xx xxxxxxx xxxxxxxxxxxx/xxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx xxxx xxxxxxxxx xxxxxx.
1.5 XXXXXX
1.5.1 Xxxxx zvířat
Každá xxxxxxxxxx x xxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxx xxx xxxxxxxxxxxxxxxx samců.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xx xxxx být xxxxx možno xxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxx (xx. xxx jedné xxxxxxxx nebo dvou xxxxxxxxxx). Xxxxxxxx látky xxxxx xxx podávány xxxx xx xxxx xxxxxxx, xxx. xxx xxxxx v týž xxx x xxxxxxx xx xxxx než xxxxxxxx hodin, aby xxxx usnadněno xxxxxxxx xxxxxxx xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxxxx xx měly xxx xxxxxxx xxxxxxxxxx.
Xx xxxxxxx x xxxxxxxx dávkou xx xxxx být xx xxxxxxxx provedeny xxx xxxxxx. Xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx xxxx xxx xxxxxxxxx xxxxxx xxxxxxxxx, xxxxxxx xx jeden xxxxx xxxxx x jeden xxxxxxxx xxxxx xxxxxxxxx 24 a 48 xxxxx po expozici. X případě xxxx xxx nejvyšší dávky xx xxx xxx xxxxx proveden xx 24 xxxxx nebo xx takové době xxxxxxxx, která xxxxxxxx 1,5xxxxxxx xxxxx xxxxxxxxx xxxxx, pokud xxxx xxxxx xxxx xxxxxxxxx xxxx pro xxxxxxx xxxxxx (6).
Xxxxx xxxxx xxx xxxxxx xxxxxxxxx xxxx v xxxx xxxx. Xxxxxxxxx x xxxxxxx xxxxxxxxxx xxxxx, xxxxx xxxxx xxxxxxxxx xxxxxxxx replikace (xxxxxxx) xxxxxxxxxx xxxx xxxxx xxxxxxxxxx X-xxxxxxxxx xxxxxx, xxxx xxx xxxxxxxxx xxxxxxxx xxxxx (1).
Xxxxxxxx xxxxx opakované expozice xxxx xxx xxxxxx xxxxxx od případu. X xxxxxxx xxxxx x xxxxxxxxxx expozicí xx xxxx být xxxxxxx xxxxxxxx 24 xxxxx (1,5xxxxxxx délky xxxxx) xx poslední xxxxxxxx. Xxxxx xxxxxxx xxxxx xxx xxxxxxxxx xxxxx odběry x xxxx xxxx.
Xxxx xxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxxxxx xxxx vhodná xxxxx xxxxx xxxxxxxxxxx metafázi (xxxx. Colcemid® xxxx xxxxxxxxx). Xxxx se xx xxxxxx době xxxxxxx x xxxxxx xxxxx. X xxxx xx xxxx xxxx xxxxxxxxx 3 — 5 xxxxx; x xxxxxx čínského xx xxxx doba xxxxxxxxx 4 — 5 xxxxx.
1.5.3 Xxxxxxxxx
Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxx zjištění xxxxxxx, xxxx xx xxx xxxxxxxxx xx xxxxxx xxxxxxxxxx, se xxxxxxx xxxxxx x kmenem x za xxxxxxxx xxxxxx xxxxxxxx, xxxxx xx použije x xxxxxx xxxxxx (7). X xxxxxxx xxxxxxxx xx pro xxxxx xxxxx xxxxxxx xxx xxxxxx dávky. Xxxx xxxxxx xxxxx xx xxxx xxxxxxxx rozmezí xxxx xxxxxxxxx a xxxxxxxxx xxxxxxxxx, xxxxxxxx xxxxxx toxicitou. Při xxxxxxxxx xxxxxx stačí, xxxx bude xxxxxxx xxxxx nejvyšší xxxxx. Xxxxxxxx xxxxx je xxxxxxxxxx jako xxxxx xxxxxxxxxxxx xxxxxx známky xxxxxxxx, xx xx xxxxx xxxxx vedly xxx stejném režimu xxxxxxxxx podle očekávání x xxxxxxxx.
Xxxxx se xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxx xxxxxxx (xxxx. hormony x xxxxxxxx) nemusí xxxxxxxxx stanovení dávky xxxxxxxxx x xxxx xx xxx xxxxxxxxx xxxxxx od xxxxxxx. Xxxxxxxx xxxxx xxxx xxx xxxx xxxxxxxxxx xxxx dávka vyvolávající xx xxxxxxxxxxxxxxx xxxxxxx xxxxxx xxxxxxxx (xxxx. xxxxxxx xxxxx spermatogonií x xxxxxx xxxxxxxx x xxxxx x xxxxx xxxxxxxxx xxxxxxxx; xxxx xxxxxxx xx xxxxxx xxxxxxxxx 50 %).
1.5.4 Xxxxxxx zkouška
Jestliže xxxxxxx x jednou xxxxxx xxxxxxx 2000 xx/xx xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxx xx dvou dávkách x xxxxxx xxx xxxxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxx účinky a xxxx-xx na xxxxxxx xxxxx x xxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx genotoxicita, xxxxxxxxxx se úplná xxxxxx xx xxxxx xxxxxxxx xxxxx xx xxxxxxxxx. Očekávaná xxxxxxxx xxxxxxx xxxx znamenat xxxxxxx použít x xxxxxxx xxxxxxx xxxxx xxxxxx dávky.
1.5.5 Podávání xxxxx
Xxxxxxxx xxxxx xx xxxxxxx podává xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxx, xxxx xxxxxxxxxxxxxxxxx injekcí. Xxxx xxxxxxx xxxxxxxx xxxx přijatelné, xxxx-xx xxxxxxxxxxxxx. Xxxxxxxxx objem xxxxxxxx, xxxxx může xxx xxxxxxxx xxxxx xxxxxxxxx sondou nebo xxxxxxxx, xxxxxx na xxxxxxxxx xxxxxxxxxxx zvířete. Xxxxx by xxxxx xxxxxxxxx 2 xx/100 x xxxxxxx xxxxxxxxx. Xxxxxxx vyšších objemů, xxx xx xxxxxxx xxxxx, musí být xxxxxxxxxx. Xx xx xxxxxxxx x xxxxxx xxxxx, xxxxx xxxxxxx xxx xxxxxxx koncentracích xxxxxxxx zesílené xxxxxx, xx xxxx xxx xxxxxxxxxxx zkoušeného xxxxxx xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx objem xxx všech xxxxxxxx xxxxx.
1.5.6 Příprava preparátů xx xxxxxxx xxxxxxxxxx
Xxxxx xx xxxxxxxx xx x jednoho nebo xxxx varlat xxxxx xxxxxxx xxxxxxxx, xxxxxxxxxxxx xx a xxxxxx. Xxxx se xxxxxx xx xxxxxxxx xxxxxxx x xxxxxx xx.
1.5.7 Xxxxxxx
X xxxxxxx zvířete xx xxxx být xxxxxxxxxxx xxxxxxx 100 xxxxx x xxxxx xxxxxxxxxxxx metafázi (xx. xxxxxxxxx 500 xxxxxxxx xx xxxxxxx). Xxxxx xxxxx lze snížit, xx-xx xxxxxxxxx xxxxx xxxxx xxxxxxx. Xxxxxxx xxxxxxxxx xxxxxx preparátů xxxxxxxxxxx x xxxxxxxxxxx xxxxxxx, xx xxxx xxx xxxx xxxxxxxxxxxxxx xxxxxxxx nezávisle xxxxxxxx. Xxxxxxxx xxx xxxxxx xxxxx dochází xx xxxxxxxxxxxxxx xxxxxx nebo xxxxxx xxxxxxxxxx x xxxxx xxxxxxxx, měly xx vyšetřované xxxxx xxxxxxxxx xxxxxxxxxx x xxxxx xxxxxxxxxxxxxx xxxxx 2 x ± 2.
2. XXXXX
2.1 ZPRACOVÁNÍ XXXXXXXX
Xxxxx xxx xxxxxxxxxx xxxxxxx xx xxxx xxx xxxxxxxxxx xx xxxxx tabulky. Xxxxxxxxxxxxxx xxxxxxxxx xx xxxxx. Xxx každé zvíře xx měl být xxxxxxxxxx xxxxx xxxxx xx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx a počet xxxxxxxxxxxxxx aberací xx xxxxx. Xxx xxxxxxxxxx x xxxxxxxxx xxxxxxx xx měly být xxxxxxx různé xxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx x xxxxxx xxxxxx x xxxxxxxx. Xxxx xx xxxxxxxxxxxxx odděleně x xxxxxxx se, xxx xxxxxx xx xxxxxxxxxx do celkové xxxxxxxx xxxxxxx.
Xx-xx xxxxxxxxxx xxxxxx x také xxxxxx, xxx xx xxx pro stanovení xxxxxxx xxxxxxxxxxxxx xxxxxx xxxx xxxx xxxxxxxxxxxx xxxxxxxx x všech xxxxxxxxxxxx xxxxxx a xxxxxx xxxxxxxxxx xxxx xxxxxxxxx kontrola poměr xxxxxxxxxxxxx x xxxxxx xxxxxxxx x xxxxx x druhé meiotické xxxxxxxx, x to x xxxxxxxx vzorku 100 xxxxxxxx se xxxxx xx xxxxx xxxxx. Xxxxx je xxxxxxxxx pouze xxxxxx, xxxxxxx x 1000 xxxxxxx xx xxxxx xx xxx xxx xxxxxxxx mitotický index.
2.2 XXXXXXXXX A INTERPRETACE XXXXXXXX
Xxx stanovení xxxxxxxxxxx xxxxxxxx existuje xxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxx buněk x xxxxxxxxxxxxxx aberacemi v xxxxxxxxxx xx xxxxx xxxx jasný xxxxxx xxxxx xxxxx s xxxxxxxxx xxx skupinu x xxxxxxx dávkou x k xxxxxxxx xxxxxxxx xxxxxx. Xxxxxxxx xx měla xxx xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx. Xxx xxxxxxxxx xxxxxxxx xxxxxxx xxxxx xxx použity xxxx xxxxxxx prostředek statistické xxxxxx (8). Xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxx jediným xxxxxxxxx xxxxxxxx xxx pozitivní xxxxxxx. Xxxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxx dalším xxxxxxxxx, xxxxxxx x xxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxxxx xxxxx, xxxxx xxxxxxxx nesplňují xxxx xxxxxxx xxxxxxxx, xx x tomto xxxxxxx xxxxxxxx xx xxxxxxxxxxx.
Xxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxx výsledky, x xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxx xxxxx xxxxxxxx konečný xxxxx x aktivitě zkoušené xxxxx. Výsledky mohou xxxxxx xxxxxxxxxx xxxx xxxxxx bez xxxxxx xx to, kolikrát xx xxxxxxxxxx opakován.
Pozitivní xxxxxxxx zkoušky xx xxxxxxxxxxxx xxxxxxx ve xxxxxxxxxxxxxxx xxxxx xx xxxx znamenají, xx xxxxxxxx xxxxx xxxxxxxx x xxxxxxxxxxxx buňkách xxxxxxxxxxx druhu xxxxxxxxxx xxxxxxxxxxxx xxxxxxx. Negativní xxxxxxxx xxxxxxxxx, že xxxxxxxx xxxxx xx xxxxxxxx zkoušky xxxxxxxxxx x xxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx.
Xxxx xx být xxxxxxxxxxx xxxxxxxxxxxxxxx, s xxxxx xx xxxxxxxx xxxxx xxxx xxxx xxxxxxxxxx dostanou xx xxxxxx tkáně.
3. ZPRÁVY
PROTOKOL X XXXXXXX
Xxxxxxxx x xxxxxxx musí obsahovat xxxx xxxxxxxxx:
Xxxxxxxxxxxx/xxxxxxxxx:
- xxxxxxxxxx xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx xxxxxxxx xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx známa.
Testovací zvířata:
- xxxxxxx xxxx/xxxx,
- xxxxx x xxxxx xxxxxx,
- xxxxx, xxxxxxxx xxxxx, xxxxxx xxx.,
- individuální xxxxxxxx xxxxxx na xxxxxxx zkoušky, xxxxxx xxxxxxx tělesné xxxxxxxxx, xxxxxxx xxxxxxx a xxxxxxxxxx xxxxxxxx xxx xxxxxx skupinu.
Zkušební podmínky:
- xxxxx xx xxxxxx xxx xxxxxxxx xxxxxxx, xxxxx byla provedena,
- xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx xxxxxxxx,
- údaje x xxxxxxxx xxxxxxxx xxxxx,
- xxxxx x xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxx xxxxxxxx,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx látky x xxxxxx xxxx xxxx (xxx) na xxxxxxxxxxxx xxxxx (mg/kg tělesné xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x xxxxxxx krmiva x xxxx,
- xxxxxxxx xxxxx xxxxxxx xxxxxxxx x xxxxxx,
- xxxxxx xxxxxxxxx toxicity,
- xxxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx, xxxx koncentrace a xxxxx aplikace,
- xxxxxx xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxx xxxxxxx,
- počet xxxxxxxxxxxxx buněk xx xxxxx xxxxx,
- kritéria xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx,
- xxxxx xxxxxxxxxxxxx x xxxxxx xxxxxxxx x xxxxx x druhé xxxxxxxx xxxxxx,
- xxx a xxxxx xxxxxxx xxxxxxx xxxxxxxxxx xxx xxxxx xxxxx,
- xxxxxxx xxxxx xxxxxxx xx xxxxxxx,
- xxxxx buněk x xxxxxxxxx xx xxxxxxx,
- xxxxx možnosti xxxxxxxxx xxxxxxxx xx dávce,
- xxxxxxxx xxxxxxxxxxx analýzy,
- xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxx,
- xxxxxxxxx xxxxx o xxxxxxxxx xxxxxxxx s xxxxxxxxx, xxxxxxxxx hodnotami x xxxxxxxxxxxx xxxxxxxxxx,
- údaje x xxxxxxxx xxxxxxxxx xxxxxxxx,
- xxxxx xxxxxxx, xxxxx xxxx xxxxxxxxxx.
Xxxxxx xxxxxxxx.
Xxxxxx.
4. XXXXXXXXXX
1) Adler, X. D., (1986), Xxxxxxxxxxx Xxxxxxxxx in Xxxxx Xxxxxxxxxxxxx xx Xxxxxxxx Mutagens Xxxxxxx xx their Xxxx-Xxxxx Xxxxxxxxxxxxxx, xx: Genetic Xxxxxxxxxx of Environmental Xxxxxxxxx, Xxxx X: Xxxxxxx Xxxxxxx and Xxxxxxx Mutagenesis, Ramel, X., Xxxxxxx, B., Xxxxxxxxx, J. (xxx) Xxxx, Xxx Xxxx, 477-484.
2) Adler, X. X., (1984), Xxxxxxxxxxx xxxxx xx Xxxxxxx, xx: Xxxxxxxxxxxx Xxxxxxx: x Xxxxxxxxx Approach, (xx.) X. Xxxxxx, X. X. Xxxxx, XXX Xxxxx, Xxxxxx, Xxxxxxxxxx XX, 275-306.
3) Xxxxx, X. P., Xxxxxxx, X., Xxxx, X. E. (1964), Xx Air-drying Method xxx Xxxxxxx Xxxxxxxxxxxx xxxx Xxxxxxxxx Testes, Xxxxxxxxxxxx Xxxx Genetics, 3, 289-294.
4) Xxxxxxx, X., Xxxxx, X., Xxxxxxxx, A., Gatehouse, X. X., Xxxxxxxxx, X. (1990), Xx xxxx Xxxxxxxxxxx Xxxxxx, xx: X. X. Xxxxxxxx (ed.), Basic Xxxxxxxxxxxx Xxxxx, XXXXX Xxxxxxxxxxx Xxxxxxxxxx. XXXXX Xxxxxxxxxxxx on Guidelines xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx. Xxxx I xxxxxxx, Cambridge Xxxxxxxxxx Xxxxx, Cambridge, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 115-141.
5) Xxxxxxxx, X., Xxxxxxx, X. (1978), A Xxx Xxxxxx for Xxxxxxxxxxx xx Xxxxxxxxx Xxxxxxxxxxxxxx Xxxxxxxxxxx, Mutatation Xxx., 52, 207-209.
6) Xxxxx, I. X., Xxxxxx M. D., Xxxxxxx, X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxxxxxx, X., Xxxxxxx, X., Xxxxxx X. (1994), Xxxxxxxxxxxxx Xxxxxxxx xx Standardisation xx Xxxxxxxxxxxx Test Procedures. Xxxxxxx Report xx xxx Xxxxxxx Xxxxx xx Xxxxxxxxx Germ Xxxx Tests, Xxxxxxxxxx Xxx., 312, 313-318.
7) Xxxxxxx, X. J., Xxxxx, X. X., Xxxxxx, X. X., Xxxxxx, X. X., Xxx, J., Esdaile, X. X., Xxxxxxxxx, X. X., Xxxxxx-Xxxxxx, X., Xxxxxx, D. X., Xxxxxxxx, X. X., Richold, M. (1992), Xxxxxx xx Xxxxxxx Xxxxxxxxxx Xxxxxxx/XX Xxxxxxxxxxxxx Mutagen Xxxxxxx Xxxxxxx Group: Xxxx Xxxxxxx xx Xx xxxx Xxxxxxxxxxxx Assays, Xxxxxxxxxxx, 7, 313-319.
8) Xxxxxx, X. P., Xxxxxxxx, X., Xxxxxxxx, X., Xxxxxxxx, X. X., Clarc, X., Xxxxxxxx, X., Xxxxxxx, X., Papworth, X. X., Xxxxxx X. X. X. (1989), Xxxxxxxxxxx Analysis xx Xx xxxx Cytogenetic Xxxxxx, xx: X. X. Kirkland (ed.), Xxxxxxxxxxx Xxxxxxxxxx xx Xxxxxxxxxxxx Test Data. XXXXX Subcommittee xx Xxxxxxxxxx xxx Mutagenicity Xxxxxxx, Xxxxxx, Xxxx XXX. Xxxxxxxxx Xxxxxxxxxx Xxxxx, Cambridge, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Xxxxxx, 184-232."
XXXXXXX 4G
"B.39 ZKOUŠKA XX NEPLÁNOVANOU XXXXXXX XXX (UDS) X XXXXXXXXX BUŇKÁCH XXXXX XX XXXX
1. METODA
Tato xxxxxx je replikou xxxxxx XXXX XX 486 — Xxxxxxx xx xxxxxxxxxxxx syntézu XXX (XXX) x xxxxxxxxx buňkách savců xx vivo (1997).
1.1 XXXX
Xxxxxx zkoušky xx xxxxxxxxxxxx syntézu XXX (XXX) v xxxxxxxxx xxxxxxx xxxxx xx xxxx xx xxxxxxxxxxxxx xxxxxxxx látky, xxxxx xxxxxxxx xxxxxxxx XXX x xxxxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxx (1, 2, 3, 4).
Tato xxxxxxx in vivo xxxxxxxxx xxxxxx xxxxxxxxx xxxxxxxxxxxxx účinků xxxxxxxxxx xxxxx x játrech. Xxxxxxxxxxx xxx xx xxxxxxxxxx xxxxxxxxx XXX x následné reparace x xxxxxxxxx xxxxxxx. Xxxxx xxxx obvykle xxxxxxx xxxxxx, xxx xxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx. Xxxx xxxx xxxxxxx xxxxxx xxx xxxxxxxxx xxxx xxxxxxxxx XXX in xxxx.
Xxxxxxxx xxxxxxxx důkaz x xxx, xx se xxxxxxxx látka xxxxxxxxx xx xxxxxx xxxxx, xxxx xxxxxx tuto xxxxxxx xxxxxx.
Xxxxxx xxxxxxxxxxx xxxxxxx XXX (XXX) xx xxxxxxxx xxxxxxxxxx xxxxxxxxxxx značených nukleosidů xx buněk, xxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx XXX (X-xxxx). Xxxxxxxxxxxxxxx xxxxxxxxx je xxxxxxxxxxxxxxxxx xxxxxxxxx inkorporace xxxxxxxxx xxxxxxxxx tritiem (3H-TdR). Xxx xxxxxxx xx XXX in vivo xx xxxxxxxxxx používají xxxxx potkana. Jiné xxxxx xxx xxxxx xxxxx xxx rovněž xxxxxxx, xxxxxx xxxx xxxxxxxxx této metody.
Detekce xxxxxxxx XXX závisí xx xxxxx bází XXX vyštěpených x xxxxxxxxxxx v místě xxxxxxxxx. Xxxxxxx xx XXX je xxxx xxxxxx zvláště xxx xxxxxxx xxxxxxxx reparací ("xxxx-xxxxx xxxxxx") (20 xx 30 xxxx) xxxxxxxxxxxx xxxxxx. Xxxxxx xxxxxx ("xxxxx-xxxxx xxxxxx") (xxxxx až xxx xxxx) jsou naproti xxxx detekovány x xxxxxx menší xxxxxxxxxx. Xxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx reparace, xxxxxx xxxxxxxx nebo xxxxxx xxxxxxxxx xxxx XXX xxxxx x mutagenním xxxxxxxxx. Xxxxxx odpovědi XXX xxxxxxxxxxx žádnou xxxxxxxxx x věrnosti xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx, xx xxxxxxx reaguje s XXX, xxx xxxxxxxxx XXX xxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxxxx xxxxxxxxxxxx informací, které xxxx zkouška xxxxxxxxx x xxxxxxxxx aktivitě, xx xxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxx xxxx, xxxxx xx vyšetřován x xxxxx xxxxxx.
Xxx xxxx xxxxxx úvod, xxxx X.
1.2 XXXXXXXX
Xxxxxxxxxx xxxxx : xxxxx xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx xxxxxx (XXX), xxxxx než xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxxx zkoušku.
Čistý xxxxx xxx odpovídajících xxxxxxxx xxxxxx (XXX) : xxxxxxxxxxxxx xxxx UDS xxxxxxxx xxxxx v xxxxxxxxxxxxxxxxx xxxxxxx na XXX, xxxxxxxxx xxxxxxxxx xxxxxxxxxx počtu xxx x xxxxxxxxxxxxxxxxx oblastech (XX) odpovídajících xxxxxx xx xxxxx xxx xxxxxxxxxxxxxx xxxxxxxx xxxxxx (XX): NNG = XX — XX. Xxxxxxx XXX se xxxxxxx pro jednotlivé xxxxx, poté xxxxxxxx xxx xxxxx x xxxxxxx, x paralelních xxxxxxxxx xxx.
Xxxxxxxxxxx xxxxxxx XXX (XXX) : Xxxxxxx xxxxxxxx DNA xx xxxxxxxxx x xxxxxxxxxx úseku XXX xxxxxxxxxxxx xxxxxx s xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxxxxx xxxxxxxx.
1.3 XXXXXXXX ZKUŠEBNÍ XXXXXX
Xxxxxxx na XXX x xxxxxxxxx xxxxxxx xxxxx xx vivo xxxxxxxx syntézu xxxxxxxx XXX xx xxxxxxxxx x xxxxxxxxxx úseku XXX xxxxxxxxxxxx xxxxxx x xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxxxxx xxxxxxxx xx xxxxxxxxxxx 3X-XxX xx XXX jaterních xxxxx, xxx je xxxx četnost xxxxx x X-xxxx xxxxxxxxx xxxxx. Inkorporace 3X-XxX xx obvykle xxxxxxxxx xxxxxxxxxxxxxxx, xxxxxxx xxxx xxxxxxxx xxxx tak xxxxxxx xx vliv X-xxxx xxxxx xxxx xxxx. xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx.
1.4 XXXXX XXXXXX
1.4.1 Xxxxxxxxx
1.4.1.1 Xxxxx xxxxx xxxxxxx
Xxxxx xx používán xxxxxx, xxxxxx lze xxxxxx xxxxxxxx vhodný xxxx xxxxx. Xxxx xx xxx použity xxxxx používané xxxxxxxxxxx xxxxx mladých xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxx. X xxxxxxxx xxxxxxxx xxxxxx by xxxx xxx xxxxxxxx v xxxxxxxxx xxxxxx xxxxxxxxx x xxxxxx xx xxxxxxxxx ± 20 % střední hodnoty xxxxxxxxx xxx obě xxxxxxx.
1.4.1.2 Xxxxxxxx chovu x xxxxxx
Xxxxx xxxxxx xxxxxxxx xxxxx xxxxxxxx xxxxx x xxxxx X, xxxxxxx xx xxxx xxx xxxxxxxx xxxxxxxx xxxxxxx 50 - 60 %.
1.4.1.3 Xxxxxxxx xxxxxx
Xxxxxx pohlavně xxxxxxx xxxxxxx se xxxxxxxx xxxxxxx xxxxxxx xx kontrolní xxxxxxx x xxxxxxx, která xx xxxxxxxx. Xxxxx xx měly být xxxxxxxxxx xxx, xxx xxx xxxx xxxxxx xxxxxx xxxxxxxxxxxxx. Xxxxxxx xx xxxxxxxxxxx identifikují x xxxx započetím xxxxxx xx xxxxxxx x xxxxxxxxxxxxx podmínkách xxxxxxx xxx xxx xxxxxxxxxxxxx.
1.4.1.4 Příprava xxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx xx měly být xxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxx xxxxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxxx a xxxxxxxxx xxxxxxx. Xxxxxxx xxxxxxxx xxxxx mohou xxx xxxxxxxx xxxxx xxxx xxxxx xxx xxxx xxxxxxx zředěny. Xxxx xx xxx xxxxxxx xxxxxxx připravené xxxxxxxx xxxxxxxx xxxxx, xxxxx xxxxx x xxxxxxxx neprokazují možnost xxxxxxxxxx.
1.4.2 Zkušební xxxxxxxx
1.4.2.1 Xxxxxxxxxxxx/xxxxxxxxx
Xxxxxxxxxxxx/xxxxxxxxx by xxxxxx xxx xxx použitých xxxxxxxx dávek xxxxxxx xxxxxx x mělo xx být xxxxxxxxx xxxxxxxxx, že xxxxxxx xx xxxxxxxxx xxxxxx. Xxxx-xx xxxxxxx xxxx xxx xxxxx xxxxxxxxxxxx/xxxxxxxx, xxxx xx xxx xxxxxx xxxxxxxx xxxxxxxxx xxxxx x jejich xxxxxxxxxxxxx. Xxxxxxxxxx xx xxxxxxxx xxxxxx xxxxxxx xxxxx xxxxx vodných xxxxxxxxxxxx/xxxxxxx.
1.4.2.2 Kontroly
Součástí každé xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx by xxxx xxx souběžné xxxxxxxxx x negativní (rozpouštědlo/vehikulum) xxxxxxxx. S výjimkou xxxxxxxx xxxxxxxx xxxxx xx měla zvířata xxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxx proces xxxx xxxxxxx xx xxxxxxxxx, x xxxxx dojde x expozici.
Pozitivními kontrolami xx xxxx být xxxxx, x xxxxx xx xxxxx, xx xxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxxxxxx koncentracích xxxx x xxxxxxx XXX detekovatelnému nad xxxxxxx. Xxxxxxxxx xxxxxxxx xxxxxxxxxx metabolickou aktivaci xx xxxx xxx xxxxxxx x dávkách xxxxxxxxxxxx xxxxxx odpověď (4). Xxxxx mohou xxx xxxxxxx xxx, xxx byl xxxxxx xxxxxxxx, xxx aby xxx odečtu xxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx. Příklady xxxxx pro xxxxxxxxx xxxxxxxx:
|
Xxxx xxxxxx |
Xxxxx |
Xxxxx XXX |
Xxxxx xxxxx Xxxxxx |
|
Xxxxx xxxx xxxxxx (2 až 4 x) |
X-xxxxxxxxxxxxxxxxxxx |
62–75–9 |
200–249–8 |
|
Xxxxxx xxxx xxxxxx (12 xx 16 x) |
X-(xxxxxxx-2-xx)xxxxxxxx (2-XXX) |
53–96–3 |
200–188–6 |
Xxxxx xxx xxxxxxx xxxx xxxx látky pro xxxxxxxxx xxxxxxxx. Je xxxxxxxxx, aby byla xxxxxxxxx xxxxxxxxx látka xxxxxxxx xxxxx xxxxxxxx, xxx xxxxxxxx xxxxx.
1.5 XXXXXX
1.5.1 Xxxxx x xxxxxxx xxxxxx
Xxx by xxx xxxxxx xxxxxxxxxx xxxxx xxxxxx, xxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxx kolísání xxxxxxxx xx xxxxxxx. Xxxxx xxxxxxx by se xxxx xxxxxxx xxxxxxx xx xxx xxxxxxxxxxxxxxxx xxxxxx. Jestliže jsou xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx, je pro xxxxxxxxx x pozitivní xxxxxxxxx skupiny xxxxxxxx xxxxx xxxxx až xxx xxxxxxx.
Xxxxxxxx xxxx x xxxx studie x dispozici xxxxx xx xxxxxx se xxxxxxx druhem x xx použití stejného xxxxxxx xxxxxxxx, xxx xxxxxxxxx, xx neexistuje xxxx xxxxxxxxx xxxxxx x toxicitě, xxxx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx, nejlépe xxxxx. Xx-xx expozice xxxxxxx xxxxxxxxxx xxx určité xxxxxxx, xxxx xx xxxx například x xxxxxxxxx farmaceutických látek, xxxx by xxx xxxxxxx xxxxxxxxx se xxxxxxxx odpovídajícího xxxxxxx.
1.5.2 Xxxx xxxxxxxx
Xxxxxxxx xxxxx xxxx xxxxxxxxx podávány xxxxxxxxxxx.
1.5.3 Dávkování
Za xxxxxxxxxx xxxxxxxx xx používají xxxxxxx dvě úrovně xxxxx. Nejvyšší dávka xx xxxxxxxxxx xxxx xxxxx vyvolávající xxxxxx xxxxxx toxicity, že xxxxx xxxxx by xxxxx xxxxx xxxxxxxxx xxx stejném xxxxxx xxxxxxxxx x xxxxxxxx. Xxxxx xxxxx by xxxx xxx zpravidla 50 % xx 25 % vyšší xxxxx.
Xxxxx xx specifickou xxxxxxxxxxx aktivitou xxx xxxxxxx xxxxxxxxxxx xxxxxxx (xxxx. hormony x xxxxxxxx) nemusí xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx x měly xx xxx hodnoceny xxxxxx xx případu. Xxxxxxx-xx xx xxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxx xxx xxxxxxxx xxxxxxx, měla by xxx provedena ve xxxxxx xxxxxxxxxx, xx xxxxxxx xxxxxx, xxxxxx, xxxxxxxx x za xxxxxxxx režimu xxxxxxxx, xxx se xxxxxxx x xxxxxx xxxxxx.
Xxxxxxxx xxxxx může xxx xxxxxxxxxx xxxx xxxx xxxxx vyvolávající xxxxxx xxxxxxxx x játrech (xxxx. xxxxxxxxxx jádra).
1.5.4 Xxxxxxx xxxxxxx
Xxxxxxxx xxxxxxx x xxxxxx xxxxxx x xxxxxxx 2000 xx/xx tělesné xxxxxxxxx xxxxxxx xxxxxxxxxxx nebo xx xxxx dávkách x jednom xxx xxxxxxxxxx xxxxx pozorovatelné xxxxxxx účinky x xxxx-xx na xxxxxxx xxxxx x xxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxx, očekávána genotoxicita, xxxxxx být úplná xxxxxx xxxxxxxx. Očekávaná xxxxxxxx xxxxxxx xxxx xxxxxxxx xxxxxxx xxxxxx x limitní xxxxxxx xxxxx xxxxxx xxxxx.
1.5.5 Xxxxxxxx xxxxx
Xxxxxxxx xxxxx xx obvykle podává xxxxxxxxxxxxxx, xxxxxxxxx xxxxxx xxxx vhodnou intubační xxxxxxx. Xxxx způsoby xxxxxxxx xxxx xxxxx, xxx-xx xx xxxxxxxxx. Xxxxxxxx xxxxxxxxxxxxxxxxx se xxxx xxxxxxxxxxxx, neboť xx xxxxx xxxxx xxx xxxxxxxxxx xxxxxxxx xxxxx přímo x xxxxxx xxxxxxxxxxxxxxx oběhového xxxxxxx. Xxxxxxxxx xxxxx xxxxxxxx, xxxxx xxxx xxx xxxxxxxx xxxxx xxxxxxxxx xxxxxx xxxx xxxxxxxx, závisí na xxxxxxxxx xxxxxxxxxxx xxxxxxx. Xxxxx xx xxxxx xxxxxxxxx 2 xx/100 x xxxxxxx xxxxxxxxx. Xxxxxxx xxxxxxx objemů, xxx je xxxxxxx xxxxx, xxxx být xxxxxxxxxx. Xx na xxxxxxxx x xxxxxx xxxxx, xxxxx xxxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxx účinky, xx xxxx xxx xxxxxxxxxxx xxxxxxxxxx objemu xxxxxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx xxxxx xxx xxxxx xxxxxxxx xxxxx.
1.5.6 Xxxxxxxx jaterních xxxxx
Xxxxxxx xxxxx xx xxxxxxxxxx x xxxxxxxxxxxx xxxxxx zpravidla 12 xx 16 hodin xx xxxxxx xxxxx. Xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxx (obecně xxx xx xxxxx hodiny xx xxxxxxxx) xx xxxxxxxx, není-li po 12 xx 16 xxxxxxxx xxxxx pozitivní xxxxxxx. Mohou xxxx xxx použity xxxx xxxx xxxxxx, jsou-li xxxxxxxxxx xx xxxxxxx xxxxxxxxxxxxxxxxx údajů.
Krátkodobé kultury xxxxxxxxx buněk xxxxx xx zpravidla xxxxxxxxx xxxxxxx xxxxx kolagenasou xx xxxx x xxxxxx se, aby xx čerstvě disociované xxxxxxx xxxxx xxxxxxxxx xx xxxxxxx xxxxxxx. Xxxxxxx xxxxx z xxxxxxxxx kontroly xx xxxx vykazovat xxxxxxxxxxxxxxx (5) xxxxxxx 50 %.
1.5.7 Xxxxxxxxx UDS
Čerstvě xxxxxxxxx xxxxxxx buňky xxxxx se xxxxxxx xxxxxxx xxxx, xxxx. xxx xx xxx xxxxx, xxxxxxxx s xxxxxx xxxxxxxxxxx 3X-XxX. Xx xxxxx xxxxxxxxx xxxx xx mělo xxx xxxxxx x xxxxx xxxxxxxxxx a xxxxx xxxx xxxxx xxx xxxxxxxxxx s xxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxx, aby xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxx ("cold xxxxx"). Xxxxx xx xxxx xxxxxxx, xxxxxx x xxxxxx. Xxx delší xxxxxxxxx xxxx xxxxxx xxx xxxxxxx xxxxxxxxxxxxx xxxxxxxx. Preparáty xx xxxxxx xx xxxxxxxxxxxxxxxxx xxxxxx, xxxxxxxx xx x xxxxx (xxxx. x xxxxxx 7 xx 14 dnů), xxxxxxxx xx, xxxxxx x xxxxxxxxx xx xxxxxxxxxx xxxx stříbra. X každého xxxxxxx xx připraví dva xx xxx xxxxxxxxx.
1.5.8 Xxxxxxx
Xxxxxxxxx xx xxxx xxxxxxxxx xxxxxxxxxx počet xxxxxxxxxxxx normálních xxxxx, xxx mělo hodnocení XXX výpovědní xxxxxxx. Xxxxxxxxx xx pod xxxxxxxxxxx xxxxxxxxxx xx xxxxxx xxxxxx xxxxxxxxxxxx (xxxx. xx pyknosu, xxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx izotopem).
Před počítáním xxx by xxxx xxx preparáty xxxxxxxx. Xxxxxxxxx se xxxxxxxxx 100 xxxxx na xxxxx zvíře xxxxxxx xx dvou xxxxxxxxx; xxxxxxxxx xxxx než 100 xxxxx/xxxxx xx xxxx xxx xxxxxxxxxx. Xxx xxxxxxxx xxx xx jádra x X-xxxx nevyšetřují, ale xxxxx xxxxx v X-xxxx xxxx xxx xxxxxxxxxx.
Xxxxxxxx 3X-XxX xxxxxxxxxxxxxxx xx xxxxx a xxxxxxxxxx morfologicky xxxxxxxxxx xxxxx xxxxxxxx navrstvením xxx stříbra by xxxx xxx xxxxxxxxx xxxxxxx xxxxxxx.
Xxxxx buněk xx xxxxxxx x xxxxx xxx odpovídajících xxxxxxxx xxxxŭx (xx) x x xxŭxxxxxxx xxxxx zrn x xxxxxxxxxxxxxxxxx xxxxxxxxx (xx) xxxxxxxxxxxxxx jádrŭm. xxxx xxxxxxx xx xx xxxxxxx xxx počet xxxxx pro xxxxxxxxxx xxxxxxxxx oblast cytoplasmy, xxxx prŭměrná xxxxxxx xxxx xx xxx xxxxxxx xxxxxxxxx xxxxxxx x blízkosti xxxxxxxxx xxxxxxxxx jader. po xxxxxxxxxxxxx xxXxxxxxxx xxxxx xxx xxxxxxx i xxxx xxxxxxx xxxxxxxxx xxxxx buněk (např. xxxxxxxx xxxxxx xxxxx) (6).
2. XXXXX
2.1 XXXXXXXXXX XXXXXXXX
Xxxx xx být xxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxxxx x xxxxxxx. Xxxxx by xxxx xxx xxxx xxxxxxx xx xxxxx xxxxxxx. Xxxxxxxxx xxxxxxx XX xx xxxxxxx XX xx xxx xxx xxxxxxxx xxx xxxxxx xxxxx, pro xxxxx xxxxx a xxx xxxxxx dávku x xxx xxxxx xxxxx xxx odpovídajících xxxxxxxx jádrům (XXX). Xxxxxxxx xxxx xxxxxxxx "xxxxxxxxxx" buňky, xxxx xx xxx kritéria xxx definování "opravovaných" xxxxx xxxxxxxxxx a xxxxxxxx xx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx x negativních xxxxxxxxxx. Xxxxxxxxx xxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx. Xxxx-xx xxx xxxxxxx, měly xx xxx xxxxxxxxxxx xxxxx xxxxxxx x xxxxxxxxxx xxxx provedením xxxxxx.
2.2 XXXXXXXXX X INTERPRETACE XXXXXXXX
Xxxx xxxxxxxx kritérií xxx xxxxxxxxx nebo xxxxxxxxx xxxxxxx xxxxx:
|
xxxxxxxxx |
x) |
xxxxxxx XXX xxxx nad xxxxxxxx xxxxxx, xxxxx xx xxxxxxxxxx na xxxxxxx xxxxxxxxxxx údajů xxxxxxxxxx; |
|
xxxx |
xx) |
xxxxxxx XXX xx xxxxxxxx vyšší xxx xxxxxxx xxx xxxxxxxxx xxxxxxxx; |
|
xxxxxxxxx |
x) |
xxxxxxx XXX xxxx xx dosavadní xxxxxxx xxxxxxx xxxx xxx xx; |
|
xxxx |
xx) |
xxxxxxx XXX není xxxxxxxx xxxxx xxx xxxxxxx xxx souběžnou xxxxxxxx. |
Xxxx xx xxx xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx, xx. xxxx xx být xxxxx x xxxxx parametry, xxxx jsou xxxxxxxxxxx xxxxxx, xxxxx dávky x odpovědi a xxxxxxxxxxxx. Xxx hodnocení xxxxxxxx xxxxxxx xxxxx xxx xxxxxxx jako xxxxxxx xxxxxxxxxx statistické xxxxxx. Statistická xxxxxxxxxx xx xxxx xxxxxx xxx jediným xxxxxxxxx xxxxxxxx pro xxxxxxxxx xxxxxxx.
Xxxxxx většina xxxxxxxxxxx xxxxxxxx jasně xxxxxxxxx xxxx xxxxxxxxx xxxxxxxx, x xxxxxxxxxxx případech xxxxxxxx xxxxxx xxxxx xxxxxxxx xxxxxxx výrok x xxxxxxxx zkoušené xxxxx. Xxxxxxxx xxxxx xxxxxx xxxxxxxxxx xxxx xxxxxx bez ohledu xx to, kolikrát xx xxxxxxxxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx xxxxxxx na XXX v xxxxxxxxx xxxxxxx savců in xxxx znamenají, xx xxxxxxxx xxxxx indukuje x xxxxxxxxx xxxxxxx xxxxx in xxxx xxxxxxxxx XXX, xxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxxx XXX in xxxxx. Negativní xxxxxxxx xxxxxxxxx, xx zkoušená xxxxx xx podmínek xxxxxxx xxxxxxxxxx xxxxxxxxx XXX, které lze xxxxxxxxx touto xxxxxxxx.
Xxxx xx být xxxxxxxxxxx xxxxxxxxxxxxxxx, s xxxxx xx xxxxxxxx xxxxx xxxxxxx xx xxxxxxxx xxxxx xxxx. do xxxxxx xxxxx (xxxx. xxxxxxxxx toxicita).
3. XXXXXX
XXXXXXXX X XXXXXXX
Xxxxxxxx x xxxxxxx xxxx obsahovat xxxx informace:
Rozpouštědlo/vehikulum:
- xxxxxxxxxx xxxxx xxxxxxxx,
- xxxxxxxxxxx x xxxxxxx zkoušené xxxxx x xxxxxxxxxxxx/xxxxxxxx, xx-xx známa.
Testovací zvířata:
- xxxxxxx xxxx/xxxx,
- xxxxx, xxxxx x pohlaví xxxxxx,
- xxxxx, xxxxxxxx xxxxx, xxxxxx xxx.,
- xxxxxxxxxxxx xxxxxxxx xxxxxx xx počátku zkoušky, xxxxxx xxxxxxx tělesné xxxxxxxxx, xxxxxxx xxxxxxx x směrodatné xxxxxxxx xxx xxxxxx xxxxxxx.
Xxxxxxxx xxxxxxxx:
- xxxxxxxxx x xxxxxxxxx (vehikulum/rozpouštědlo) kontroly,
- xxxxx xx xxxxxx xxx xxxxxxxx xxxxxxx, xxxxx byla xxxxxxxxx,
- xxxxxxxxxx zvolených úrovní xxxxx,
- xxxxx x xxxxxxxx xxxxxxxx xxxxx,
- xxxxx o xxxxxxxx xxxxxxxx xxxxx,
- xxxxxxxxxx xxxxxxx podávání,
- xxxxxxxxx xxxxxx xxxxxxx, xxx xx xxxxxxxx xxxxx xxxxxxx xx xxxxxxxx xxxxx xxxx do xxxxxx tkáně,
- xxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx x xxxxxx xxxx xxxx (xxx) xx xxxxxxxxxxxx xxxxx (xx/xx xxxxxxx xxxxxxxxx/xxx),
- xxxxxxxx xxxxx x xxxxxxx krmiva x xxxx,
- xxxxxxxx xxxxx xxxxxxx expozice x odběru,
- metody xxxxxxxxx xxxxxxxx,
- metody xxxxxxxx a xxxxxxxxx xxxxxxxxx xxxxx,
- použitá xxxxxxxxxxxxxxxxx technika,
- počet xxxxxxxxx x xxxxx xxxxxxxxxxx buněk,
- xxxxxxxx xxxxxxxxx,
- xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx.
Xxxxxxxx:
- xxxxxxx hodnoty xxxxx xxx xxxxxxxxxxxxxx buněčným xxxxxx x xxxxx xxx xxxxxxxxxxxxxx xxxxxxxxxx, x xxxxx počet xxx, xxxxxxxxxx pro xxxxxxxxx, xxxxxxx a xxxxxxx,
- xxxxx xxxxxxxx xxxxxxxxx odpovědi na xxxxx,
- případné xxxxxxxxxxx xxxxxxxxx,
- xxxxxx xxxxxxxx,
- xxxxx x xxxxxxxx xxxxxxxxx (rozpouštědlo/vehikulum) x xxxxxxxxx xxxxxxxx,
- dosavadní xxxxx x xxxxxxxxx (xxxxxxxxxxxx/xxxxxxxxx) a xxxxxxxxx xxxxxxxx x xxxxxxxxx, xxxxxxxxx xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxx,
- počet xxxxx "xxxxxxxxxxxx" xxxxx, xx-xx stanoven,
- počet xxxxx x X-xxxx, xx-xx xxxxxxxx,
- xxxxxxxxxxxxxxx xxxxx.
Xxxxxx výsledků.
Závěry.
4. XXXXXXXXXX
1) Xxxxx, X. Xxxxxxx, X. X., Burlinson, X., Xxxxxx, X. X. (1985), Xx Xxxxxxxxxx xx xxx Xx xxxx Rat. Xxxxxxxxxx XXX Repair Xxxxx, Xxxxxxxxxx Res., 156, 1-18.
2) Butterworth, X. E., Xxxxx, X., Bermudez, X., Xxxxxxxx, D., Xxxxxxxx, X., Xxxxxx, G., Xxxxxxxx, G. (1987), X Xxxxxxxx and Xxxxx for xxx Xx vivo Xxx Xxxxxxxxxx XXX Repair Xxxxx, Xxxxxxxxxx Res., 189, 123-133.
3) Kennelly, X. X., Xxxxxx, X., Xxxxx, X., Xxxxxxx, X. A., Xxxxxxxxx, B., Benford, X. X., Xxxx, X. X., Xxxxxxxx, X. xx X. (1993), In xxxx Xxx Xxxxx UDS Xxxxx, xx: Kirkland X. X., Xxx X., (xxx), Supplementary Xxxxxxxxxxxx Xxxxx: XXXX Xxxxxxxxxxx Xxxxxxxxxx. XXXXX Xxxxxxxxxxxx xx Guidelines xxx Xxxxxxxxxxxx Xxxxxxx. Xxxxxx. Part II xxxxxxx, Xxxxxxxxx University Xxxxx, Xxxxxxxxx, Xxx Xxxx, Xxxx Xxxxxxx, Xxxxxxxxx, Sydney, 52-77.
4) Xxxxx, X., Dean, X. X., Xxxxxx, X., Xxxxxxxxx. G., Xxxxxxxxx, B., Xxxxxxxxx, X. J., Furihata, X., Hertner, X., XxXxxxx, C. X., Xxxx, X. (1993), Xxxxxxxxxxxxxxx for xxx Xxxxxxxxxxx of UDS Xxxxx Xx xxxxx xxx Xx vivo, Xxxxx. Xxx., 312, 263-285.
5) Fautz, X., Xxxxxxx, X., Xxxxxxxxxx, X., Hechenberger-Freudl, C. (1993), Xxxxxxxxxx xx xxx Relation Between xxx Xxxxxxx Xxxxxxxxx xxx the Xxxxxxxxxx xx Xxxxxxx Xxxxxxxx Xxx Xxxxxxxxxxx Xxxx xxx the In xxxx/Xx vitro DNA Xxxxxx Assay (UDS), Xxxxxxxxxx Res., 291, 21-27.
6) Xxxxxxxx, X. X., Xxxxx, X. X., Butterworth, X. X. (1982), Xxxxxxxxx xx Xxxxxxxxx Xxxxxxxxxxx xx the Xx xxxx/Xx vitro Hepalocyte XXX Repair Xxxxx, Xxxxxxx.Xxxxxxx. 4, 553-562."
XXXXXXX 5
XXXXXX XXXXXXXXX XX XXXXXXXXXXX A XXXXXXXXXX XXXXXXXXXXXX XXXXX X XXXXXXXXX
Xxx xxxxxxxx Xxxxxx 2001/59/XX, Úř. xxxx. L 332, 28. 12. 2000, x. 81.
PŘÍLOHA 6
"
PŘÍLOHA XX
XXXX X
xxxxxxxx xxxxxxxx se xxxxxxx odolných xxxxx xxxxxxxx xxxxx
Xxxxx xxxxxxxxxx xx. 22 xxxx. 1 písm. e) xxxx xxxxxxxx, musí xxx xxxxx x xxxxxxxxx xxxxxx xxxxxxxxxx xxxxx, x xxxxx xx spojeno xxxxxx xxx xxxxxxxxxx (Xn; X 65) a xxxxx xxxx xxxxxxxxxxxxx x xxxxxxxx xxxxx xxxx 3.2.3 xxxxxxx XX xxxx směrnice, x výjimkou látek xxxxxxxxx na xxx xx xxxxx xxxxxxxx xxxx x xxxxxxxx xxxxxxxxxx aerosolovým rozprašovačem, xxxxxxxx xxxxxxx xxxxxxxx xxxxx otevření xxxxx.
1. Xxxxxxxxx uzavíratelné xxxxx
Xxxxxxx xxxxxx xxxxx xxxxxxxx xxxxx xxxxxxx xx xxxxxxxxx xxxxxxxxxxxxxx obalech xxxx xxxxxxxx xxxxxxxxx xxxxx XXX 8317 (xxxxxx xx xxx 1. července 1989) "Xxxxx xxxxxx dětem — Požadavky xx xxxxxxxxx uzavíratelné xxxxx x xxxxxx xxxxxx xxxxxxxx" xxxxxxxx Mezinárodní xxxxxxxxxx xxx xxxxxxxxxxx (XXX).
2. Xxxxxxxxx neuzavíratelné xxxxx
Xxxxxxx odolné proti xxxxxxxx xxxxx xxxxxxx xx xxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxx musí xxxxxxxx xxxxxxxxx xxxxx XXX XX 862 (xxxxxx x xxxxxx 1997) "Xxxxx — Xxxxx xxxxxx xxxxx — Xxxxxxxxx a xxxxxxxx xxxxxxx xxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxx xxx farmaceutických xxxxxxx" xxxxxxxx Xxxxxxxxx xxxxxxx xxx xxxxxxxxxxx (XXX).
3. Xxxxxxxx
1. Xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxx xxxxx xxxxxxxxxx xxxxx laboratoře, xxxxx xxxxxxx xxxxxxxx normy xxxx XX 45000.
2. Xxxxxxxxxx xxxxxxx
Xx-xx xxxxxx, xx xxxx xx xxxxxxxxxx xxxxxxxx pro xxxx, xxxxx xx xxxxxxx xxxxxx k xxxxxx xxx xxxxxx xxxxxxxx, xxxxxx xxx xxxxxxx provedena.
Ve všech xxxxxxxxx xxxxxxxxx x xxxxx existují xxxxxxxxx xxxxxx x xxxxxxxx x xxxxxxxxxxx xxxxxxx xxx xxxx, může xxxxxxxxxxxx orgán xxxxxxxxx, xxx osoba xxxxxxxxx xx xxxxxxx výrobku xx xxx xxxxxxxxxx xxxxxxxxxx xxxxxx laboratoří xxxxx xxxx. 3 xxxx 1 konstatující, xx xxx
- xxx xxxxxxx je takový, xx jej není xxxxxxxx zkoušet xxxxx xxxx xxxxxxxxx xxxxx XXX x XXX,
xxxx
- xx xxxxxx byl xxxxxxx a xxx xxxxxxx xxxxxxxxxxx podle xxxx xxxxxxxxx norem.
ČÁST X
Xxxxxxxx týkající se xxxxxxxxxxxx výstrah
Technické specifikace xxx xxxxxxxxxx výstrahy xxxx být x xxxxxxx x normou XX ISO 11683 (xxxxxx x xxxx 1997) "Xxxxx — Xxxxxxxxxx výstrahy xxxx xxxxxxxxxx — Xxxxxxxxx".
"